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Abstract
Background
Inflammation is important in the development, progression and acute
complications of atherosclerosis. Increased levels of inflammatory markers in
humans predict the occurrence of future atherothrombotic events. Recognised 
risk factors for atherosclerosis have been shown to cause endothelial dysfunction,
characterised by impaired endothelial nitric oxide-dependent vasodilator
responses. Whether a similar mechanism underlies the effects of inflammation is 
not fully understood. This work explores this relationship, with a particular 
emphasis upon changes in the endothelial nitric oxide synthesis pathway.
Methods
In vitro experiments were performed using organ bath pharmacology and western 
blotting to determine the effects of incubation of vascular tissue with high 
concentrations of the inflammatory marker C-reactive protein. An in vivo model 
of inflammation, using typhoid vaccination in healthy volunteers, was used to 
explore the time course of the vascular responses in comparison to the 
inflammatory markers. Further in vivo experiments involved selectively 
supplementing components of the nitric oxide pathway to determine if any were 
the cause of the endothelial dysfunction.
Results
The work showed that acute inflammation caused transient endothelial 
dysfunction and that this was associated with increased oxidant stress. 
Supplementation experiments showed no substrate deficiency, rather that there 
was increased consumption of both nitric oxide and the co-factor 
tetrahydrobiopterin required for its production. In vitro and in vivo experiments 
indicated that, although C-reactive protein was a strong predictor of future events, 
it did not itself cause endothelial dysfunction, and in fact may be associated with 
an improvement in nitric oxide bioavailability through increased 
tetrahydrobiopterin.
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Conclusions
Overall, inflammation is associated with transient endothelial dysfunction and this 
may be important in the destabilisation of atherosclerotic disease and lead to 
clinical events. This change seems to be mediated by an increase in oxidant 
stress, which then has a number of related detrimental effects upon the nitric oxide 
pathway. However the acute phase marker, C-reactive protein, is only a marker of 
the underlying process and does not in itself appear to be causal in the 
development of endothelial abnormalities. Further work will be needed to more 
clearly characterise these effects and determine their clinical relevance.
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1 Introduction
1.1 Epidemiology of Atherosclerosis
Atherosclerosis and its complications account for 15 million deaths per annum
worldwide, and within 50 years it is predicted that atherosclerosis will overtake
1infectious diseases to become the single commonest cause of death( ’ ). Each year 
110,000 people in the United Kingdom die from coronary disease and nearly half 
of these are less than 75 years old. 90,000 patients have a myocardial infarction 
annually and stroke remains the largest cause of severe disability, and the third 
most common cause of death, in the United Kingdom. Atherosclerosis has a long 
pre-clinical phase, with early lesions being evident as young as six months old (3). 
Although it is a disease that originates in early life, its clinical burden is most 
heavy upon the late middle and old aged. As a consequence it has a huge social 
and economic burden, and understanding the mechanisms of atherosclerosis 
remains a vital prelude to the discovery of new treatments.
1.2 Pathology of Atherosclerosis and the Natural History 
of Plaque Formation
The first stages of the development of atherosclerosis are poorly understood in 
humans. Animals treated with a high lipid diet initially deposit small lipoprotein 
particles in the intima, which coalesce to form fatty streaks(4). Initially intimal 
thickening occurs in regions of the vasculature prone to the development of 
atherosclerosis, such as bifurcation points(5). This may be followed by lipid 
accumulation and development of fatty streaks. With increasing age more
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complex lesions develop, characterised by the presence of extracellular lipid, 
fibrosis and accumulation of lymphocytes, smooth muscle cells and macrophages.
Lesions are divided into precursor (type I-III) and advanced lesions (IV-V) 
according to their structure^). Type I lesions have isolated scattered macrophages 
containing lipid droplets, whereas type II lesions contain macrophage foam cells 
in layers with lipid deposits within the intimal smooth muscle cells and T- 
lymphocytes; these are seen macroscopically as fatty streaks. Type III lesions 
differ importantly in that the lipid pool is now extracellular. Once this coalesces 
to a tight “lipid core” the lesions are classed as type IV and the final lesion type is 
present once fibrous tissue becomes a significant feature (although these may 
again be subdivided according to the presence of calcification [Vb] or relative 
dominance of fibrosis [Vc]).
Although increasing lesion complexity is associated with greater bulk, the 
development of vessel wall remodelling allows the incorporation of large lesions 
without necessarily impeding flow(7). Post-mortem and intra-vascular ultrasound 
studies suggest that the lesions which lead to atherothrombotic events differ 
structurally from those leading to luminal stenosis; they are predominantly located 
within the intima and media with outward expansion (positive remodelling), and 
have an higher lipid content containing increased numbers of inflammatory
O 1 A
cells(' ). Lesions that demonstrate high degrees of stenosis may occur due to 
rupture, thrombosis and subsequent rapid growth of intramural plaques with 
resultant smooth muscle proliferation and show a large number of areas of healed
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plaque disruption^!). Such a process may explain the phasic rather than linear 
progression of lesions seen in repeat angiography studies(12).
Atherosclerosis is a prolonged process that starts early in life. The human post­
mortem studies of Stary and McGill have demonstrated that by the third decade of 
life 20% of individuals will have advanced lesions present in the coronary 
circulation(3;13). In childhood, type I and II lesions are present, with type III 
lesions appearing around puberty and type IV lesions in the third decade. 
Recently, data from intra-vascular coronary ultrasound studies have shown that 
nearly 17% of donor hearts from individuals aged less than 20 years of age have 
detectable atherosclerosis, and this proportion is nearly 50% in donors over 50 
years old(14). Further, in individuals where lesions are demonstrable 
angiographically widespread atheroma can be detected by ultrasound in other 
apparently normal parts of vessels^5).
1.3 Theories of Pathogenesis of Atherosclerosis
The three fundamental processes in the pathogenesis of atherosclerosis are the 
accumulation of lipid in the vessel wall, smooth muscle proliferation and 
inflammation.
Virchow’s imbibition hypothesis proposed that the cellular proliferation seen in 
the intima was a form of ‘low-grade inflammation’ as a reaction to infiltration, or 
imbibition, of proteins and lipids from the blood. The encrustation theory 
proposed by von Rokitansky postulated that small thrombi composed of platelets,
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fibrin, and leukocytes collect over sites of endothelial injury, which then organise 
with smooth muscle proliferation to form atherosclerotic plaques(16;17).
Benditt and Benditt and others have demonstrated in human plaques, by use of X- 
chromosome inactivation according to the Lyon hypothesis, that the intimal cell 
proliferation is monoclonal18). This is not due to allele selection and has not 
been demonstrated in other animals, at least in part due to methodological 
difficulties. This monoclonality could indicate three possibilities; firstly the insult 
could be very localised leading to one clone expanding, secondly the expanding 
“plaque smooth muscle” cells could preferentially over-proliferate due to infection 
with a virus or other pathogen or thirdly the proliferating cells could be 
genetically distinct and favour growth(19). The details and importance of this 
mechanism in atherosclerosis are not clear particularly as monoclonal expansion 
has been detected in regions of normal intima and media(20).
Preferential retention of lipoproteins has been suggested as the key step in 
atherosclerosis. This is based on the observation that there is adequate influx of 
lipid into all cells, whereas the failure to excrete it is characteristic of plaques, 
thus leading to excess retention in areas of atheroma. This occurs at the points of 
shear stress that typically demonstrate plaque development and it has been 
proposed that retained lipid is then oxidised and acts as the stimulus for other
iaspects of atherosclerosis( ).
In the 1970s Ross suggested a mechanism whereby lipid deposits might gain 
access to the vascular wall, the so-called "the response-to-injury hypothesis'^22).
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This proposes that the initiation of atherosclerosis involves endothelial 
denudation, allowing adhesion of platelets, monocytes and leukocytes to the 
vessel and increasing permeability to plasma constituents. As a further 
modification to this theory, the endothelium need not be denuded, rather merely 
dysfunctional( ) to act as a substrate for atherosclerosis. However, irrespective of 
the details of the late mechanisms of atherosclerosis, a common theme in each of 
these theories is the presence, early in the pathogenesis of atherosclerosis, of 
endothelial dysfunction.
1.4 Physiology of endothelium
The endothelium is the single layer of cells that lines the luminal surface o f blood 
vessels and regulates numerous blood vessel functions including vascular tone, 
cell adhesiveness, and coagulation by the generation of local mediators. These 
include vasodilators, of which the most important are nitric oxide (NO), 
prostacyclin (PGI2), and endothelium derived hyperpolarising factor (EDHF). The 
endothelium, also generates a number of locally acting vasoconstrictors including 
thromboxane (TX) and endothelin (ET).
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Figure 1-1: Endothelial vasodilators and vasoconstrictors
(EC = endothelial cell; SMC = smooth muscle cell; NO = nitric oxide; EDHF = 
endothelial derived relaxing factor; PG = prostaglandin; TX = thromboxane; ET = 
endothelin)
1.4.1 V asoactive m ediators
In health, the endothelium favours the production of vasodilators with the relative 
importance of each pathway being dependent on the vasculature studied. This 
section will describe the important vasoactive pathways.
1.4.1.1 Nitric Oxide
Nitric oxide (NO) is a freely diffusible gas generated from the amino acid L- 
arginine via a five-electron oxidation of a guanidino-nitrogen by nitric oxide 
synthase. Nitric oxide synthase (NOS) has three isoforms, named according to 
their original description; neuronal NOS (nNOS), endothelial NOS (eNOS) and 
inducible NOS (iNOS). eNOS is probably constitutively expressed within 
caveolae in the endothelial plasma membrane bound to calveolin(24) and releases 
NO following stimuli that act upon the endothelial cell surface. NOS is a
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myristoylated multi-domain enzyme consisting of an N-terminal oxygenase 
domain containing binding sites for heme, L-arginine and tetrahydrobiopterin 
( B H 4 )  and a reductase domain containing binding sites for flavine adenine 
dinucleotide (FAD), reduced nicotinamide adenine dinucleotide phosphate 
(NADPH), flavin mononucleotide (FMN) and calmodulin(25).
At rest, although some eNOS produces a tonic level of NO, the majority of eNOS 
is inactive, but an increase in intracellular calcium activates calmodulin that 
displaces the calveolin, and possibly also a polypeptide inserted into the FMN 
domains(26), and activates the enzyme(27). Intracellular calcium is increased by 
receptor-mediated agonists, such as acetylcholine (ACh) and bradykinin (BK) and 
physical stimuli, such as shear stress. The calmodulin binding allows NOS 
activation by enabling the reductase domain of the enzyme to transfer electrons to 
the oxygenase domain where the heme iron can bind O2 and catalyse the stepwise
j o
production of NO( ). By contrast iNOS is neither calcium nor calmodulin 
dependent, or constitutively expressed; instead its expression can be induced by 
inflammatory stimuli.
The active form of NOS that preferentially generates NO is a dimer of two 
identical subunits. The maintenance of this dimer is a process that requires the 
presence of adequate concentrations of B H 4 , the exact actions of which are 
unclear, though it probably acts in an allosteric and redox fashion, at least in part 
by facilitating L-arginine binding(29,30). In the absence of adequate B H 4 , or L- 
arginine, eNOS changes its phenotype to preferentially produce superoxide anion 
(C>2*X31) which will bind to NO producing peroxynitrite that is potentially harmful
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to the vasculature. Superoxide can also further deplete B H 4  by oxidation to 
dihydrobiopterin and thereby worsen the uncoupling of eNOS - thus producing a 
cascade of deleterious effects.
Once generated NO acts both within the lumen of the vessel, where it is a potent 
inhibitor of leukocyte adhesion and platelet activation(32), and also on surrounding 
smooth muscle cells and tissues. Vascular NO is involved in the control of 
angiogenesis both as a direct messenger and also by its control of growth factor 
expression(33). Within adjacent smooth muscle cells it increases soluble 
guanylate cyclase (sGC) activity by up to four hundred-fold(34), following binding 
of NO to two heme molecules and causing a conformational change(35). Once 
activated sGC leads to the production of cyclic 3’, 5’ guanosine monophosphate 
(cGMP) which reduces intracellular calcium and thereby causes smooth muscle 
relaxation(36).
In addition to stimulated increases in NO production basal eNOS activity is 
involved in the maintenance of vascular tone. Blockade of NOS activity 
systemically with N^monomethyl-L-arginine (L-NMMA) in healthy human 
volunteers resulted in an increase in blood pressure( ), and blockade of NOS 
activity in the forearm reduced forearm blood flow( ), indicating the importance 
of basal NO release. Endogenous basal NO-production has been demonstrated in 
coronary, pulmonary and systemic vasculature, indicating its importance in the 
regulation of flow in numerous vascular beds(39,40).
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Figure 1-2: Intra and intercellular NO signalling
T h i s  d ia g r a m  s h o w s  t h e  a c t iv a t i o n  a n d  i n t r a c e l lu la r  e f f e c t  o f  n i t r ic  o x i d e .  
B r a d y k i n in  ( B K )  a n d  a c e t y l c h o l i n e  ( A C h )  o r  s h e a r  s t r e s s  i n c r e a s e  in t r a c e l l u la r  
c a l c i u m  in  e n d o t h e l i a l  c e l l s ,  a c t iv a t e  c a l m o d u l i n  a n d  i n c r e a s e  e N O S  a c t i v i t y .  
A l t e r n a t i v e l y  c y t o k i n e s  a c t ,  in  a  c a l c i u m - i n d e p e n d e n t  w a y ,  t o  i n c r e a s e  n i t r ic  o x i d e  
t h r o u g h  i N O S  a c t iv a t i o n .  N i t r i c  o x i d e  d i f f u s e s  t o  s m o o t h  m u s c l e  c e l l s  ( s h o w n  i n  
b l u e )  a n d  b y  a c t iv a t i n g  g a u n y l a t e  c y c l a s e  c a u s e s  a  r e d u c t io n  in  c a l c i u m  
c o n c e n t r a t i o n s  a n d  m u s c l e  r e l a x a t io n .
1.4.1.2 Prostaglandins
P r o s t a g la n d i n s  a r e  p r o d u c e d  f r o m  a r a c h id o n i c  a c id ,  w h i c h  i s  r e l e a s e d  f r o m  
m e m b r a n e  l ip id s  b y  p h o s p h o l i p a s e  A 2  a n d  m e t a b o l i s e d  b y  c y c l o - o x y g e n a s e  
( C O X ) ( 41) .  C O X  h a s  t w o  i s o f o r m s ;  C O X - 1 ,  w h i c h  i s  c o n s t i t u t i v e l y  e x p r e s s e d ,
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and COX-2 that is induced by cytokines and differs by a single amino acid 
substitution in the enzymatic site. Nitric oxide or its breakdown product 
peroxynitrite may be involved in upregulating COX activity in inflammatory 
cells, though this process is complex and may be isoform and tissue dependent(42).
Endothelial cells produce a range of prostaglandins according to their tissue type, 
with prostacyclin and thromboxane A2 being the most important in the 
vasculature in health. Prostacyclin binds to specific receptors and activates 
adenylate cyclase to increase cyclic AMP(43) that, in smooth muscle cells, causes 
relaxation by protein kinase phosphorylation of contractile proteins(44) and, within 
the lumen, inhibits platelet aggregation(45). By contrast thomboxane A2 is a 
vasoconstrictor that acts as a potent platelet aggregator through a calcium 
dependent pathway(46). COX, particularly the constitutive isoform, may in certain 
circumstances also be an important source of oxygen free radicals(47).
In healthy individuals COX-1 inhibition with aspirin (and other non-steroidal anti­
inflammatory agents) has been shown to reduce blood flow in human forearm 
resistance vessels(48). This is suggestive of a role for prostanoids in vascular tone 
in the forearm, a phenomenon that has also been demonstrated in the coronary 
circulation(49). Anti-inflammatory doses of aspirin have been shown to prevent 
inflammation induced endothelial dysfunction in the forearm, though a direct 
local effect of prostanoid inhibition could not be demonstrated(50).
1.4.1.3 Endothelium-derived hvperpolarizing factor (EDHF)
In addition to NO and prostaglandins, a contribution to vasodilatation has been 
attributed to the unidentified EDHF. EDHF causes hyperpolarisation by a
24
potassium channel-dependent mechanism that leads to vasorelaxation. Not only is 
the character of EDHF uncertain, it may in fact vary between different vessels and 
has been “identified” variously as potassium ions, cytochrome P450 metabolites, 
C-type natriuretic peptide and myo-endothelial gap junctions(51;52). The relative 
importance of EDHF is thought to increase as the vessel diameter decreases, 
which correlates with an increase in the prevalence of gap junctions(53,54).
Human studies of the effects of EDHF are made difficult due to the uncertainty 
about its identity and the toxicity of many of the potassium channel blockers used 
in its study in animals; there has been some work with barium, ouabain and 
miconazole that may inhibit EDHF-dependent effects. Dawes et al have shown a 
reduction in basal flow and dilatation to 50-200pmol/min potassium infusion in 
the human forearm by plethysmography following the infusion of barium chloride 
and ouabain at doses thought to selectively affect inward-rectifier potassium 
channels(55). Inhibition of cytochrome-P450 metabolism, with miconazole, has 
also shown a reduction in NO-independent vasodilatation in the human forearm to 
bradykinin(56). In humans with hypertension an increased NO-independent 
vasodilator effect of bradykinin has been demonstrated, which is inhibited by 
ouabain, suggesting that the relative importance of non-NO pathways may change 
in diseased vessels(57).
1.4.1.4 Endothelin
Endothelins are a family of 21-amino acid vasoconstrictor peptides encoded by 
three genes, of which the predominant vascular form is endothelin-1. This acts in 
a paracrine and autocrine manner on two receptors, ETa and ETb, present on both 
endothelial cells and adjacent smooth muscle(58). The primary effects of ETa
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receptor activation are to cause vasoconstriction, cell proliferation and 
hypertrophy(59), though, in certain circumstances, stimulation of ETb can increase 
production of NO and prostacyclin -  leading to vasodilatation(60).
Endothelin infusion intra-brachially reduces human forearm blood flow in healthy 
volunteers^1), whereas antagonists cause an increase in flow suggesting a role for 
basal and stimulated endothelin release in determining vascular tone(62). Similar 
effects on basal tone have been demonstrated in human coronary arteries(63). In 
individuals with essential hypertension, endothelin and its antagonists have been 
shown, by some investigators, to have an increased effect compared to controls in 
both the hand vein and resistance vasculature (by plethysmography), indicating a 
potential increase in importance in diseased vessels^4,65). In addition to its tonic 
effects, endothelin has been shown to be chemoattractant for macrophages and 
monocytes and may be involved in smooth muscle mitogenesis(66), indicating a 
potential role in the development of atherosclerosis. In support of this, raised 
levels of endothelin are present in the plasma and tissue in proportion to the 
plaque burden of advanced atherosclerosis and in individuals with early 
atherosclerosis and cardiac risk factors( ’ ).
1.4.2 Regulation of circulating cells and cell adhesion
In addition to the release of paracrine substances described, the endothelium acts 
upon circulating cells and contributes to the regulation of their tendency to 
adhesion by a number of additional mechanisms. Early atherogenesis may be 
dependent upon the ability of the endothelium to capture leukocytes from the 
circulating blood, which then transform into foam cells. This is dependent upon
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three types of molecule expressed on the surface of endothelial cells -  selectins, 
integrins and immunoglobulins.
1.4.2.1 Selectins
Selectins are transmembrane glycoproteins containing an amino-terminal calcium- 
binding lectin domain that mediate the first step in leukocyte adhesion at the site 
of inflammation and injury(69). There are three types of selectin: E-selectin is 
synthesised in response to interleukin-1, tumour necrosis factor, oxygen radicals
7ftand bacterial toxins( ) and found primarily on endothelial cells; P-selectin is 
stored within Weibel-Palade bodies in endothelial cells and a-granules of platelets 
and can be very rapidly expressed following exposure to histamine or 
thrombin(71); L-selectin is basally expressed on leukocytes(72). The major ligand 
for all the selectins is a specific sialyl-Lewisx-type glycoprotein on circulating 
neutrophils and platelets.
1.4.2.2 Integrins
These are heterodimeric molecules consisting of non-covalently bound a and P 
subunits, which are divided into families according to the subtype of p subunit. 
Although there are large numbers of variations, three groups are most important in 
atherogenesis ( P 1 - P 3 X  ). The “very late appearing antigen” intergrins, Pi family, 
are the group expressed on endothelial cells and primarily mediate cell adhesion 
to extracellular matrix proteins such as collagen and laminin. Although expressed 
only on leukocytes, p2 intergrins are involved in the movement of cells across the 
endothelium. The endothelial ligand is dependent upon the a subunit, either being 
a member of the immunoglobulin family or other large matrix proteins(74).
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1.4.2.3 Immunoglobulin gene superfamilv
The immunoglobulin gene superfamily consist of a series of 90-100 amino acid 
domains that act as endothelial ligands for integrins expressed by leukocytes and 
platelets. These are involved in cell-cell interaction and signal transduction. The 
most important members are vascular cell adhesion molecule (VCAM-1), 
intercellular adhesion molecules (ICAM-1 and 2) and platelet-endothelial cell 
adhesion molecule (PEC AM). Both ICAM and VC AM expression (the latter of 
which is not expressed on endothelial cells basally) is upregulated by cytokines, 
primarily tumour necrosis factor and interleukin-1, leading to increased leukocyte
nc
adhesion( ). Recognised cardiovascular risk factors, such as oxidised low- 
density lipoprotein have been shown to increase ICAM-1 expression(76). In 
animal models VCAM-1 expression occurs early after the initiation of an
77atherogenic diet( ) and VC AM knock-out mice have reduced atherosclerotic 
lesion development^8).
1.4.3 Regulation of coagulation and  fibrinolysis
The endothelium is critically involved in haemostasis and this is central to the 
progression of atherosclerosis and the development of acute thrombotic 
syndromes. Primary haemostasis is initiated by injury to the vascular wall with 
the formation of a “platelet plug” and represents a failure in the balance between 
coagulation and fibrinolytic pathways. Under normal conditions the endothelium 
is anticoagulant by its regulation of enzymes within the coagulation cascade, most 
notably thrombin.
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Thrombin production is kept in check by antithrombin III bound to the endothelial 
surface on heparan sulphate proteoglycans(79). In the presence of damaged 
endothelium, thrombin acts to convert fibrinogen to fibrin and promote clot 
formation. In health thrombin also binds to a specific receptor, thrombomodulin, 
and upregulates the protein C and S pathways that degrade key clotting factors 
and reduce the activity of plasminogen activator inhibitor 1 (PAI-1), the
OA
predominant inhibitor of the fibrinolytic system( ). Inflammatory mediators and 
bacterial toxins downregulate the expression of thrombomodulin, and upregulate 
PAI-1 expression and vessel injury leads to further reductions by cleavage of 
thrombomodulin from the endothelium.
As a result of reduced PAI-1 production the endothelium favours fibrinolysis 
driven by tissue plasminogen activator (tPA) that increases conversion of 
plasminogen to plasmin. tPA activity is dependent upon PAI-1 levels as they 
form a stable inactive complex. NO enhances the activity of the fibrinolytic 
pathway by increasing tPA expression, as well as acting directly to reduce platelet 
aggregation by a prostaglandin-dependent pathway.
The endothelium also generates a number of pro-coagulant mediators, von 
Willebrand factor (vWF), fibronectin, tissue factor and thrombospondin, which 
are important in the haemostatic response. Thrombospondin promotes platelet 
aggregate stabilisation and depresses fibrinolysis, fibronectin contributes to fibrin 
clot stabilisation and vWF acts, in part, to allow the initial adhesion and further
o 1
aggregation of platelets( ). Tissue factor is an integral membrane glycoprotein 
associated with phospholipids, not constitutively expressed on endothelial cells,
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which binds factor-VII and triggers coagulation(82). Following injury, or 
exposure to proinflammatory cytokines, the endothelium can rapidly alter its 
phenotype to favour the procoagulant and adhesive pathways described.
1.4.4 Endothelial m onolayer integrity
The endothelium controls the extravasation of solutes, macromolecules and 
leukocytes. The healthy endothelium is usually a closed barrier to 
macromolecules that are taken up only by specific receptors or vesicular shunting. 
Following inflammation and angiogenesis the endothelium can become locally 
hyperpermeable. The degree of leak and its duration are dependent upon the 
stimulus, from transient pericellular gaps that develop following agonist 
stimulation to more prolonged defects following injury( ). Increased 
permeability lasting 60-90 minutes is induced by thrombin in a mechanism 
involving both calcium/calmodulin and Rho kinase activation. As indicated in the 
section 1.4.3 active thrombin is increased by inflammation and may be important 
in the associated breakdown in membrane integrity(84). Under basal conditions 
the effects of cyclic AMP on endothelial junctions and cyclic GMP on the
Of
inactivating thrombin maintain the integrity of the barrier( ).
1.5 Endothelial Dysfunction and Atherosclerosis
In healthy endothelium the production of vasodilators and anticoagulants 
predominate. Following endothelial injury there is a change in the phenotype of 
the vessel wall leading to the promotion of the development of atherosclerosis 
and, potentially in mature lesions, the destabilisation of existing plaques. The
30
pivotal importance of endothelial dysfunction is demonstrated in both animal and 
human models of atherosclerosis.
1.5.1 Animal data
Animal models of atherosclerosis, and high atherosclerotic risk, demonstrate
O Z  O Q  O Q . A A
impaired endothelium-dependent relaxation of conduit( ‘ ) and resistance( ’ ) 
vessels prior to significant anatomical changes. Generally endothelium- 
independent responses are not impaired, except in advanced lesions.
Later, anatomical changes involve an alteration in the orientation of endothelial 
cells, which appear more rounded, and changes in the subcellular cytoplasmic 
filaments(91). There are macroscopic differences in the intima and media with 
relative thickening of the latter and ultrastructural changes in the internal elastic 
lamina to produce a more porous structure(92'94).
1.5.2 Human data
Evidence exists for endothelial dysfunction in the presence of atherosclerosis and 
its risk factors in all arterial vessels that have been studied, suggesting it is an 
early event and that it may presage acute episodes. Endothelial dysfunction of the 
coronary and peripheral circulation correlates with the occurrence of 
cardiovascular events in patients at high risk of cardiovascular disease(95'99). 
Individuals with multiple risk factors for cardiovascular disease, with a high 
Framingham Risk Score, also have an associated reduction in endothelial 
function^ 00). Abnormalities in the coronary artery acetylcholine response, 
indicating endothelial dysfunction, have been shown in individuals without
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structural changes on intra-coronary ultrasound scans, indicating alterations in 
function even before structure(101). Given the invasive nature of assessing 
coronary endothelial function interest has focused on peripheral vessels as 
surrogates. Flow-mediated dilatation of human conduit arteries (a recognised test 
of endothelial function described later in this thesis; section 2.2.2) correlates with 
the extent of coronary atherosclerosis and the presence of coronary vascular 
abnormalities^ 02; 1 °3).
In young humans, endothelial dysfunction has been shown in peripheral conduit 
vessels, by assessment of flow mediated dilatation, in individuals with high 
cholesterol, diabetes, a family history of heart disease and smokers(104' 107). 
Similar abnormalities have also been shown in resistance vessels, by forearm 
venous occlusion plethysmography, in patients with hypercholesterolaemia, 
insulin dependent diabetes and hypertension^08' 1 n ) prior to the development of 
clinical atherosclerosis. Treatment of these risk factors for coronary artery disease 
with HMG CoA reductase inhibitors or LDL apheresis, or angiotensin-converting 
enzyme inhibition has been shown to improve endothelial dysfunction, an effect 
that may contribute to the reduction in cardiovascular events seen in randomised 
controlled trials(112'114). In hypercholesterolaemia, the role the nitric oxide 
pathway plays in endothelial dysfunction is shown by its improvement with oral 
or intra-venous administration of the substrate for NO synthesis, L- 
arginine(106,115), and in hypertension by the change in sensitivity to NO blockade 
with NG-monomethyl-L-arginine(116).
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The loss of normal coronary responses to agonists, acetylcholine, serotonin and 
substance P, and to a flow stimulus have all been demonstrated in atherosclerotic 
vessels with the retention of a normal response to endothelium-independent 
vasodilators(39;103;117' 120). There is evidence of a progressive loss of responses, 
with a reduced response to acetylcholine and serotonin initially, followed by 
reduced response to substance P and then to flow. This suggests that different
1 0 1 19^mechanisms may be affected at different stages of atherosclerosis( * ) .
In addition to changes in vasoactive function, abnormalities occur in the 
production of soluble factors by the endothelium in response to risk factors for 
atherosclerosis leading to a pro-coagulant phenotype(124). Reduction in 
vasodilator function by FMD has been associated with an increase in von 
Willebrand factor(125,126) which itself has been shown to be raised with 
hypercholesterolaemia and atherosclerosis(127 128). Dysfunctional endothelium 
releases increased quantities of adhesion molecules, notably selectins and ICAM 
and VC AM, and these have also been correlated with the presence and activity of 
atherosclerotic disease(129,130).
1.6 Inflammation in Atherosclerosis
There is increasing evidence that atherosclerosis is an inflammatory disease. The 
response-to-injury hypothesis proposes that inflammation initiates and promotes 
atherosclerosis through phenotypic changes in the endothelium leading to cell 
adhesion, inflammatory cell migration and thrombosis( ). Evidence to support 
this theory comes from both animal models and multiple human diseases, as will 
be discussed below.
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1.6.1 Animal data
Early studies have shown that inflammatory cells are major components of
111atherosclerotic plaques( ). As previously discussed, inflammatory cytokines and 
oxidised LDL lead to up-regulation of VCAM-1, which then aids endothelial 
binding of inflammatory leukocytes. Other chemokines stimulate monocyte 
chemoattractant protein-1 (MCP-1) expression that then allows bound cells to 
infiltrate the vessel wall. The presence of inflammatory cells within the 
endothelium perpetuates the local inflammatory response and, under the influence 
of further cytokines (especially monocyte-colony stimulating factor; MCSF), 
these cells engulf lipids and form foam cells. Mice deficient in either MCP-1 or 
MCSF show reduced inflammatory cell uptake and atheroma even in the presence
i i ^of an atherogenic diet( ’ ). Inflammatory cells may be important in the 
destabilisation of atherosclerotic plaques, with data from mouse models 
suggesting that inhibition of CD40 ligand, a potent signalling molecule between 
leukocytes, changes the character of the lesions to a more stable form(134).
Experimental models also demonstrate that infection accelerates the development 
and severity of atherosclerosis. Chickens infected with Mareks disease virus, 
develop atherosclerosis that closely resembles human disease and is preventable 
by vaccination(135). New Zealand white rabbits on a normal diet infected with 
Chlamydia pneumoniae develop intimal thickening and atherosclerotic lesions 
within the aorta that can be prevented by antibiotic treatment with 
azithromycin(136,137). In cell culture studies C. pneumoniae has been shown to 
induce a murine macrophage cell line to change to a foam cell phenotype(138). It 
is proposed that this is due to the ability of the chlamydial lipopolysaccharide to
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stimulate lipid uptake by the macrophages, though, in contrast to other 
endotoxins, it does not induce a strong enough response to facilitate pathogen 
clearance.
Animal models have suggested that systemic inflammation can have generalised 
effects, additional to local changes, and that these can accentuate a prior 
predisposition to atheroma. In Apo-E knockout mice, infection with murine 
herpes virus 8(139) or cytomegalovirus^40) leads to accelerated atherosclerosis, as 
does endotoxin treatment of hypercholesterolaemic rabbits(141). The use of C. 
pneumoniae in ApoE-deficient mice, however, has produced contradictory results 
dependent on the age of the animals, their sex and the exact characteristics of the 
infections used(142,143).
Studies with double knock out animals have indicated the importance of the 
adaptive immune system to the development of atherosclerosis. 
Hypercholesterolaemic Apo-E knockout mice produce significantly fewer 
atherosclerotic lesions if crossed with immunodeficient scid/scid mice(144). The 
tendency to atheroma formation could be re-instigated by the transfer of CD4+ T 
cells from atherosclerotic donors to deficient mice.
These changes with inflammation could be mediated by a number of different 
mechanisms. Infectious agents may increase atherosclerosis directly, by initiating 
an inflammatory response in the vessel wall, or indirectly either by a generalised 
immune response or by inducing autoimmunity against cell wall components. 
That autoimmune cross-reactivity contributes to the inflammatory state is
35
supported by the observation that immunisation of mice with endogenous p2 
glycoprotein-I (a ligand recognised by anti-phospholipid antibodies)(145) or heat 
shock protein 60/65 led to increased atherosclerosis(146). Similarly 
normocholesterolaemic rabbits have increased atheroma formation when 
immunised with heat shock protein 60 or Mycobacterium tuberculosis, which is 
rich in this antigen, and heat shock protein-60 expression is detectable within the 
plaques(147 148).
1.6.2 Human data
1.6.2.1 Acute infections and cardiovascular disease
There is evidence for an increased incidence of acute coronary events following 
acute infections. This could occur through an alteration in the properties of 
inflammatory cells within atherosclerotic plaques to favour rupture, by the 
induction of endothelial dysfunction (which is discussed further in section 1.9) or 
by changes in the coagulation system to favour thrombosis.
Short-term increases in the risk of atherothrombotic disease have been seen 
following a wide range of inflammatory insults including respiratory infections, 
sepsis and surgery(149' 151). Patients presenting with acute coronary syndromes 
have raised inflammatory cytokines on admission and their level predicts
1 Ooutcome( ). That this is not true for individuals with variant angina suggests 
that ischaemia per se does not increase cytokines.
Atherectomy samples taken during percutaneous coronary interventions support a 
role for acute inflammation. Meuwissen et al showed a correlation between the
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presence of excess macrophages and T lymphocytes and the risk of future 
episodes of unstable angina(153). These histological changes favour plaque 
rupture and consequent thrombosis. In children, acute infections have been 
shown to increase the presence of oxidised LDL and to be associated with a 
greater carotid intima medial thickness on ultrasound three months later(154).
Cytokines released in response to acute infection induce an acute phase response 
that favours thrombosis by increasing fibrinogen, PAI-1 and tissue factor 
expression and increasing platelet expression of CD40. Fibrinogen concentration 
is itself predictive of future cardiovascular events(155). Ex vivo experiments with 
human monocytes have shown that they activate the clotting cascade more 
readily, largely through tissue factor expression, when infected with C. 
pneumoniae or cytomegalovirus (CMV)(156).
The incidence of acute myocardial infarction and strokes increases in the winter
1 <7months, co-incident with an increase in the incidence of influenza infections ( ). 
However, whether vaccination to reduce the incidence of influenza prevents 
events is not clear, as trials have found contradictory effects(158;159).
1.6.2.2 Chronic infections and cardiovascular disease
In children under 15 years Pesonen et al showed, in a necropsy study, a 
correlation between infectious disease at the time of death and intimal thickening, 
which could be a precursor to atherosclerosis(160). Serological studies have 
suggested that numerous agents, including H.pylori, C. pneumoniae, CMV and 
herpes simplex, may be involved in the inflammatory process that leads to
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atherosclerosis(161;162). In large studies there is a weak association between IgG 
antibodies against H. pylori and future cardiac events and a non-significant trend 
in favour of C.pneumoniae{ ), although in a later metaanalysis Danesh et al 
could not demonstrate a relationship with H. pylori(164).
Associations shown by serological data are weakened by the common nature of 
these infections and the questionable importance of acute serological changes to 
chronic infective processes. It has been suggested that IgA levels are more 
relevant, as they may reflect ongoing infection, and these have been associated 
with acute coronary events. In addition, the lack of changes in antibody 
expression may mask an underlying cell mediated immune response that is more 
relevant to the development of atherosclerosis.
Local infection of atherosclerotic plaques has been shown, with varying degrees 
of certainty, for herpes viruses(162), C. pneumoniae(165), H. pylori(166) and dental
1 f s lpathogens( ) by a combination of electron microscopy, polymerase chain 
reaction, in situ hybridisation and directly from cultures. These data are also 
somewhat inconsistent as agents may only be detectable by one technique and in 
some cases are found in normal as well as diseased portions of arteries.
If infections are relevant to the development of cardiovascular disease they may 
allow the reduction in the risk of disease by treatment with readily available 
antibiotics. Given the relative preponderance of data for C pneumoniae, and to a 
lesser extent H. pylori, antibiotics against these agents have been investigated. 
Parchure and coworkers have shown that 5 weeks of treatment with azithromycin
38
leads to an improvement in endothelial function compared to placebo(168). 
Antibiotic trials using clinical endpoints have been less clear. A secondary 
prevention trial of azithromycin (AZACS) failed to show any reduction in 
cardiovascular events after a short course of antibiotics(169). The ROXIS study, 
using roxithromycin, only showed a significant effect in secondary prevention for 
the combined endpoint of death, myocardial infarction and recurrent 
ischaemia(170). In a further secondary prevention study using roxithromycin even 
the secondary combined endpoint did not achieve significance, although this study 
was under-powered due to poor recruitment(171). In the ACADEMIC trial, of 
azithromycin, the authors showed a reduction in inflammatory markers without
1 70any change in the clinical outcome in the 2-year follow-up( ). Using 
clarithromycin as the treatment, the CLARIFY study showed a trend towards a 
reduction in cardiovascular events and a significant fall in the secondary endpoint 
of cardiovascular events and stroke(173). It has been pointed out by a number of 
authors that in order to gain effective clearance a much longer duration of 
antibiotic treatment is required(174). Larger studies with greater durations of 
antibiotics and longer follow-up periods are at present underway that will 
hopefully eliminate these areas of uncertainty.
A body of data has linked chronic periodontal infections with an increased risk of
1 <7C
cardiovascular disease( ), though this needs to be treated with caution to ensure 
it is not confounded by social class. In some studies there appears to be a 
correlation between the severity of the dental disease, in terms of alveolar bone 
loss, and the degree of coronary atherosclerosis^76). This has been supported by 
animal data showing that oral inoculation of the periodontal pathogen
39
177Porphyromonas gingivalis is associated with accelerated atherosclerosis( ). 
Although the mechanism of this deleterious effect is not clear, studies in humans 
have shown an association between chronic severe dental disease, an 
inflammatory state and impaired endothelial function^78).
The contradictory nature of serological and antibiotic intervention studies and 
their individual lack of power, has lead to the development of the concept of the 
“pathogen burden”, the presence of a combination of multiple viruses and
1 7 0bacteria, as a cardiovascular risk factor( ).
This can be further refined by considering the response of the host to infections 
and thereby their propensity to lead to atherosclerosis. Responses could in part be
i findetermined by the sex of the host( ) or modified by genetic make-up. 
Polymorphisms of the CD14-monocyte-receptor gene promoter (the receptor for 
bacterial lipopolysaccharide), the tumour necrosis factor-a (TNFa) gene and the 
interleukin-1 gene have all been associated with an increased development of
1 O 1
coronary heart disease in the presence of inflammatory stimuli( ).
1.6.2.3 Chronic inflammatory conditions and cardiovascular disease
In addition to low-grade chronic infections as a stimulus for atherosclerosis it has 
been suggested that non-infectious inflammatory processes could also predispose 
to cardiovascular disease. Autoimmune diseases produce a similar inflammatory 
environment to infections, with raised cytokines, acute phase proteins, and 
cellular adhesion molecules and activated inflammatory cells.
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Epidemiological studies have shown an excess of cardiovascular disease in 
individuals with systemic lupus erythematosis (SLE) (up to fifty-fold) and 
rheumatoid arthritis that cannot be explained by other “classical” risk factors 
(I82;i83). in SLE an association has been noted between the presence of TNFa and 
its soluble receptors (sTNFRl and 2) and cardiovascular disease(184). Treatment 
with TNFa antibodies has been shown to reduce disease activity in rheumatoid
1 or
arthritis and also to improve endothelial function in these patients( ). Effects of 
anti-TNFa antibodies on cardiovascular outcome have not been assessed. SLE 
may also increase the risk of atherosclerosis by mechanisms other than a 
generalised induction of an inflammatory response. For example SLE leads to the
i oz
generation of autoantibodies against oxidised LDL( ), which, in animal models, 
have been shown to combine with anti-cardiolipin p2-glycoprotein-l antibodies
1 87and favour plaque formation( ). Whether the increased prevelance of the 
antibodies to oxidised LDL are themselves pathogenic or reflect an increased 
concentration of oxidised lipids in this condition, is not yet clear. SLE has also 
been shown to be associated with markers of increased oxidant stress, which may
i oo
also explain the increased oxidised lipids and consequent atherosclerosis( ). 
Later in this section the association between C-reactive protein (CRP) values and 
cardiovascular risk will be explored (section 1.8.1.1). Interestingly, although SLE 
is correlated with an increased cardiovascular risk it is also associated with 
polymorphisms of the CRP gene, which lead to reduced basal and stimulated 
serum concentrations^89).
In giant cell arteritis, an inflammatory condition associated with ischaemic 
cerebral events, a reduced concentration of the inflammatory cytokine interleukin-
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6 (IL-6) was associated with increased adverse events(190). It was suggested in 
this paper that the lack of IL-6 retards the development of neo-vascularisation that 
may protect from ischaemic events. Therefore although it is clear that chronic 
inflammatory conditions are associated with increased atherosclerosis, it is not yet 
apparent whether this is a consequence of the inflammation or a more direct 
autoimmune phenomenon.
1.6.2.4 Inflammatory markers and cardiovascular disease
In humans, elevated concentrations of circulating markers, even in the pre-clinical 
phase of disease, suggest that inflammation is important to pathogenesis. 
Observational studies have shown a correlation between raised levels of CRP, IL- 
6, intracellular adhesion molecule-1, serum amyloid A, E-selectin, P-selectin, 
TNFa, fibrinogen, vWF, PAI-1, homocysteine or prior infection with common 
pathogens, and atherosclerosis and its complications(191"195). This will be covered 
in more detail in section 1.8.1.1.
1.6.2.5 Atherosclerosis itself as an inflammatory stimulus
Several lines of evidence suggest that atherosclerosis is not only influenced by 
systemic inflammation, but that pro-inflammatory mechanisms occur locally in 
lesions. Histological data shows the presence of inflammatory cells within 
atherosclerotic plaques, primarily macrophages early on in the process and then 
increasingly neutrophils during periods of instability^96).
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Activated macrophages within atherosclerotic plaques have been shown to 
increase the expression of pro-inflammatory cytokines such as TNFa, IL-ip, IL-8,
1 Q*1. 1 Q O
MCP-1 and membrane expressed type 3 matrix metalloproteinase (MMP)( ’ ). 
Activated endothelial cells overlying atherosclerotic plaques express adhesion 
molecules (VCAM-1, ICAM-1 and selectins) in the same way as activated 
endothelial cells in post-capillary venules. These mediators could then play a role 
in developing and destabilising lesions within the vasculature.
Generalised inflammation within the coronary tree has been shown in individuals 
with acute coronary syndromes by the presence of activated neutrophils not just at 
the site of the “unstable” plaque(199). The presence of inflammation within
1 ftplaques has also been demonstrated by both [ F]-flurodeoxyglucose positron 
emission tomography scans and assessment of the local temperature of plaques 
and been shown to be correlated with the presence of increased numbers of 
inflammatory cells and a detrimental clinical outcome(200;201). As such the 
association between inflammatory markers and outcome may reflect a response to 
unstable plaques, rather than a response of plaques to inflammatory markers.
1.6.2.6 Effects of cardiovascular therapies on the indices of the 
inflammatory response
A number of therapies have been shown to significantly improve outcome in 
cardiovascular disease. Most dramatically acetylsalicylic acid (aspirin) has been 
shown to reduce atherothrombotic events in the coronary, cerebral and peripheral 
circulations in both the short and long term(202). This effect of aspirin is generally 
thought to be largely due to its inhibition of prostanoid production by platelets,
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which is anti-aggregatory, although anti-inflammatory effects cannot be 
discounted. Aspirin is known to reduce levels of inflammatory marker( ). In 
support of an anti-inflammatory role, the protective effect of aspirin appeared 
greater in those individuals with an elevated baseline CRP value in one 
epidemiological study(204).
Anti-inflammatory mechanisms have been proposed as a mechanism of action of 
HMG-CoA reductase inhibitors (statins) and angiotensin converting enzyme 
inhibitors (ACEi) in addition to their effects on lipid profiles( ) and renin- 
angiotensin system(206) respectively.
Studies of human carotid atherectomy specimens have shown a change in plaque 
morphology after 3 months of statin treatment to one containing greater amounts 
of collagen and a reduction in inflammatory cells and MMP-2 expression, which 
is typical of plaques at low risk of rupture( ). Whether this apparent anti­
inflammatory effect is due to reduction in oxidised lipid locally (over and above 
that seen systemically) or an as yet undefined alternative action of statins is not 
apparent. Likewise ACEi could be potentially anti-inflammatory by their effects 
on bradykinin concentrations( ) or through the inhibition of angiotensin-II 
induced IL-6 production(209). However, whether these are important effects in 
vivo over and above the known alteration in blood pressure induced by these 
agents is not clear.
In the same way, favourable effects on the level of inflammatory markers have 
been reported for both peroxisome proliferator-activated receptor (PPAR)-a and
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910 '9  11PPAR-y agents, in particular their ability to lower CRP concentrations( ’ ).
These effects may represent direct changes by reduction in IL-1(212), or rather 
reflect the positive effects of increased high-density lipoprotein and improved 
glycaemic control.
1.7 Focus of this thesis
This introduction indicates the importance of inflammation and endothelial 
dysfunction in the development and progression of atherosclerosis. The 
remainder of this chapter will focus upon the two areas of particular interest that 
form the background to the experiments described in this thesis.
Firstly it will explore the present understanding of the relationship between 
inflammatory markers and cardiovascular disease, with a very strong emphasis on 
C-reactive protein. Secondly there will be a discussion of the phenomena of 
inflammation-induced endothelial dysfunction.
These areas will be discussed in detail, as the thesis will then go on to describe a 
set of experiments that attempt to determine the direct vascular effects of CRP 
both in vitro and in vivo and further work looking at the mechanisms of 
inflammation-induced endothelial dysfunction.
45
1.8 Inflammatory markers and cardiovascular disease
1.8.1 O bservational s tu d ies  of inflam matory products and 
cardiovascular d isease
If sub-clinical inflammation is important in atherosclerosis, concentrations of 
inflammatory factors should be associated with the risk of future cardiovascular 
disease and their measurement might serve as a useful predictive tool. Given the 
proposition that “traditional” risk factors incompletely predict the occurrence of 
cardiovascular disease at both a population and individual level a great deal of 
interest has been focused on so called “novel” risk factors. Some of these are 
other biochemical abnormalities with a basis in basic research, such as 
homocysteine, whereas others are sub-fractions of existing parameters, like 
lipoprotein a (Lpa). This section will discuss the association of inflammatory 
markers and the risk of future cardiovascular disease.
1.8.1.1 C-reactive protein
There has recently been an enormous interest in using CRP concentration as a tool 
to predict clinical atherosclerotic events. This has largely been fuelled by the 
development of high sensitivity assays that allow the reliable quantification of 
CRP concentrations within the range of values observed in overtly healthy adults 
(less than 5mg/L). Individual differences in the concentration of CRP in this 
range can stratify risk in individuals without evident cardiovascular disease.
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In initially healthy male individuals, enrolled in the MONICA study, a raised 
baseline CRP concentration was associated with an increased future risk of an
atherothrombotic event over a follow-up period of 8 years (hazard ratio 1.5, 95%
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confidence interval 1.14-1.97)( ). A similar result was seen in the Physician’s
Health Study where healthy men were followed up for over 8 years and CRP 
concentration at baseline again predicted the frequency of atherothrombotic events 
(odds ratio 2.9 comparing lowest to highest quintiles of CRP [0.1-0.7mg/L vs. 
3.8-15mg/L])(204). Likewise baseline CRP concentrations were found to predict 
the development of peripheral vascular disease(214). The Women’s Health Study 
also showed that a raised basal CRP value, in apparently healthy women, was 
predictive of atherothrombotic events during the 3 year follow-up of this study 
(relative risk 4.8 for same groups as described in Physicians Health Study)(194). 
In a further healthy population, women on average have a higher CRP 
concentration than men (but lower cardiovascular risk), and this is further 
increased if they are on hormone replacement therapy. It is not clear, however, 
whether this increase in CRP is correlated with an increased risk or whether the 
baseline value for normality is different in men and women( ).
In the setting of an acute coronary syndrome CRP has been shown in a number of 
studies to predict future risk of recurrent events. In the FRISC study, a 
randomised controlled trial of low molecular weight heparin in acute coronary 
syndromes, a CRP concentration of <2mg/L was associated with a 5.7% risk of a 
cardiovascular event during follow-up (mean 37 months), whereas a 
CRP>10mg/L carried a 16.5% risk (P<0.01)(216). A European study showed a 
similar trend over a shorter follow-up period (mean 6 months)(217). Similarly, the
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degree of elevation of CRP following an acute myocardial infarction stratifies
o
individuals in terms of the risk of death and their life expectancy( ).
Coronary angioplasty for the treatment of obstructive atherosclerosis is known to 
carry a degree of risk according to the anatomy of the disease and the pre-morbid 
condition of the patient. CRP concentration, prior to the procedure, has been 
shown to predict an adverse event, myocardial infarction and death, in the 
following 30 days, after adjustment for other risk factors(219). In a detailed study 
of the time course of changes in CRP concentration following angioplasty, a rise 
in inflammatory markers was only seen in those with unstable symptoms and a 
pre-existing increase in CRP value( ), thereby pointing towards a group with 
increased tendency to develop a marked inflammatory response. Following 
percutaneous intervention, the rise in inflammatory markers, CRP, IL-6 and 
TNFa, is predictive of an adverse outcome, while intra-procedural glycoprotein 
Ilb/IIIa inhibition damps this inflammatory response(221). The ability of CRP to 
predict outcome of coronary artery bypass grafting surgery is less clear as some 
studies indicate a link and others do not(222 223). CRP values may also predict the 
morphology of coronary plaques. In a study of patients presenting with an acute 
coronary syndrome intravascular ultrasonography demonstrated a correlation 
between a raised CRP (>3mg/L) and the presence of plaque rupture, though 
whether CRP was pathogenic or a marker could not be differentiated^24).
It is important to place CRP values within the framework of existing predictors of 
cardiovascular risk. One study has suggested that CRP concentration is actually a 
superior predictor of cardiovascular disease than any other risk factor(225), though
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this has been challenged by a large prospective analysis of an Icelandic 
population( ). Interestingly an inflammatory milieu has been shown to predict 
the development of Type 2 diabetes mellitus, itself a powerful risk factor for 
cardiovascular disease, though in this case only IL-6 concentrations were 
predictive when body habitus was controlled for( ). Likewise a cross-sectional 
study and a prospective cohort study have suggested an association between CRP 
values and hypertension, indicating it may, in part, have an inflammatory 
aetiology(228;229).
Not every correlation study has identified CRP as a predictor of adverse outcome. 
CRP concentrations do not correlate with the presence of coronary artery 
calcification, which is thought to represent existing disease and is itself a predictor 
of future complications^30).
The stimulus leading to the increased basal levels of CRP is not clear. It may 
represent a response to a mild systemic inflammatory stimulus, the presence of 
atherosclerosis or reflect an underlying genetic tendency. Studies with 
monozygotic twins have shown a significantly higher correlation of baseline CRP 
concentrations compared with dizygotic twins, indicating an important genetic 
component to the control of basal production(231). A number of genetic variations 
in both the CRP gene and the genes of the cytokines that stimulate its release have 
been described. A dinucleotide repeat polymorphism in the intron of the CRP 
gene has been shown to predict CRP values(232), as has a polymorphism in the 3’ 
untranslated region (+1444C/T)(233). Further variants, which are associated with 
an increased antinuclear antibody production, are also predictive of lower basal
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CRP concentrations^89). Likewise polymorphisms in IL-1 and IL-6 can alter the 
basal and stimulated concentrations of these cytokines, and thereby change CRP 
values(234;235). The importance of these genetic factors in the use of CRP as a 
predictive marker is not yet fully determined(236).
Most of the studies described rely on a single measure of CRP at baseline. This 
has been questioned by a reanalysis of the MONICA database, which shows an 
intra-subject variation in CRP concentrations on re-measurement after 3 years, 
with a reliability coefficient of only 0.54. The authors suggest that CRP ought to 
be repeated three times before confirming a baseline level( ). A much smaller 
degree of variation was found when CRP was reassessed over a short period, such 
as a few days. Similarly, in the Icelandic population, where remeasurement 
occurred after 12 years, they found a correlation of 0.59( ).
1.8.1.2 Interleukins
Similar studies looking at the prognostic implications of raised inflammatory 
cytokines have been performed, though these suffer from the more dynamic 
nature of these markers in response to intercurrent infections and circadian 
rhythms.
Increased concentrations of IL-6 have been shown to be predictive of future 
cardiovascular events in a prospective study of nearly 15000 apparently healthy
i i o
men( ). In individuals with angiographically documented coronary artery 
disease, IL-6 and IL-1 P predicted the presence of ischaemia on 48 hour Holter 
monitoring (IL-6 concentration 3.9pg/ml for cases vs. 1.7pg/ml for controls) and
50
IL-1 p predicted multi-vessel disease( ). Unlike CRP, concentrations of IL-6 are 
predictive of the presence of diffuse atherosclerosis, both in the form of three- 
vessel coronary artery disease and peripheral vascular disease( ).
Following admission with unstable angina IL-6 and IL-IRa levels predict the risk 
of in hospital complications, particularly with comparisons between a sustained 
cytokine response and a rapidly falling inflammatory level(152). In the setting of 
unstable angina IL-IRa has also been shown to discriminate between individuals 
with atheroma and stable and unstable symptoms, and to predict prognosis(240).
Recurrent ischaemic cardiovascular events have been shown to be more common 
following an acute myocardial infarction in individuals with raised TNFa(241). In 
a prospective study of cardiovascular events, in a group of subjects with 
angiographically documented coronary artery disease, IL-18 was shown to be 
predictive of an adverse outcome, even after controlling for other inflammatory 
markers(242).
1.8.1.3 Other inflammatory markers
Fibrinogen, which is an acute phase protein, has been shown to predict the 
occurrence of cerebrovascular events and advanced atherosclerosis, though not 
plaques with a large lipid content which are thought to be more prone to 
rupture(243). Another acute phase protein, serum amyloid A, has been shown to 
predict mortality in the setting of an acute coronary syndrome(244).
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Macrophage numbers are increased in unstable atherosclerotic plaques and serum 
monocyte chemoattractant protein-1 concentrations have been shown to predict 
future cardiovascular death following an acute coronary syndrome(245).
In addition to inflammatory markers other soluble factors have been found to be 
predictive of cardiovascular disease and of endothelial dysfunction. In particular 
soluble adhesion markers have been correlated with future events in individuals 
with documented coronary artery disease, though only sVCAM-1 remained 
predictive once markers of inflammation were included in a regression 
analysis(246). However, doubt has been cast as to whether the presence of raised 
soluble adhesion markers adds any information over that provided by other risk 
factors(247). This is important mechanistically in terms of inflammation as 
VCAM-1 in critical to the adherence of inflammatory cells to the endothelium and 
thereby their margination and the commencement of changes within the vessel 
wall.
1.8.1.4 Conclusion
As CRP has become pre-eminent due to its high degree of self-correlation over 
time, easy assay and strength of association sections 1.8.2 and 1.8.3 will discuss 
this protein further. The observed association of CRP concentrations with 
cardiovascular risk has driven a great deal of interest in the idea that CRP may be 
causal in atherosclerosis. This work is detailed in a later section (1.8.3), though it 
is important to state early on that an association does not indicate causality. All of 
these correlation studies rely on adequate control for confounding, for example by 
smoking and age, which are known to be pro-inflammatory. Even in those where
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this has occurred this does not allow for unmeasured confounders, such as other 
inflammatory markers, and the possibility of reverse causality, as would occur if 
atherosclerosis itself raised CRP concentrations. To understand this better the 
next sections (1.8.2 and 1.8.3) will describe the physiology and pathophysiology 
of CRP.
1.8.2 Physiology of CRP
CRP was identified by its ability to bind the somatic C-polysaccharide of 
streptococcus pneumoniae and was the first acute phase reactant described(248). 
The acute phase response consists of non-specific physiological and biochemical 
responses to most forms of tissue damage. This involves the synthesis of a 
number of largely hepatic proteins, under the control of cytokines generated at the 
site of injury. In healthy young adult blood donors the median circulating CRP 
concentration is 0.8mg/L (90th centile 3.0mg/L), though this can increase during 
an acute infection to more than 500mg/L(249). In this section I will describe the 
structure, metabolism and proposed functions of CRP.
1.8.2.1 Structure of CRP
The human CRP molecule consists of five identical non-glycosylated polypeptide 
subunits each containing 204 amino acids with a total molecular weight of 115135 
Daltons. The protomers are non-covalently linked in an annular configuration to 
form a cyclic pentamer(250). As such CRP is one of two human calcium- 
dependent ligand-binding plasma protein pentraxins, the other being serum 
amyloid P component, from the Greek penta (five) ragos (berries). Each subunit
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has a characteristic “lectin-fold” made up of a two-layered p sheet with flattened 
jellyroll topology. The ligand-binding site, on the concave surface, consists of 
loops with two calcium ions bound 4A apart by protein side chains, while the 
convex face carries a single a helix(250).
Figure 1-3: Structure of C-reactive protein showing the pentameric 
structure and calcium ion binding sites(249).
The structure of CRP, in terms of sequence, subunit organisation and protein 
folding, is highly conserved with homologous proteins throughout the vertebrates 
and even in the arachnid Horseshoe crab (Limulus polyphemus). However there 
are variations with respect to ligand-binding specificity, the presence and 
distribution of glycosylation and protomer assembly(251,252). As a consequence 
species differ in terms of the capacity o f the CRP to precipitate and aggregate 
ligands, and to activate autologous complement proteins(253).
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1.8.2.2 Synthesis and Metabolism
Plasma CRP is produced by hepatocytes, predominantly under the control of IL-6, 
in response to “tissue injury”. IL-1 p or TNFa alone cannot increase CRP 
production in human cells(254255), though IL-1 can act synergistically with IL-6 to 
increase CRP transcription. Although extra-hepatic sites of CRP synthesis have 
been proposed, their importance and whether they can secrete as well as 
synthesise CRP is not clear(256). The half-life of CRP is very stable at 19 hours, 
being unchanged by autoimmune diseases, diabetes, sepsis or neoplasia and as 
such the circulating concentrations are almost entirely dependent upon the 
synthesis rate( ). In this study 90% of the labelled CRP used was recovered in 
the urine by the 7th day, where it was excreted unchanged.
CRP is encoded by a single gene on chromosome 1 which consists of two exons 
with an intervening intron and 5’ promoter and 3’ untranslated region. 
Polymorphisms of this gene and the genes for the stimulatory cytokines were 
discussed in section 1.8.1.1. Two pathways have been found to be important in 
the transduction of the effect of IL-6. In response to IL-6 CCAAT/enhancer 
binding protein beta and delta bind to multiple sites on the CPR promoter, 
including a critical site at -53. IL-6 has also been shown to act through signal 
transducer and activator of transcription-3 (STAT-3), which binds at -108 in the 
CRP promoter. Whereas IL-1 activates first the Rel protein/NF-kB family of 
transcription factors, in particular Rel p50 protein (or in some cases p50/p65 
heterodimers) that then recognises a non-consensus kappaB site at -46 in the
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promoter(258). Although IL-1 p alone cannot increase CRP production, maximal 
stimulation is only achieved when both these overlapping sites are occupied. 
Over-expression of nuclear factor-kappaB (NF-kB) can lead to a similar 
synergism in the IL-6 stimulation of CRP production, perhaps at the classical NF- 
kB binding site at -2652(259).
Shortly after synthesis, monomers of CRP are formed into the stable pentameric 
structure within the endoplasmic reticulum (ER). There is some evidence in 
rabbit models that CRP can be retained in the ER and its efficiency of secretion
9 Aftcan be increased in the setting of an acute phase response( ). It is not clear if 
this also occurs in humans and caution must be exercised when comparing species 
as basal CRP values vary and CRP does not behave as an acute phase protein in 
all species. For instance the basal circulating concentrations in the rat are high 
(300-600mg/L) and do not vary with acute injury(251).
Although human CRP concentrations increase during illness they are reasonably 
stable over time (provided acute inflammatory episodes are discounted, the 
variation is similar to that seen with cholesterol), and in particular do not appear
7A1to possess diurnal variation( ). This is despite a well recognised diurnal 
variability in IL-6 concentration ). This most likely represents a “damping” of 
the diurnal variation of IL-6 since a rise in CRP lags by approximately 6 hours 
after exogenously administering IL-6(263).
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CRP concentration is positively correlated with age, body mass index (BMI),
911smoking history, hypertension and diabetes and may vary with menstruation( ). 
Smoking and obesity (BMI>30 vs <25kg/m ) are each associated with a doubling 
of CRP value. Eating does not alter CRP values and there are no specific 
pharmacological inhibitors of production. Agents, such as statins, that reduce 
CRP most likely acting by altering the level of inflammatory stimulation(212).
Some inflammatory disorders, notably systemic lupus erythematosus, 
scleroderma, ulcerative colitis and leukaemia, result in a disproportionately small 
rise in CRP. In these conditions, the ability to increase CRP concentration is 
maintained during infection and it is not clear at this stage why this marker does 
not adequately reflect the level of inflammation of the underlying condition(249). 
It is however of interest, as although CRP does not rise with SLE, this condition is 
associated with a marked increase in cardiovascular disease, as discussed in 
section 1.6.2.3.
1.8.2.3 Function of CRP
Although it is clear that CRP forms part of the acute phase response it is less clear 
exactly what functions it performs. It has been shown to be able to recognise and 
preferentially bind to phosphocholine and oxidised lipoproteins in damaged cell 
membranes, though not native lipoproteins(264). CRP is also able to recognise 
other autologous ligands, including phosphoethanolamine, small 
ribonucleoprotein particles and extrinsic ligands including many glycan and 
phospholipid constituents of microorganisms(265). This specific binding repertoire
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allows it to selectively attach to capsulated bacteria, fungi, parasites and apoptotic 
cells.
Human CRP bound to these macromolecular ligands, or aggregated, is recognised 
by C lq and can therefore activate the classical complement pathway. Through 
engaging the adhesion component C3 this results in the formation of the terminal 
membrane attack complex (C5-C9)( ). There is some evidence that bound CRP 
is also able to activate the alternative complement pathway by binding factor H 
and activating C5 esterase(267). There is conflicting data as to whether rat CRP is 
able to activate its autologous complement ’ ). Activation of complement will 
lead to opsonisation and clearance of pathogens and necrotic host tissue. Given 
these observations it has been proposed that CRP forms part of the innate immune 
system, which provides initial protection prior to the upregulation of the acquired 
immunity.
Some authors have proposed that CRP possesses a low affinity Fey ligand that 
will allow it to opsonise cells directly and activate the immune system in the same 
way as immunoglobulins( ). These observations have been questioned in terms 
of the quality of controls used and in particular the use of whole IgG anti-CRP 
antibodies in the studies. The Fey ligands on this IgG are of very high affinity and 
any contamination would swamp any proposed effect of CRP. In carefully 
controlled studies using recombinant highly purified CRP binding to Fey ligands 
could not be confirmed(270,271).
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Support for a protective role for CRP has been provided by studies with 
transgenic mice expressing rabbit CRP. In this model the animals are relatively 
protected from lethal endotoxaemia, when compared to litter mates not over
979expressing CRP( ). Mice can also be protected from Streptococcus pneumoniae 
by either passive injection of human CRP(273) or transgenic modification(274). 
Importantly these effects require the presence of complement and do not appear to 
be mediated by the controversial Fey ligands, suggesting that to a large extent the 
protective effects of CRP are mediated by its ability to activate complement(275). 
It is of note that CRP is not an acute phase protein in mice and the effects seen are 
thereby mediated by the heterologous human pentraxin.
A large number of other potentially pathological functions have been ascribed to 
CRP, which will be considered in the next section (1.8.3). Caution has to be 
applied to a large amount of this work as not all authors have rigorously 
controlled for potential contamination of substrates, especially with 
lipopolysaccharide and immunoglobulins, or accounted for the possible pitfalls of 
using heterologous CRP to the system being studied. Particular importance also 
has to be drawn to the near universal usage of commercially sourced CRP (from 
Calbiochem, Beeston, UK), which is produced for use as a standard to calibrate 
CRP assays and which is not necessarily completely free of protein contaminants 
and is supplied with a buffer containing sodium azide as an anti-bacterial agent. 
Previous work has shown the importance of sodium azide as a mitochondrial 
respiratory chain inhibitor and metabolic poison and as such it may interfere with 
any physiological process under investigation^76'278). A group using rabbit 
vessels showed that CRP preserved in sodium azide caused acute vasorelaxation,
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while CRP either made without sodium azide or in which the azide had been 
removed by dialysis showed no acute vasoactive effects(279). Similarly another 
group has shown that the vasorelaxant effects of CRP in rat aortic rings are
^OA
mediated by the azide( ). Sodium azide is known to be a direct NO donor and
9 7 7this was thought to be the mechanism of this effect( ).
1.8.3 Pathophysiology of CRP
A large number of studies have been performed looking at actions of CRP that are 
potentially harmful to the host. These are detailed in the sections below.
1.8.3.1 Animal Studies
Using a rat model of myocardial infarction (ligation of the left anterior descending 
artery) the size of an infarct can be determined by nitroblue tetrazolium viability 
stains. Intra-peritoneal injection of human (azide free) CRP, but not its buffer, led
9521to a 40% increase in infarct size( ). This effect was prevented if the complement 
system of the animals was previously depleted with cobra venom, suggesting that 
complement fixation is required for this deleterious effect. Immunohistochemical 
staining located the human, but not rat, CRP to the infarct site, where it was co­
localised with complement.
In a murine model of SLE, injection of chromatin leads to acceleration of the 
course of the disease, whereas when it is co-injected with human CRP, which is 
known to bind to chromatin, the animals did not suffer increased morbidity or
• 9 8 9mortahty( ). Similarly a transgenic model of mouse SLE which also over-
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expresses human CRP showed a reduction in morbidity and mortality( ). These 
results are used to support a role for CRP in preventing autoimmunity and
immune complex clearance, though the relevance of co-injection or
overexpression of an heterologous pentraxin into a mouse model of SLE, where 
CRP is not an acute phase protein, to the human condition is not clear.
The same group has studied the effects on vessel injury in human CRP over­
expressing mice, in comparison to wild type, and shown a marked increase in
'yoA
femoral artery thrombosis (from 17 to 75% of animals)( ). This correlated with 
a decrease in clotting time in these animals ex vivo. Whether these changes are a 
consequence of over-expression of tissue factor or other pro-coagulant proteins 
has not been explored.
Taken together these studies suggest potentially important effects of CRP. 
However given the concerns about interpreting studies performed in one animal 
with CRP from another animal (usually human) caution must be applied to their 
findings. As previously indicated, CRP although largely preserved between 
species does have different biological properties and dynamic responses and these 
may influence any results. The next section will describe studies in human 
models that therefore avoid this cross-species difficulty.
1.8.3.2 Human Studies
1.8.3.2.1 Histopathological studies
A number of authors have shown, with immunohistochemical techniques, that 
CRP can be found within atherosclerotic plaques and that it appears to co-localise
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with complement ’ ). It is not clear whether this is a primary effect or a 
reflection of the presence of oxidised LDL within these lesions. Intriguingly one 
group has shown the colocalisation of CRP in atherectomy samples with p22phox, 
a component of NADPH, although the functional importance of this observation is 
not clear particularly as other circulating proteins can also be found within 
atherosclerotic plaques(287).
In addition to its localisation to atherosclerotic plaques CRP has been found in 
increased quantities in infarcted myocardial tissue. In areas of infarct of greater 
than 12 hours age, a post mortem study showed co-localisation of CRP with 
activated complement, suggesting a role for CRP in this situation( ). This is of 
particular importance given the animal study described above using experimental 
infarcts, and supports a role for CRP in determination of myocardial viability 
post-infarct and a possible role in ischaemia-reperfusion injury.
1.8.3.2.2 Cell culture studies
Incubation of human aortic endothelial cells with CRP leads to an increase in the 
expression and activity of plasminogen activator inhibitor-1, which may favour 
atherothrombosis( ). In the presence of serum, CRP (lOmcg/mL) was shown to 
increase expression of VC AM-1, ICAM-1 and E-selectin by flow cytometry in 
human coronary artery cells and umbilical vein cells(290). A similar model has 
also been used to show that CRP increases monocyte chemoattractant protein-1 
and reduces NO production by venous endothelial cells and that this can be 
reversed with co-incubation with the PPARy agonist rosiglitazone(291). Human 
umbilical vein endothelial cells have also been shown to release endothelin-1 in
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response to exposure to CRP, an effect that could be inhibited by blockade of IL-6
292and endothehn receptors( ).
Peripheral monocytes incubated with CRP appear to increase their expression of 
tissue factor, which has pro-coagulant properties and may favour 
atherothrombosis( ). In follow on studies it has also been suggested that this 
effect can be potentiated by interferon-y and lipopolysaccharide(294). In addition 
to altering monocyte protein expression it has been suggested that CRP can induce
2QSmigration of these cells( ), though not all investigators have demonstrated 
this(296).
In human vascular smooth muscle cells incubation with CRP has been 
demonstrated to increase angiotensin type-1 receptor mRNA and protein 
expression and, as a consequence, increase cell migration and reactive oxygen 
species generation in vitro(291).
Of particular relevance to endothelial function two groups have studied the impact 
of incubating human aortic endothelial cells with commercial CRP and have 
shown a reduction in the expression of eNOS and reduced production of NO and
29R-299cGMP( ’ ). In these experiments, the presence of contaminating 
lipopolysaccharide was excluded by the use of Detoxigel columns and specificity 
was explored by heat degradation of the CRP.
Taken together, these effects point towards CRP producing a marked 
prothrombotic and atherogenic phenotype within the endothelium and vasculature,
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suggesting it performs a direct role in atherosclerosis rather than purely acting as a 
marker of underlying inflammation. As previously indicated caution must be 
applied to these conclusions as all studies used commercial CRP where concern 
has been expressed as to the importance of interactions with contaminants and the 
specificity of effects seen(249).
1.8.3.2.3 Ex vivo studies
Very little experimental work has been performed demonstrating the effects of 
CRP on human tissues.
One group used sections of internal mammary arteries obtained at the time of 
bypass surgery to study contractile function of the vessels in organ baths. CRP, 
from a commercial source, caused a dose dependent relaxation of the vessel rings 
pre-contracted with endothelin-1, which was not dependent upon the presence of 
the endothelium or nitric oxide synthase activity. The effect appeared to be 
mediated by an alteration in potassium channel function as it was attenuated by 
pre-incubation with barium chloride that can inhibit inward rectifier potassium 
channels(300). Surprisingly nearly 50% relaxation of the vessel occurred with 10* 
8M of CRP (equivalent to 0.2mg/L), which would suggest that “normal” 
concentrations of CRP would tonically relax these arteries in vivo. Caution must 
be applied to these findings in light of the studies indicating the direct vascular 
effects of CRP are mediated by sodium azide(279;280).
In vivo correlation studies are considered in section 1.9.2.1, and also within the 
section (1.8.1.1) on CRP and epidemiology.
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In summary there are multiple potential pathogenic mechanisms described for 
CRP, which could make it instrumental in the development of atherosclerosis and 
not merely a marker for other inflammatory markers with a causal role. It could 
increase atherothrombosis by stimulating changes in both the coagulation system 
and the phenotype of the endothelium and mediate greater myocardial injury by 
increasing complement dependent cell lysis. Not all of the studies described 
include detailed and rigorous controls and some lack biological plausibility. As a 
consequence there is still a need for more, rigorously performed, investigations 
into the potential functions of C-reactive protein. One of the main aims to this 
thesis was to explore the direct vascular effects of CRP, free from commercial 
contaminants.
1.9 Inflammation and Endothelial function
This introduction has discussed evidence that atherosclerosis is an inflammatory 
disease and that acute inflammation may be involved in the development o f acute 
coronary syndromes, while chronic, low-grade inflammation could increase the 
risk of later cardiovascular events. It has also indicated that endothelial 
dysfunction is probably an early process in the development of atheroma and may 
be important for the destabilisation of established plaques. Particularly as it 
occurs with all orthodox cardiovascular risk factors, is a systemic phenomenon 
and predicts future adverse events. A number of studies provide evidence for a 
link between inflammation and impaired endothelial function, and these are 
described in the next section (1.9.1).
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1.9.1 Animal stud ies
It has been known for some time that in a large number of animal models bacterial 
endotoxin induces changes in vascular responses, whether given in vivo or ex vivo 
(Soi'305). Depending on the model, endotoxin causes either widespread vascular 
changes or an impairment restricted only to endothelium-dependent mechanisms. 
It has been shown that endothelium-dependent changes are due to alterations in 
NO synthesis, with an increase in iNOS activity with consequent downregulation 
of eNOS function resulting in endothelial dysfunction(306). The importance of 
increased iNOS activity in this process has been confirmed by the inability to
• • in ninduce endothelial dysfunction in iNOS knockout mice exposed to endotoxin( ). 
These functional changes are combined with changes in both basal and stimulated 
nitric oxide release(304).
In rats, intravenous infusion of the inflammatory cytokine TNFa, prior to 
sacrifice, also led to a marked reduction in relaxation of blood vessels to the 
endothelium-dependent vasodilator acetylcholine, in comparison to control 
animals, with no alteration in the response to a direct nitric oxide donor( ). 
Similarly in vitro exposure of bovine pulmonary arteries to TNFa for at least 30 
minutes led to impairment in receptor mediated endothelium-dependent 
relaxation(309).
Using cultured bovine endothelial cells it has been shown that exposure to 
endotoxin causes a reduction in both basal and stimulated nitric oxide from
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endothelial NOS, indicating the development of endothelial dysfimction(304). In 
these experiments a mixture of ILlp and TNFa alone did not produce the same 
effect, however a separate group has shown that TNFa can reduce eNOS mRNA 
stability and thereby decrease eNOS expression in a bovine model(310).
1.9.2 Human stud ies
1.9.2.1 Correlation studies
Using CRP as a marker of underlying inflammation, several groups have shown
an association between a raised concentration of this protein and endothelial
dysfunction. Fichtlscherer et al demonstrated that a raised CRP was associated
with impaired responses of the forearm vasculature to endothelium-dependent
vasodilatation with acetylcholine, in subjects with documented atherosclerosis, in
1^1a manner independent of classical cardiac risk factors( ). Cleland et al expanded 
this by showing that, in healthy volunteers, the relationship between serum CRP 
concentrations and endothelial responses is dependent on nitric oxide as the 
response to L-NMMA is also correlated with CRP values(312). In a further study 
examining flow-mediated dilatation (FMD) in patients with documented 
peripheral artery disease, there was an association between raised CRP and 
fibrinogen and a relative reduction in FMD(313). In children an association has 
been demonstrated between a raised CRP value and impaired FMD and increased 
intima medial thickness, though this was a cross-sectional study and did not look 
at future atherosclerotic disease(314). In one study CRP, but not erythrocyte 
sedimentation rate (ESR), was correlated with endothelial dysfunction, shown by 
FMD, and then only in individuals with established atherosclerosis( ).
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In the setting of unstable angina one group has shown a correlation between the 
presence of a raised CRP concentration (>5mg/L) and increased vasoconstriction 
in a cold pressor test and increased vasodilatation to GTN at the point of the 
culprit intracoronary lesion( ). Whether this is directly related to a change in 
endothelial function is not clear, although in other studies a correlation has been 
found between increased vasoconstriction to acetylcholine and the cold pressor 
test in human coronary arteries(317).
These studies therefore show an association between an inflammatory phenotype 
and endothelial dysfunction though do not explore the specific mechanism or 
allow inference about a causal role for CRP or other inflammatory products. 
Other circulating inflammatory markers or other cardiovascular risk factors with 
which it is closely correlated may confound a correlation between CRP and 
endothelial dysfunction. This is highlighted by a similar study using FMD in 
subjects with familial hypercholesterolaemia and without clinical atherosclerosis, 
which found no association between CRP or selectins and endothelial 
dysfunction(318). In this study no change in FMD was found with statin treatment, 
in contrast to a number of other studies described previously.
Evidence also exists that the presence of underlying infections is correlated with 
impaired endothelium-dependent responses. In a mixed diabetic and non-diabetic 
population seropositivity for CMV, but not H. pylori or C. pneumoniae, was 
associated with impaired vasodilatation to bradykinin(319). In contrast to these 
positive studies Khairy et al failed to show an association between endothelial
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dysfunction, assessed with FMD, and the presence of antibodies to C. 
pneumoniae, CMV, EBV or H. pylori, or to CRP concentrations, in healthy young 
male volunteers(320). As indicated before, advanced periodontal disease has been 
shown to be associated with an elevation in CRP and a reduction in FMD, relative 
to healthy controls(178). Again these studies are unable to determine the 
mechanism by which these effects occur, or whether they are causal or simply 
associative.
1.9.2.2 Hand vein studies
The dorsal hand vein provides a relatively accessible vessel to study in vivo, as it
can be isolated from the circulation and agents selectively instilled and the
responses studied. Impairment in the response to noradrenaline in these vessels
has been shown following the instillation of pro-inflammatory endotoxin,
1indicating an increase in NO production( ). In this case the effects were not 
reversible with either inhibitors of nitric oxide or cyclo-oxygenase synthesis, 
though they were preventable with hydrocortisone. In the same model the 
cytokines IL(3 and TNFa reduced vasodilatation to the endothelium-dependent 
agent bradykinin, with no effect on endothelium-independent vasodilators. 
Endothelial dysfunction was prevented by both hydrocortisone and aspirin. The 
effect for each cytokine was of short duration; but could be prolonged by their 
combination(322). This work suggests that the endothelial dysfunction seen 
following an inflammatory insult can be modelled in vivo in humans and may be 
relevant to cardiovascular disease. As indicated in an earlier section, this model 
was also used to demonstrate that IL-1 P induced the up-regulation of BH4
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synthesis, and that the balance of this and increased co-factor requirements may 
be important in the development of endothelial dysfunction( ).
1.9.2.3 Arterial studies
Arterial studies using a combination of venous occlusion plethysmography and 
FMD have been performed in vivo in humans using two inflammatory models -  
typhoid vaccination and intravenous endotoxin administration.
Our group has developed a model of acute inflammation, using typhoid 
vaccination, which allows the study of changes in vascular reactivity in the period 
before and shortly after the stimulus. It has been shown that 8 hours following 
vaccination there is a marked reduction in vasodilatation in the forearm in 
response to the endothelium-dependent vasodilators acetylcholine and bradykinin. 
There is no change in the response to endothelium-independent vasodilators and 
all effects have normalised by 32 hours. A similar reduction in endothelial 
function has also been shown in response to a flow stimulus(324). These changes 
are accompanied by an inflammatory cytokine response and it has been separately 
shown that an anti-inflammatory dose of aspirin prior to vaccination can prevent 
the endothelial dysfunction and modify the cytokine response. No improvement 
was seen with the use of local aspirin 8 hours post vaccination(50). These studies 
show that acute inflammation, which may be prostanoid driven, causes endothelial 
dysfunction; however local dysregulation of prostanoid pathways do not account 
for the endothelial function that has been observed. At the time the work for this 
thesis was undertaken it was not clear whether the changes are due to alterations 
in NO, EDHF or vasoconstrictor agents, or how inflammation leads to these 
changes.
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Another group has shown somewhat contradictory results, where typhoid 
vaccination did not alter the response to bradykinin or acetylcholine although it 
did cause increased release of tissue plasminogen activator( ). The failure to 
demonstrate endothelial dysfunction in these studies may be the result of different 
methodology, particularly the use of higher doses of vasodilators that may have 
been beyond the linear portion of their response curves and the use of a shorter (6 
hour) time point.
Acute administration of endotoxin intravenously (l-2ng/kg) to healthy volunteers 
has been shown to induce a hyporeactivity to adrenoceptor agents and the 
endothelial dependent vasodilator acetylcholine at 4 hours, by a mechanism not 
thought to involve changes in iNOS expression( ). The same group has gone on 
to show that administration of high doses of ascorbic acid can restore the impaired 
response to acetylcholine to normal, though the mechanism of this effect is not 
explained(327).
Taken together these various studies suggest that inflammation can induce 
endothelial dysfunction and that this may represent an important mechanism in 
the development and progression of atherosclerotic disease. The published data 
thus far does not clearly demonstrate the mechanisms involved in inflammation- 
induced endothelial dysfunction and more information is needed on the relevant 
inflammatory products involved. The last section of this introduction will explore 
potential pathways through which endothelial dysfunction can occur, and the
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second half of the thesis will describe the experiments performed in an attempt to 
address these in this vaccine model of inflammation in vivo.
1.10 Mechanisms of Endothelial Dysfunction
In theory endothelial dysfunction may be caused by a deficiency in vasodilators, 
or increased vasoconstrictor activity. Available evidence indicates a predominant 
role for reduced activity of the NO pathway in experimental and human 
atherosclerosis.
1.10.1 L-arginine-NO pathway
Animal models of atherosclerosis show reduced endothelial nitric oxide synthase 
activity and nitric oxide synthase inhibition leads to accelerated 
atherosclerosis(328’329). Human hypertension is associated with reduced whole 
body NO production(330) and reduced vasoconstriction response to NOS inhibition 
with NG-monomethyl-L-arginine(116). These changes in nitric oxide 
bioavailability could reflect either decreased NO production or increased 
breakdown.
1.10.1.1 Reduced NO production
Production of NO can be reduced by a number of mechanisms. There may be a 
lack of substrate for NOS, a deficiency in essential co-factors for the enzyme or a 
reduction in the quantity of the protein.
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7.10.7.7.7 Substrate deficiency
The substrate for eNOS is L-arginine and as endothelial cell and circulating 
concentrations are several-fold higher than the Michaelis constant (Km) of the 
enzyme, direct deficiency seems at first an unlikely explanation for reduced NO 
bioactivity. However it has been shown in both animal and human models that 
supplementation with L-arginine can improve endothelial function. This could be 
explained by changes in the Km of the enzyme, the presence of a competitive 
inhibitor of NOS, compartmentalisation of the enzyme and substrate, or 
mechanisms that reduce arginine concentrations within the endothelium.
1.10.1.1.1.1 Animal data
In animal models of atherosclerotic risk factors, specifically 
hypercholesterolaemia, acute and chronic supplementation with oral L-arginine 
leads to an improvement in vascular function and a reduction in the progression of 
atheroma( ’ ). This paradoxical effect given the usual excess of substrate could 
be mediated by any of the mechanisms described above.
There are at least two endogenous methyl-substituted arginines that compete with 
arginine for the active site of NOS. NGNG-dimethyl-L-arginine (asymmetric 
dimethylarginine; ADMA) has been shown in cholesterol fed rabbits, a model of 
atherosclerosis, to be increased and to act as a competitor to L-arginine for nitric 
oxide production, which may make NOS substrate dependent in this 
setting(333,334). Acute administration of ADMA or N^monomethyl-L-arginine 
(L-NMMA) in rats has been shown to raise blood pressure, at least in part through
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an increase in peripheral vascular resistance( ). Likewise in rat models of salt- 
sensitive hypertension increases in ADMA have been implicated in the tendency 
to increased blood pressure by antagonising basal NO production and in separate 
experiments L-arginine supplementation has been shown to reduce this form of 
hypertension(336,337).
One possible explanation of this “arginine paradox” has been the demonstration, 
in porcine pulmonary artery endothelial cells, of compartmentalisation of NOS. 
Studies have shown co-localisation of eNOS and the arginine transporter (cationic 
amino acid transporter 1) in caveolae formed by the cytoplasmic membrane( ). 
This may lead to preferential utilisation of extracellular L-arginine by eNOS 
meaning that extracellular (generally 50-200pM) rather than intracellular (usually 
>800pM) concentrations of arginine are relevant to the enzyme’s efficiency. In 
bovine aortic endothelial cells this dependence on transport mechanisms has been 
demonstrated by the observation of a ten-fold higher Km for eNOS for L-arginine 
in intact cells to cell lysate( ).
In addition to breakdown by NOS to form L-citrulline and NO, L-arginine can 
also be degraded by arginase to produce ornithine and urea. In rat aortic 
endothelial cells Buga et al have shown the presence of both constitutive enzyme 
(arginase-1) in large concentrations and a form inducible by lipopolysaccharide 
(arginase-2)(340). Initially it was thought that these high arginase concentrations 
may metabolise sufficient L-arginine to make it rate limiting. These experiments, 
however, also indicated that lipopolysaccharide and cytokines also increase the 
production of N -hydroxy-L-arginine from iNOS that inhibits arginase-1 and
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therefore prevents the limitation of supply of substrate for this high-output 
isoform. As such the importance of arginase in maintaining L-arginine levels or 
making NOS dependent upon its concentration is not clear.
1.10.1.1.1.2 Human data
In humans with cardiovascular risk factors the reports on the effect of L-arginine 
supplementation are inconsistent. Some authors have shown an improvement in 
resistance and conduit vessel function in individuals with hypercholesterolaemia, 
hypertension, smoking and diabetes(106;115;341*343). In contrast, other groups, 
including our own, have failed to show any increase in endothelium-dependent 
responses after supplementation with L-arginine in subjects with hypertension or 
diabetes(344;345). No improvement in similar experiments was seen in healthy 
volunteers without cardiovascular risk factors(346,347).
Like the animal models, there are a number of possible explanations for this 
apparent paradox. In human studies an association has been shown between 
increased serum ADMA levels and the presence of some cardiovascular risk 
factors and markers of atherosclerosis(348’350). In particular the study by Boger et 
al showed that ADMA is raised in asymptomatic hypercholesterolaemics and is 
associated with impaired vascular reactivity that is reversible with systemic L- 
arginine(349). Infusion of ADMA into the forearm of healthy volunteers leads to
t c i  ^  C'y. *5 c i
reduced blood flow( ), whereas systemic doses increase blood pressure( ’ ).
A rare disorder of amino acid transport, lysinuric protein intolerance, may indicate 
the presence of compartmentalisation of L-arginine and NOS in humans. In this 
condition there are low plasma levels of L-arginine and L-lysine and reduced NO
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production, which can be improved with supplemental L-arginine(354). Genetic 
studies have localised the defect to one of the cationic proteins involved in L- 
arginine transport and suggest that at least in this setting L-arginine transport may 
be rate limiting(355).
There are only limited data to suggest a role for arginase activity in the regulation 
of L-arginine availability. In diabetic men, who are prone to erectile impotence 
that may be related to deficient NO availablity, increased expression of arginase II 
has been demonstrated with reduced NOS activity that can be improved by
'Xinhibition of the arginase pathway( ). The importance of this pathway in 
atherosclerosis is not clear.
1.10.1.1.2 Cofactor deficiency
As described previously (section 1.4.1.1) NOS requires a number of co-factors to
j 1
function efficiently, including tetrahydrobiopterin ( B L L X  ). B H 4  availability is 
dependent upon the balance between its breakdown, by oxidation or utilisation by 
aromatic amino acid hydroxylases, and synthesis, which occurs locally by two 
pathways. In its reduced state B H 4  is biologically active as a cofactor for NOS. 
When NOS is deficient in B H 4  electron transfer by the enzyme is uncoupled and 
superoxide is synthesised rather than NO(357). De novo production of B H 4  from 
guanosine triphosphate, which is thought to be the predominant synthetic 
pathway, occurs through a series of steps initiated by the rate-limiting enzyme, 
G T P  cyclohydrolase-1 ( G T P C H - 1 ) .  In monocytes, once G T P C H -1  is 
upregulated, 6-pyruvol-tetrahydrobiopterin synthase can become rate-limiting, 
leading to an accumulation of neopterin that is therefore a reflection of monocyte
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a c t iv a t i o n (  ) .  T h i s  d o e s  n o t  o c c u r  i n  a  m o u s e  m o d e l  o f  G T P C H -1  o v e r -  
e x p r e s s i o n ^ 59) a s ,  i n  o t h e r  s p e c i e s ,  6 - p y r u v o l - t e t r a h y d r o b i o p t e r i n  s y n t h a s e  d o e s  
n o t  b e c o m e  r a te  l i m i t i n g  a n d  BH4 i s  p r o d u c e d  i n  e x c e s s .  A  s a l v a g e  p a t h w a y  a l s o  
e x i s t s ,  u s in g  s e p ia p t e r in  a s  a  s u b s t r a t e ,  w h i c h  d o e s  n o t  i n v o l v e  G T P C H - 1 . W h e n  
in  e x c e s s ,  B H 4 a c t s  t h r o u g h  G T P  c y c l o h y d r o l a s e -1  f e e d b a c k  r e g u la t o r y  p r o t e in  
( G F R P )  t o  in h ib i t  i t s  o w n  p r o d u c t i o n  b y  r e d u c i n g  G T P C H -1  a c t iv i t y .
G u a n o s i n e  t r ip h o s p h a t e
lGTP cyclohydrolase-1 y  
N e o p te r in ^  D ih y d r o n e o p t e r i n  t r ip h o s p h a t e
1 - v e6-pyruvol-tetrahydrobiopterinsvnthase
6- P y r u v o y l - t e t r a h y d r o p t e r i n
^  Sepiapterin reductase
T etrah vd robiopterin
O x id a t io n  
/
7,8 D ihydrobiopter in  \  Dihydropterin reductase
q - D i h y d r o b i o p t e r i
+ v e
G F R P  
-r a
- v e
A r o m a t i c  a m i n o  a c i d
Amino acid hydroxylases
D o p a m i n e / s e r o t o n i n
Figure 1-4: Pterin pathway showing synthesis and potential routes of 
breakdown of BH4.
B H 4 i s  g e n e r a t e d  f r o m  G T P  i n  a  t h r e e - s t a g e  p r o c e s s  c o n t r o l l e d  b y  t h e  r a t e - l i m i t i n g  
e n z y m e  G T P C H - 1 . B H 4 i s  t h e n  b r o k e n  d o w n  b y  o x i d a t i o n  o r  a m i n o  a c i d  
h y d r o l y s e s .  G T P C H -1 i s  c o n t r o l l e d  b y  i n h i b i t i o n  w i t h  G F R P ,  w h i c h  i t s e l f  i s
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under the control of B H 4 .  ( B H 4  = tetrahydrobiopterin, G T P C H -1  =  G T P  
cyclohydrolase-1, G F R P  =  G T P  cyclohydrolase-1 feedback regulatory protein)
The exact effect of B H 4  on NOS is not clear. As NOS bears similarities to 
monooxygenases, for which B H 4  is also a cofactor, it has been proposed that B H 4  
aids hydroxylation of one of the amidine nitrogens of L-arginine; however there 
are no data to support the cycling of B H 4  concentration that would then be 
expected during NO production if it acted in this way(360).
A number of studies suggest that B H 4  stabilises the dimeric peptide structure of 
NOS which facilitates L-arginine binding and favours production of NO, over 
superoxide, and the maintenance of enzyme stability(30,361,362). However, concern 
has been expressed as to the existence of dimerisation in vivo as it is uncertain 
whether the properties of the enzyme in a cold gel (used to determine dimer 
formation) are the same as in vivo(363).
1.10.1.1.2.1 Animal data
A deficiency of B H 4  has been shown to contribute to endothelial dysfunction in 
various vascular models. Studies in diabetic rats and mice have shown an 
improvement in endothelial function with B H 4  supplementation^64,365), although 
this work lacks direct measurement of B H 4  in the vessel wall. In addition 
endothelial dysfunction of spontaneously diabetic rats has been shown to be 
mediated by a deficit in GTPCH-1 activity leading to reduced BH4(366), rather 
than by a reduction in eNOS protein. In these studies other NOS cofactors, 
calmodulin and calcium, were not different between control and diabetic animals, 
with NADPH and arginine actually being more abundant in diabetic cells.
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Hypercholesterolaemic rabbits have been shown to have reduced quantities of 
B H 4  in vessel walls, with a relative increase in B H 2 .  Addition of sepiapterin 
increased the levels of B H 4  only in hypercholesterolaemic rabbits although this 
did not translate into improvements in vascular NO-dependent responses( ), 
perhaps due to co-existent increases in B H 2  that may compete with B H 4  at the 
eNOS binding site. In an isolated vessel porcine model of ischaemic vascular 
injury, addition of sepiapterin or, to a lesser extent, methyltetrahydropterin 
improved previously impaired endothelium-dependent responses( ). Similar 
experiments with pigs with atherosclerosis, following 4 months of a cholesterol- 
rich diet, also showed an improvement in the response to serotonin and substance 
P with sepiapterin(369).
A number of theories have been put forward to explain this apparent deficiency in 
B H 4 .  An excess of oxidant free radicals, which are seen in hypercholesterolaemia
T 7 0  “5 7 1( ), DOCA-sensitive hypertensive rats and mice( ) and apoE knockout
7^7
mice( ), can inhibit B H 4  by a number of mechanisms. Firstly they may deplete 
NADPH or prevent the recycling of B H 4  by flavin nucleotides. Peroxynitrite, in 
particular, by oxidising B H 4  to B H 2 ,  may uncouple the NOS in favour of 
superoxide production. Ascorbic acid (an anti-oxidant) has been shown in porcine 
endothelial cells to increase NO release by increasing B H 4  concentrations, 
presumably by favouring the reduced form of the pterin over B H 2 ,  and thereby
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producing “coupled” NOS( ). A reduction in generation of BH4 would have the 
same effect as increased breakdown and there is some evidence, in rat 
macrophages, that oxidised low-density lipoprotein can prevent the normal up- 
regulation of GTPCH-1 by cytokine stimulation(374).
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GTPCH-1 expression, and thereby BH4, can be increased by the same cytokines 
that increase NO production through iNOS induction(375). Direct inhibition of 
GTPCH-1 in this model leads to a reduction in NO production. In addition, 
oestrogens have also been shown to increase GTPCH-1 expression(376). In a 
murine diabetic model, GTPCH-1 over-expression led to increased BH4 relative to 
BH2 and consequent improvement in endothelial function in comparison to wild
J CQ
type diabetic animals( ).
1.10.1.1.2.2 Human data
In human studies relative BH4 deficiency has also been implicated in endothelial 
dysfunction. In isolated vessels from individuals with known atherosclerosis on 
angiography, sepiapterin improved responses to acetylcholine and histamine with 
no effect on endothelium-independent vasodilators(369). The same experiments 
showed no effect of sepiapterin in vessels from subjects undergoing valvular 
surgery and not known to have macroscopic atheroma.
Cell culture studies in endothelial cells also favour the paramount importance of 
adequate BH4 for NO production(377). As is evident ex vivo, adding ascorbic acid 
to human endothelial cells caused increased NO production in a BH4-dependent 
manner(378,379). As the control anti-oxidant {Mn (III) tetrakis (4-benzoic acid) 
porphyrin chloride; a superoxide scavenger) had no effect on NO production, and 
ascorbic acid had no effect in the presence of sepiapterin, it was proposed that in 
this model the ascorbic acid acted primarily through changes in BH4 and not 
directly on NO. These effects are most likely by chemical stabilisation of the
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pterin and reducing B H 3  (the oxidative free radical of B H 4  produced by 
peroxynitrite(363)) to active B H 4 .  It has also been proposed that B H 4  partly acts to 
improve NO production by acting directly as an anti-oxidant; however in studies 
in smokers and hypertensive (animals) although B H 4  improved vascular reactivity 
an alternative reduced pterin with anti-oxidant properties (tetrahydroneopterin) 
did not(371'380).
In human endothelial cells increased G T P C H -1  expression, using an adenoviral 
plasmid vector, leads to increased NO production in conjunction with an increase
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in NOS dimerisation( ). Similarly, inflammatory cytokines in an in vivo human 
hand vein study have been shown to increase NO release by increasing B H 4  
availability through excess G T P C H - 1  expression(323).
Infusion of B H 4  improves endothelial dysfunction in coronary vessels of patients 
with atherosclerosis in vivo( ). In the presence of risk factors for atherosclerosis
505 50A 5 0^
(hypercholesterolaemia( ), smoking( ) and diabetes( )) B H 4  infusion 
improves endothelial function in the forearm, but has no effect in control 
individuals. In all these experiments the concentrations of B H 4  achieved are 
likely to be way in excess of the Km of eNOS for B H 4  and therefore non-specific 
effects cannot be ruled out.
Inadequate concentrations of B H 4  could represent a deficiency in production or 
excess breakdown. Smoking is thought to affect both mechanisms, with the
5 0 f
aromatic amines of smoke inhibiting B H 4  production( ) and the free radicals, 
particularly peroxynitrite, increasing its breakdown. Other cardiovascular risk
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factors are also known to increase oxidant free radicals, as will be discussed 
below (section 1.10.1.2), and these may then lead to BH4 deficiency.
7.10.1.1.3 Reduced eNOS expression
A reduction in expression of eNOS could limit NO availability. Animal work 
suggests that eNOS expression can be diminished by TNFa, hypoxia and a high 
LDL concentration ). Reduced expression of eNOS, accompanied by decreased 
NO production, has been shown in human vessels with established 
atherosclerosis, compared to normal arteries taken at surgery(387). Changes in 
NOS expression, thought to be due to alterations in mRNA stability, have been 
observed in advanced atherosclerotic lesions, which show enhanced iNOS and 
diminished eNOS compared to normal sections of vessel( ). The importance of 
these changes in the development or continuation of endothelial dysfunction is not 
clear.
1.10.1.1.4 Alterations in NO signalling
Endothelial dysfunction measured as an attenuation of agonist-mediated 
vasodilatation could also reflect an abnormality in agonist-mediated signal 
transduction. Nitric oxide release in response to signalling through G-protein 
coupled receptors is generally attenuated to a greater degree than that elicited by 
agonist independent increases in intracellular calcium mediated by a calcium 
ionophore (A23187) in both atheroscelerotic and post-transplantation 
models(389,390). In a porcine model of hypercholesterolaemia, inhibition of G- 
proteins with pertussis toxin did not further impair endothelial function, in
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contrast to control animals, suggesting that excess cholesterol had already altered 
the actions of these proteins(391). Expression of G-proteins has shown to be 
reduced in tissue culture by exposure to oxidised LDL( ) and in coronary 
arteries with age, hypertension and hypercholesterolaemia( ). These changes 
could explain diminished responses to receptor-mediated agonists (such as 
serotonin) and also the variable impairment to different stimuli, though their 
importance in cardiovascular disease is as yet not clear.
1.10.1.2 Increased NO breakdown
Nitric oxide is rapidly oxidised in a number of steps culminating in the formation 
of nitrite and nitrate, and also by nitrosylating other molecules, particularly redox- 
activated thiols. As suggested previously (section 1.10.1), excess reactive oxygen 
species, especially peroxynitrite formed by reaction of superoxide and NO, may 
contribute to endothelial dysfunction and atherosclerosis. Free radicals can act 
directly to oxidise NO, reduce the bioavailability of BH4 through oxidation or, as 
indicated above, alter G protein-coupled receptor function(392).
Superoxide has emerged as an important free radical mediator and the sources of 
superoxide vary between vessels and species and include vascular NADPH 
oxidases(394), present in endothelial and smooth muscle cells, “uncoupled” 
NOS(30,361,362’395), xanthine oxidase(370), and cytochrome p450. Mitochondria also 
generate superoxide as a bi-product of oxidative phosphorylation. Superoxide is 
metabolised by superoxide dismutase; the product, hydrogen peroxide, is 
subsequently metabolised by catalase to oxygen and water. Although superoxide 
reacts with NO three times more readily than with dismutase
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(km=6.7xlOI0mol/L/s), in healthy vessels adequate tonic dismutase activity 
prevents NO breakdown, and oxidant stress only becomes pathological when 
superoxide production escalates or dismutases are inhibited(396). Excessive 
oxygen free radicals may directly contribute to atherosclerosis by stimulating 
smooth muscle proliferation^97), oxidising lipoproteins(398) and favouring platelet 
aggregation and leukocyte adhesion(399), in addition to reducing the 
bioavailability of NO.
1.10.1.2.1 Animal data
A number of animal models have shown the importance of changes in oxidant 
stress in the development of endothelial dysfunction and atherosclerosis.
In DOCA-sensitive hypertensive mice there is a reduction in NO bioavailability 
due to increased oxidant stress that is derived from eNOS. In knock-out models 
this has been shown to be initiated by superoxide, from NADPH oxidase, 
increasing B H 2  relative to B H 4  and thereby “uncoupling” NOS(371). In the 
spontaneously hypertensive rat excess superoxide has been shown to be produced 
from xanthine oxidase, and inhibition of this enzyme with oxypurinol causes a fall 
in blood pressure(400).
Hypercholesterolaemia is associated with endothelial dysfunction in part due to 
increased superoxide production, largely from xanthine oxidase, and thereby NO
• 7^0degradation( ). Early atherosclerotic lesions in hypercholesterolaemic rabbits 
exhibit increased NADH oxidase activity, which can be reversed by angiotensin II 
inhibition, in keeping with the role of angiotensin II in the production of oxidant 
stress by the upregulation of angiotensini (ATi) receptors by lipids(401).
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Importantly, in this model, chronic angiotensin II inhibition led to the 
development of fewer atherosclerotic lesions. Similarly chronic administration of 
anti-oxidant vitamins can inhibit the development of atherosclerosis in a primate 
model(402) and the development of endothelial dysfunction in cholesterol-fed 
rabbits(403).
An alternative approach has been to supplement superoxide breakdown with 
polyethylene-glycolated superoxide dismutase, which has been shown in a rabbit 
model to partially correct impaired endothelial function(404).
1.10.1.2.2 Human data
Excess NO breakdown in human vessels has been studied both ex vivo, by 
determining the presence of increased oxidant stress, and in vivo, with 
supplementation experiments.
In isolated human vessels the amount of superoxide produced by NADPH 
oxidases and the degree of endothelial dysfunction correlate with the number of 
cardiac risk factors(405). Similarly increased levels of the components of NADPH, 
specifically p22phox, are seen in atherosclerotic vessels and vessels from 
individuals with diabetes(395,406). Increased superoxide production from smooth 
muscle cells by NADPH oxidase occurs following stimulation by factors thought 
to be involved in atherosclerosis, including angiotensin II, thrombin, platelet- 
derived growth factor, tumour growth factor-a and lactosylceramide(407). Studies 
in human coronary vessels suggest that there is a marked increase in xanthine 
oxidase and a decrease in extracellular superoxide dismutase in individuals with
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atherosclerosis(396). These assays were performed on the circulating enzyme after 
their release was evoked by heparin infusion, and therefore the importance of 
these observations to basal enzyme activity is not clear.
One manifestation of increased oxidant stress is the presence of oxidised 
phospholipids, in particular oxidised low-density lipoprotein (oxLDL). This has 
been localised within atherosclerotic plaques(408) and been shown to be 
chemotactic to monocytes and scavenged by specific receptors(409). OxLDL has 
been shown to promote an inflammatory state and atherosclerosis within 
endothelial cells by upregulation of growth factors and inflammatory 
proteins(410;411). The susceptibility of LDL to oxidation (by measuring conjugated 
diene formation) is also correlated with the coronary vasomotor response to 
acetylcholine in hypercholesterolaemic individuals, even when considered 
independent of cholesterol lowering therapy(412).
Increased oxidant stress in type 2 diabetes has been inferred from raised F2a 
isoprostanes (stable eicosanoids formed by arachodonic acid oxidation), 
particularly following acute hyperglycaemia(413), and F2a isoprostanes have been 
found to be localised to atherosclerotic plaques in smokers(414). A fall in total 
anti-oxidant status of plasma has been seen with the polycystic ovary syndrome, 
which is itself predictive of future cardiovascular disease(415).
Ascorbic acid supplementation, that quenches superoxide, has been shown to 
improve endothelial function in the coronary and peripheral circulations in 
diabetics(416), hypercholesterolaemics(417'419), hypertensives(420), smokers(421) and
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patients with chronic renal failure(422). Whether these effects are mediated by an 
action of ascorbic acid to inactivate superoxide in vivo, despite the relatively low 
affinity of ascorbic acid (km=105M/s) compared to NO, through changes in 
BH4(363) or glutathione (423), remains to be determined. Ascorbic acid 
supplementation improved endothelial function in individuals with established 
coronary artery disease(424) and the degree of improvement, which correlates with 
the degree of oxidant stress, is predictive of future cardiovascular 
complications^25). Concern over the interpretation of the effects of ascorbic acid 
have been raised due to its ability to be pro-oxidant in the presence of iron, the 
“Undenfriend effect”(426). In particular ascorbate does not protect against protein 
oxidation from stressors such as cigarette smoke(427). It is not clear whether these 
effects are important in vivo, as there is little “free” iron present (428). Studies 
with vitamin E (a-tocopherol), another anti-oxidant vitamin that can be recycled 
by the anti-oxidant effects of ascorbate, have produced conflicting results with 
some studies showing enhanced vascular function(429;430) and others indicating no 
positive effect(431,432).
Consumption of the dietary antioxidant vitamin E and ascorbic acid, as part of a 
balanced diet and not by supplements, reduced cardiovascular events in 
prospective studies(433,434). However randomised trials of anti-oxidant vitamin 
supplementation have produced conflicting results, with some showing reduced 
events(435) but most others showing no improvement^36'438). This may indicate 
that the prospective studies are confounded by a relationship between ascorbic 
acid intake and other cardiac risk factors, as has been suggested for social class in 
further studies from the EPIC-Norfolk group(439).
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Inhibition of superoxide production with the xanthine oxidase inhibitor 
oxypurinol has been shown to improve endothelial dysfunction of the forearm that 
occurs in hypercholesterolaemia, though it had no effect in individuals with 
hypertension(440).
Oxygen free radicals are released in large quantities during sepsis, largely from 
the NADPH oxidase of neutrophils activated to clear the invading organism. 
Excessive oxidant stress in individuals with sepsis was predictive of organ 
dysfunction and impaired survival(441,442). Endothelial dysfunction that occurs 
during sepsis may be mediated by iNOS induction and consequent eNOS down- 
regulation, though a role for increased oxidant stress, acting directly or indirectly 
upon the endothelium, has also been proposed(443).
In summary there is a wealth of evidence suggesting that increased oxidant stress 
occurs in individuals with cardiovascular risk factors and this can lead to a 
reduction in NO bioavailability and endothelial dysfunction. The exact order of 
these events along with the relative importance of each component still needs to 
be determined.
1.10.2 Other pathw ays
Thromboxane is a potent vasoconstrictor, platelet-aggregating agent, and activator 
of adhesion molecule expression on monocytes. In animal models of 
atherosclerosis levels are increased. Inhibition of prostanoid synthesis, or 
selective thromboxane antagonists inhibit atherosclerosis(444). In patients with
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hypercholesterolaemia or those with established atherosclerosis, aspirin improves 
impaired endothelium-dependent dilatation(445;446). These data suggest that the 
activity of vasoconstrictor prostanoids may be increased in human atherosclerosis. 
In contrast, assessment of the importance of EDHF has been hampered by the 
failure to conclusively identify it and therefore any role in atherosclerosis is 
unclear. EDHF appears to be more important as a dilator in resistance vessels that 
determine blood pressure, but are not themselves particularly prone to 
atherosclerosis.
l . l l Obiectives of this Thesis
The objectives of this thesis are:
• To document the vascular effects of an acute change in inflammatory 
markers in a human in vivo model
• To explore the mechanism of acute human inflammation-induced 
endothelial dysfunction
• To specifically explore the role of oxidant stress in the development of 
endothelial dysfunction during inflammation
• To explore the direct vascular effects of C-reactive protein in vitro using 
highly purified protein
These areas will be covered in the subsequent chapters.
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2 Methods
In this chapter I have described the methods used in this thesis. Detailed 
protocols will be described in each of the data chapters, so only outlines of the 
methods are included in this section.
2.1 Assessment of vascular function in vitro
Although studies in humans in vivo provide the most physiologically relevant 
model they are not always practical or appropriate. In order to study the changes 
caused by one isolated system it is necessary to explore the effects in in vitro 
models. Without specific inhibitors it is not always possible to divorce one event 
from the milieu in which it occurs to determine the relative importance of each 
component. This work describes the development of an in vitro model to study 
the effects of a raised concentration of C-reactive protein on blood vessels. 
Completing these studies in in vitro human vessels is very difficult due to the lack 
of a steady supply of suitable tissue and the heterogeneity of the material as a 
result of its complex previous in vivo exposures. As a result the majority of the 
work described is performed using a rat model, though the phenomenon is 
demonstrated with human vessels to show an absence of interspecies differences.
90
2.1.1 V essel harvesting and  incubation
2.1.1.1 Rationale
Studies in animals in vivo do not allow the observation of the effects of one 
individual mediator without a specific inhibitor or genetic manipulation. Vessels 
removed quickly after sacrificing the animal, or during coronary bypass grafting 
in humans, and handled appropriately will continue to function for a reasonable 
period of time. During this time the vessels can be exposed to different conditions 
to observe the effects on their function. By dividing the vessels into a number of 
2-3mm rings prior to exposure allows the comparison of untreated and actively 
exposed samples.
2.1.1.2 Basic Protocol
Animal experiments were carried out on male Sprague-Dawley rats (200-250g) 
reared by Central Biological Services (University College London) on standard 
chow with water ab libitum. Animals were killed after stunning and cervical 
dislocation. The thoracic aorta was immediately exposed and removed in its 
entirety with minimal trauma to maintain an intact endothelium. After removal 
the aorta was transferred to pre-oxygenated Dulbecco’s Modified Eagle Medium 
(with L-glutamine, lOOOmg/L D-glucose and sodium pyruvate; GibcoBRL, 
Paisley, UK: DMEM) and extraneous fat and connective tissue removed. The 
vessel was then cut into 2-3mm rings and incubated in a 24 well plate for 4 hours 
at 37°C, 95%02/5%C(>2. Each ring was incubated in a total of 0.5ml of solution 
made up of fresh DMEM and the specific treatments as detailed in later sections 
(6.2).
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Human internal mammary arteries (IMA) were obtained at the time of coronary 
artery bypass surgery (CABG). All subjects gave informed consent prior to 
surgery and the University College London Ethics Committee approved the study. 
Mr S Kolvekar performed all operations at the Heart Hospital (UCLH NHS trust) 
on patients with indications for CABG. Operations were performed according to 
normal clinical procedures and small sections of IMA were harvested at the end of 
the grafting procedure only if they were excess to the clinical need. Mr Kolvekar 
did not routinely use vasodilators in the preparation of his arterial conduits. 
Harvested tissue was immediately collected into chilled oxygenated DMEM. 
Vessels were then cleaned and cut into 2-3mm rings and incubated in the same 
way as rat aorta.
2.1.2 Organ bath pharm acology
2.1.2.1 Rationale
Measuring isometric tension of isolated vessels in an organ bath is a widely used 
technique to assess vascular function(447). This technique allows the study of 
pharmacological effects in the absence of the influences of haemostatic 
mechanisms, the autonomic nervous system and physical interactions, such as 
changes in shear stress. Tissues are suspended in a physiological oxygenated 
solution to allow preservation of function and can be interrogated with known 
concentrations of agonists and antagonists to explore changes in isometric 
contraction. As it is possible to treat multiple rings from the same vessel in 
different baths simultaneously this technique lends itself to exploring the effects 
of different pre-treatments. In this work the technique was used to study the
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different effects of endothelium-dependent and independent agonists on vascular 
rings pretreated with CRP or other inflammatory products.
2.1.2.2 Basic Protocol
All organ baths were cleaned prior to studies with 10% hydrochloric acid and 
30% ethanol followed by multiple washes with purified water (190). Organ baths 
were then filled with Krebs solution (composition (mM): Na+ 143; K+ 5.9; Ca2+ 
2.5; Mg2+ 1.2; C f 128; H C03’ 25; H P042' 1.2; S 042* 1.2; D-glucose 11) that was 
maintained at 37°C and bubbled with 95%02/5%C02. Each channel was 
calibrated with a standard 5g weight prior to mounting tissues. Vessel rings were 
suspended, with the minimal stretching possible, between a fixed stirrup and one 
connected to a force transducer (FT03, Grass Transducer, USA) connected to a 
MacLab (AD instruments) attached to a Macintosh Computer using Chart for 
Macintosh. Rat aorta were pre-tensioned to lg and IMA to 2g initially and during 
a 60-minute equilibration period the tension was adjusted, by means of a micro­
adjuster on the fixed stirrup, to maintain this level. All rings were returned to 
these tensions between studies. The organ bath set up is shown in the figure 
below (figure 2-1).
Following the period of equilibration the maximal contraction of each vessel was 
determined by contraction to potassium chloride (48mM), which was repeated to 
ensure consistency of effect. Vessels were washed and re-equilibrated before 
endothelial integrity was confirmed by initially constricting with phenylephrine 
(PE; 10‘7M) and subsequent relaxation with acetylcholine (ACh; 10'6M); 
relaxation by >50% indicated an intact endothelium and other vessels were
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discarded. Vessels were re-equilibrated again prior to the specific protocols that 
are described in the relevant data chapters.
MacLab Force Transducer
aortic
Drugs
Krebs
37°C water 
blanket
95% 02 / 5% C 0 2 OUTLET
Figure 2-1: Diagram of organ bath experimental set up
In general a concentration response curve to PE was initially generated by 
cumulative addition of stock solutions o f PE (IO 'M o^M) to achieve half log unit 
changes at each step. This allowed the addition o f 25-50pL at each step to a total 
volume of 25mL -  thus not significantly altering the total volume over a standard 
concentration-response curve. PE was selected as the standard vasoconstrictor 
due to its ability to selectively stimulate a adrenoceptors, and because it is easy to
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wash out of the organ bath. In studies where an ACh concentration curve was 
generated, the vessels were initially pre-constricted with PE to 80% of the ECmax 
for PE and allowed to stabilise before the cumulative aliquots of ACh were added. 
In these vessels, ACh largely acts by increased production of nitric oxide from the 
endothelium by eNOS following muscarinic receptor-mediated calcium 
influxf448), which then acts in a paracrine fashion to decrease intracellular calcium 
in smooth muscle cells. Changes in sensitivity to ACh therefore act as a marker 
of changes in endothelial function. Between all concentration response curves the 
vessels were washed 3 times and allowed to return to baseline over at least 30 
minutes.
On completion of each protocol the vessels were removed and their weight 
determined. Organ baths were again cleaned prior to further experiments.
2.2 Assessment of vascular function in vivo
The studies described were performed on the human upper limb vascular bed, as 
this is readily accessible and a suitable surrogate for disease-relevant vessels. 
Selective cannulation of the brachial artery at the antecubital fossa allows the 
observation of changes in the resistance vascular bed following the infusion of 
pharmacological agents. Specific agents can be used to explore changes in blood 
flow that are dependent on signalling from the endothelium and those that are 
dependent on smooth muscle integrity. The same route can be used to assess the 
effects of high local concentrations of components of the nitric oxide pathway. In 
other studies high-resolution ultrasound of the brachial artery was used to detect 
changes in the vessel diameter, a response that is dependent on NO
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bioavailability. These models have been used in a large number of studies by a 
variety of groups worldwide. Venous occlusion plethysmography was the 
preferred method only when local infusions of agonists were required, as 
otherwise flow mediated dilatation allowed for repeated measures without any 
inherent risk of arterial cannulation.
2.2.1 Venous occlusion p lethysm ography
2.2.1.1 Rationale
Venous occlusion plethysmography allows the investigation of the tone of the 
resistance vasculature within the forearm. This technique measures the rate of 
increase in forearm volume occurring when the venous outflow is temporarily 
obstructed. Arterial blood continues to enter the forearm and consequently the arm 
expands as blood accumulates. Forearm volume is derived from changes in 
forearm circumference by mercury-in-silastic strain gauges. The rate of blood 
flow is represented by the initial linear rate of rise in forearm volume, and is 
quantitated from the gradient of the slope transduced from the strain gauges.
Pharmacological agents can be infused locally at doses 20-100-fold lower than 
would be required to produce a systemic effect. As blood vessel responses within 
the hand are largely dependent on skin blood flow, excluding the hands with wrist 
cuffs inflated to suprasystolic pressures reduces variability during the recording 
period. Simultaneous recording of blood flow in the contra-lateral (uncannulated) 
arm allows for correction for systemic changes, such as alteration in sympathetic 
tone, during recording. As a consequence data from cumulative dose response
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curves is presented as percentage changes in the ratio of blood flow measured 
simultaneously in both arms(449).
2.2.1.2 Basic protocol
All studies were performed on healthy volunteers who were taking no 
medications, did not have a family history of premature coronary artery disease 
and were non-smokers. Subjects were supine in a temperature-controlled 
laboratory with both forearms raised to above the level of the heart to allow 
efficient venous drainage. Drugs were administered in saline (sodium chloride 
0.9% (w/v)) and infused using an infusion pump (Harvard) at 0.5 ml/min through 
a 27G needle inserted into the non-dominant brachial artery (Cooper’s Needle 
Works, UK) under local anaesthetic (lignocaine 1%). Blood flow was allowed to 
return to baseline for 30 minutes following cannulation before recordings were 
made and for 15 minutes between each dose response curve. During recordings 
the hands were excluded from the circulation by wrist cuffs inflated to 
200mmHg(450). Upper arm congesting cuffs were inflated to 40mmHg for 10 
seconds of every 15-second recording cycle. Measurement of forearm 
circumference was simultaneously made in both arms by mercury-in-rubber strain 
gauges connected to a plethysmograph and recorded electronically (Maclab, UK). 
The strain gauges were calibrated at the start of each experiment. The initial linear 
slope of the last four recordings of both arms during baseline and each subsequent 
infusion were collected. These were exported to a spreadsheet (Excel) and the 
ratios of infused to non-infused arms were calculated and then averaged over the 
four recordings. The percentage change in blood flow due to increasing doses of
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drugs over the baseline was calculated and plotted in a separate graphics program 
(GraphPad Prism).
Infusion
needle
Exclusion 
cuff .
Congesting cuff
Strain gauge
Figure 2-2: Diagram of se t up of active forearm for venous
plethysmography (control arm lacks infusion needle)
2.2.2 Flow m ediated dilatation
2.2.2.1 Rationale
Although it is widely used and very reproducible venous occlusion 
plethysmography has the disadvantage of requiring an intra-arterial needle to 
probe vascular reactivity pharmacologically. An alternative technique is to 
measure the change in arterial diameter induced by a change in blood flow(107,451). 
Endothelial cells release nitric oxide (NO) and other endothelium-derived relaxing 
factors in response to mechanical shear stress. The precise mechanisms for the 
acute detection of shear forces and subsequent signal transduction to modulate
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vasomotor tone are not fully understood, but probably involve calcium-activated 
potassium-channel opening, membrane hyperpolarization and calcium-mediated 
activation of endothelial nitric oxide synthase. In vivo the endothelium can 
respond to shear stress due to increased flow, by releasing NO that causes 
relaxation of the underlying smooth muscle and vasodilatation(452). In humans, in 
vivo, it is possible to image the radial, brachial, femoral or tibial arteries with 
high-resolution ultrasound in longitudinal section. Direct visualisation of the 
brachial artery with ultrasound allows the detection of changes in the vessel’s 
diameter in response to this shear stress induced endothelial-dependent nitric 
oxide release. Unlike plethysmography that measures changes in resistance vessel 
tone, this technique directly visualises changes in conduit arteries. As a result 
caution is needed in comparing results between techniques.
Although originally the measurement of the arterial diameter was performed using 
callipers with B-mode recordings this has evolved to the use of quantitative 
ultrasound techniques and customised edge-detection software. This allows the 
serial recording of multiple time points during a study and the production of a 
dilatation curve for each individual from which the change in diameter can be 
determined.
An increase in shear stress is achieved by the production of reactive hyperaemia 
following a period of ischaemia in a distal vascular bed. To control for non­
specific smooth muscle effects changes in the diameter of the reference artery can 
be studied following systemic nitrate vasodilators. Each study is performed after
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the vessel had been allowed to return to the same baseline diameter as variation in
1 07the baseline diameter has been shown to affect the degree of dilatation( ).
222.2 Basic protocol
All studies were performed on healthy male volunteers who were taking no 
medications, did not have a family history of premature coronary artery disease 
and were non-smokers. Subjects were supine in a temperature-controlled 
laboratory and in all cases the right arm was studied. Three ECG leads were 
attached to the chest for continuous ECG recording. After 10 minutes rest and 
recording a baseline blood pressure, oral and peripheral temperature and pulse rate 
the arm was abducted horizontally and placed in a cradle and a blood pressure 
cuff positioned around the mid-forearm. The brachial artery was imaged 
longitudinally in the upper arm (5-10cm above the cuff) with high-resolution 
vascular ultrasound (Acuson XP10, 5-10 MHz broad bandwidth linear array 
transducer) with adjustments in the depth and gain settings made to ensure 
adequate visualisation of the anterior and posterior vessel wall over as long a 
section as possible. The ultrasound probe was then fixed in place with a 
stereotactic clamp that allowed small adjustments to maintain the image during 
the procedure. The position of the probe was marked after each study and images 
printed to ensure that at future sittings the same portion of the vessel, with the 
same baseline diameter, could be visualised. Ms Clare Storry, a technician at the 
Institute of Child Health, London, performed the ultrasound studies for this work.
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Figure 2-3: Diagram of se t up for flow mediated dilatation study.
Pulse wave Doppler was used to measure blood flow velocity expressed as the 
velocity time integral (VTI; average distance moved by a red cell in one cardiac 
beat) with the cursor set at 70 degrees to the longitudinal axis of the artery with 
the range gate set to 1.5mm. Although there are inherent limitations in this 
assessment relative changes are accurate. The B-mode image was set to update on 
the R wave of the ECG and longitudinal end-diastolic images were acquired to a 
PC every three seconds over a 2-3cm segment of the vessel.
Following an initial 60-second base line recording the forearm cuff was inflated to 
suprasystolic pressure (300mmHg) for 5 minutes to occlude flow to the hand and 
provide a hyperaemic stimulus on deflation. Following deflation recordings were
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continued for 5 minutes. Any change in blood pressure was recorded and then a 
two minute rest occurred before a further 60-second baseline recording. 
Sublingual GTN (25mcg) was administered sublingually and changes in vessel 
diameter were recorded for a further 5 minutes before a final recording of the 
blood pressure was made.
All scans were analysed off-line, using customised software with an automated 
edge detection algorithm (Brachial Tools, Iowa, USA), to determine the maximal 
change in diameter in response to both changes in flow, endothelial-dependent, 
and secondary to sublingual GTN, endothelial-independent. These are expressed 
as a percentage change from the minute long baseline. Following each study the 
baseline diameter, haemodynamic data, maximal flow mediated dilatation, 
maximal GTN-induced dilatation and the change in velocity-time integral was 
recorded.
2.3 Human model of systemic inflammation
In order to study the effects of an acute inflammatory episode, a model using 
typhoid vaccination has been developed(324). This allows the study of different 
subjects and the use of different protocols in a safe and reproducible fashion.
2.3.1 Inflammatory stim ulus
Inflammation was induced by the injection of Typhoid vaccine (Typhim Vi) as 
this produces a low-grade inflammatory response, as evidenced by a rise and fall 
in cytokine levels without a systemic haemodynamic response that could interfere 
with the interpretation of changes in blood flow.
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In all cases studies were repeated in the same individuals 16 hours before and 8 
hours after the vaccination with Salmonella typhi capsular polysaccharide vaccine 
0.025mg (Typhim Vi, Pasteur Merieux MSD) given into the gluteus maximus 
muscle. In some cases further studies were repeated at 32 and 56 hours after the 
stimulus.
2.4 Cell culture models
2.4.1 Primary cell lines
2.4.1.1 Rationale
As differences exist in the basal levels of CRP in different species and in their 
properties and quaternary structure, as described earlier (section 1.8.2), it is 
important to attempt to perform experiments in the same species as the CRP is 
sourced. As experiments in this thesis had been done with human internal 
mammary arteries, but the supply of tissue was difficult, it was important to also 
investigate effects on protein expression in a human cell line. Human coronary 
artery endothelial cells were chosen due to the appropriateness of their lineage to 
atherosclerotic disease, the avoidance of cross-species effects and their ready 
availability within the laboratory. Cells were exposed to a low inflammatory level 
of CRP (limited by the concentration of the samples used to 50mg/L) and after 24 
hours harvested and protein expression studied.
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2.4.1.2 Protocol
Passage five human coronary artery endothelial cells (HCAECs; Promocell, 
Heidelberg, Germany) were grown to 80% confluence in six well plates with 
supplier’s growth media (supplemented with fetal calf serum (2%), amphotericin 
B (0.05mg/ml) and gentamicin (50pg/ml)) at 37°C in 95%C>2/5%CC>2. Achieving 
80% confluence took on average 4 days and the media was replaced on alternate 
days. All procedures were performed under a sterile positive-pressure hood and 
cells were checked for integrity by light microscopy before and after each step. 
Cells of earlier passage were grown to confluence in T flasks and then washed 
with phosphate buffered saline (PBS) and mobilised with 1ml of trypsin solution. 
Following addition of the trypsin solution the plates were incubated for 1 minute 
and gently agitated to release the cells (confirmed by light microscopy). Before 
being aliquoted into fresh six well plates (2.5ml per well) or a fresh T flask 
(3.5ml) the trypsin was neutralised with the addition of an excess of culture media 
(2.5ml if for return to T flask and 17ml if for addition to six well plates). In this 
way for each experiment all cells were grown for the same duration and were of 
the same passage.
Media was then removed and stored and cells were washed with PBS before 
incubation for 24 hours with fresh media containing pure human CRP (final 
concentration 50mg/l), commercial human recombinant CRP (Calbiochem; 
50mg/l, containing sodium azide, final concentration 380pM), or an equal volume 
of buffer (TRIS buffer without sodium azide) to a total volume of 1ml per well. 
All treatments were performed in triplicate and all experiments were also done in 
triplicate.
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Following incubation cell integrity was confirmed by light microscopy, and by 
survival assay in some cases (described below; 2.4.1.3), and conditioned media 
was then removed and stored at -80 C until analysis. Cells were lysed with 200pl 
RIPA buffer (l%w/v Nonidet, l%w/v sodium deoxycholate, 0.1% w/v SDS, 
0.01M sodium phosphate with EDTA-free complete protease inhibitor; Roche), 
disrupted by sonication and collected by centrifugation (10 minutes at 14,000g) 
for assays of protein expression as described in section 2.5.1. Equivalence 
between groups was achieved by cell counting and protein quantification assay of 
lysed cells.
2.4.1.3 Cell viability assay
In order to confirm that treatment with different agents does not cause a change in 
cell viability a cell proliferation assay was performed. This was performed with 
Thiazolyl Blue Tetrazolium Blue (MTT), which is a yellow solution, which is 
converted to water-insoluble MTT-formazan, a dark blue substance, by 
mitochondrial dehydrogenases in living cells(453). The blue crystals are then 
solubilized and measured colorimetrically. The optical density of the resultant 
samples reflects the quantity of viable cells and therefore confirms whether 
culture treatments alter cell survival.
Following incubation of cells for 24 hours with control and active media this was 
replaced, under sterile conditions, with 2ml of fresh media containing MTT 
(0.2mg/ml; Sigma) and the cells were incubated for a further 60 minutes at 37°C, 
95% 02/5% CO2. The media was discarded and replaced with 400pl of dimethyl
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sulfoxide (Sigma), before a further 5 minutes incubation. Finally lOOpl of 
solution was transferred, in triplicate, to a 96 well flat-bottomed plate and the 
optical density read at 490nm on an automated plate reader. Results were 
averaged over the triplicates and expressed as optical density for each treatment.
2.4.2 Transfected cell lines
2.4.2.1 Rationale
In an attempt to explore the effects of CRP on the pterin pathway, modified 
murine endothelioma cell (sEnd-1) lines were employed. This was a model that 
had been used by Dr M Nandi, another member of the group, to look at the 
changes in pterins following stimulation with lipopolysaccharide and 
inflammatory cytokines. In this model two strains of sEnd-1 cells were used, the 
first had been transfected with an empty pcDNA vector and the second with a 
gene to over express GTP cyclohydrolase-1 feedback regulatory protein (GFRP), 
the endogenous inhibitor of GTPCH-1. In the stimulated cells an increase in 
nitrite and nitrate, by the Griess reaction, had been observed that was markedly 
attenuated in the cells over-expressing GFRP. To explore the effect of CRP on 
this system, particularly to look at the differences between commercially available 
preparations and the in house extraction, similar experiments were performed. As 
changes were seen in the colour of the media of cells treated with the different 
protein preparations (which is pH dependent due to its phenol red content), the pH 
of the media were quantified by a colourimetric technique.
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2A.2.2 Protocol
The preparation and transfection of the cells described in the next two sections 
were performed by M Nandi, a member of our department, as part of her PhD.
2.4.2.2.1 Expression and cloning o f human kidney GFRP
First strand cDNA synthesis of GFRP was performed using human kidney poly 
A+ RNA (Clontech) as a template and was primed using an oligonucleotide 
complementary to the 3’ UTR of human GFRP [GGT GCC CCG TCT GCA 
AATC]. PCR amplification of the cDNA was performed using oligonucleotides 
complementary to nucleotides 3-17 and 255-236 of the GFRP mRNA (94°C, 
lOsecs; 55°C, lOsecs; 72°C, 30 secs; 30xcycles) yielding a 0.25 kB product which 
was subsequently gel purified (Qiagen), TA cloned into pCR TOPO 2.1 
(Invitrogen) and sequenced to confirm that no mutations had been introduced 
during amplification.
In order to construct an N-terminally Myc tagged form of GFRP into the 
mammalian expression vector pcDNA 3.1 Hygro (Invitrogen) PCR amplification 
of the TA cloned cDNA was performed using a 5’oligonucleotie primer encoding 
a Hindlll restriction site (in italics) followed by the 9E10 N-Myc epitope (in bold) 
[GATC AAG CTT ACC ATG GCC GAA CAA AAA CTC ATC TCA GAA 
GAG GAT CTG GGC GGC CCC TAC CTG CTC ATC AGC ACC]. The 3’ 
oligonucleotide primer contained a downstream Xho 1 site (in italics) [CTGA 
CTC GAG TCA CTC CTT GTG CAG AC A CCA C]. PCR amplification (94°C, 
lOsecs; 40°C, lOsecs; 72°C, 30 secs; 20xcycles) produced a band approximately 
0.35kB in size. This product was gel purified, ligated into pcDNA 3.1 Hygro (pre
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digested with Xho I and Hind III), and transformed into E. Coli sub cloning 
efficiency cells (DH5a -  Invitrogen). Recombinant plasmids were selected and 
the insert verified by sequencing.
2.4.2.2.2 Tranfection o f sEnd 1 cells
Murine endothelioma cells (sEnd 1)(454) were grown to confluence in a 6 well 
plate in Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen) containing 
10% heat inactivated fetal bovine serum, 100 units penicillin G sodium and lOOug 
streptomycin sulphate (Invitrogen) and 2mM L-glutamine (Invitrogen) in a 
humidified incubator (37°C/ 5% CO2).
Either GFRP/pcDNA 3.1 Hygro or the pcDNA 3.1 Hygro (empty vector control) 
was transfected into sEnd 1 cells using TFX 20 Transfast transfection reagent 
(according to manufacturers instructions). 48 hours post transfection, medium 
was replaced with medium containing 500mg/ml hygromycin (Roche) to select 
for transfected cells. Following five days of culture in the selective medium, 
individual hygromycin colonies were isolated and transferred to 96 wells plates 
for expansion. To confirm expression of N-terminally Myc tagged GFRP, lysates 
of cells were resuspended in RIPA buffer and resolved by SDS PAGE and 
analysed by western blotting using the 9E10 monoclonal a myc antibody 
( 1:1000).
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2.4.2.2.3 Incubation with C-reactive protein
Cells were grown on 24 well plates in DMEM in the same way as described for 
HCAECs, with antibiotics to maintain pure cell lines. Cells of passage 5-7 were 
mobilised from T25 flasks with 1ml of trypsin solution and then after 
neutralisation of the trypsin with the addition of 23ml of DMEM aliquoted in 
equal volumes into a fresh 24-well plate. These were grown to 80% confluence in 
an incubator (37°C in 95%02/5%CC>2) with media being changed on alternate 
days. For each experiment one plate of GFRP overexpressing cells (Bl) and one 
of empty vector cells (pcDNA) were used and treated in the same way. Generally 
the pcDNA cells grew more quickly than the B l cells and this was accounted for 
by plating out the cells more sparsely before the incubation period and by 
correcting all NO assays for the protein content of each well as described below 
(section 2.5.1.2.2). As with the HCAECs all procedures were carried out with 
sterile equipment in a sterile positive pressure hood.
At the start of the experiments lOOpl of solution from each well was aliquoted 
into a 96 well plate and this was frozen (-80°C) for 24 hours in order to analyse all 
the samples at the same time. The cells were washed with PBS and active media 
added. Two incubation protocols were performed, with each treatment being 
applied to 4 wells from each plate and performed in triplicate.
The first set of experiments consisted of purified CRP (50mg/L), commercially 
available CRP (Calbiochem; 50mg/L), purified CRP which had then been 
depleted by incubating with sepharose beads coated with phosphoethanolamine 
(final concentration <0.01mg/L), control buffer solution, a cytokine mixture as a
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positive control (lOng/ml TNFa, lOOunit/ml interferon y and 5pg/ml LPS) and a 
negative control with no additions.
In the second set of experiments the buffer solution group was replaced by 
commercially available CRP, which had been dialysed against a large volume of 
sodium azide-ffee buffer to remove this contaminant (final CRP concentration 
50mg/L). On two occasions a further plate consisting of 12 wells with pcDNA 
and 12 with Bl cells was run containing media alone or one of two concentrations 
of the metabolic poison myxthiazole (lOpM or lpM).
Plates were incubated for 24 hours at 37 C in 95%02/5%C02 and then lOOul of 
media, in duplicate, was drawn off into the 96 well plate from the first day for the 
performance of a Greiss assay as detailed in the biochemical methods below 
(section 2.6.5). A further 10001 was drawn off into a second 96 well plate for the 
determination of pH, also detailed below (section 2.6.6), and a final 200Q1 was 
saved into eppindorfs for use on pH indicator strips. The remainder of the media 
was discarded and the cells were lysed with RIPA buffer (as described previously) 
and the total protein content of each well was determined, as indicated in section 
on western blotting (2.5.1.2.2), in order to allow correction of the NO production 
assays for the amount of cellular material in each well.
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2.5 Molecular biological techniques
2.5.1 W estern blotting
2.5.1.1 Rationale
Western blotting (immunoblotting) allows the identification and semi­
quantification of proteins within biological samples based on their electrophoretic 
properties. Equal quantities of protein are added under denaturing conditions to a 
polyacrylamide gel matrix and are separated according to their molecular weight 
as they move by one-dimensional electrophoresis towards the anode. By the use 
of a coloured protein ladder of known molecular weights it is possible to identify 
individual products. Specificity is improved by transferring the samples after 
separation to a nitrocellulose transfer membrane that fixes their relative position. 
This can then be interrogated with antibodies specific to the protein of interest. 
For practical reasons the antibody process is generally performed in two stages; 
firstly a specific antibody is used and then secondly an antibody to this, tagged 
with horseradish peroxidase, is applied. The presence of horseradish peroxidase 
allows the detection of the antibody by its emission of light under specific 
conditions, which is captured on radiographic film. Although only semi- 
quantitative the relative intensity of bands demonstrated by this technique indicate 
the degree of expression of the protein studied provided that equal quantities of 
total protein have been added to the system and complete and equal transfer has 
occurred for all samples.
I l l
2.5.1.2 Protocol
2.5.1.2.1 Sample preparation
Prior to separation with western blotting tissue samples were processed to ensure 
cellular disruption without degradation of the relevant proteins. For whole vessel 
preparations rat aorta were incubated in the same way as detailed for organ bath 
experiments; that is in DMEM for 4 hours with the relevant treatment, before 
being snap frozen by immersion in liquid nitrogen. Tissues were then smashed in 
a metal pestle and mortar, which itself had been cooled to -80°C, before being re­
suspended in a solution of protease inhibitors (complete EDTA-free protease 
inhibitor cocktail tablet, Roche, USA). Once re-suspended the samples were then 
exposed to repeated thaw-sonication-freeze cycles to ensure adequate disruption. 
Finally samples were centrifuged (10 minutes at 4000rpm) and the supernatant 
drawn off for further analysis.
Samples obtained from cell culture experiments were prepared in a different way 
to reflect the relative ease of disruption of this type of material. Incubation 
protocols are detailed in section 2.4.1.2. After all culture medium was removed, 
0.2ml of RIP A lysis buffer (1% w/v Nonidet P-40, 1% w/v sodium deoxycholate, 
0.1% SDS, 0.15M NaCl, 0.01M sodium phosphate (pH 7.2), 2mM EDTA, 50mM 
sodium fluoride, 0.2mM sodium vanadate, lOOU/ml aprotinin) was added to each 
well and the plates agitated to release the cells. Disruption of the cells was aided 
by repeated drawing up and down through a 200pL pipette, before freezing the 
samples. As with vascular tissue the samples were centrifuged and the 
supernatant stored for further analysis.
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Although western blotting is only semi-quantitative it is important to load equal 
quantities of protein to each channel. To achieve this sample protein contents 
were determined by the Bradford method. This involves quantification of the 
binding of Coomasssie brilliant blue to the unknown protein in comparison to 
different known concentrations of bovine serum albumin(455). A protein ladder 
was generated with bovine serum albumin (Promega) over a range of 1-25 jig/ml 
and 80pl added in duplicate to a 96 well plate. Unknown proteins were diluted 
100-200 fold in water and 80pl added in duplicate to the plate. To each well 20pl 
of coomassie solution (Bio-Rad Laboratories, USA) was added and mixed. The 
colour change was quantified with a colorimeter set at 595nm absorbance and 
results compared to the standards with an appropriate correction for prior dilution. 
The quantity of solution added was then adjusted according to this concentration 
and the individual protein under investigation. Prior to loading into the stacking 
gel the desired quantity of sample was added to a loading buffer in a ratio of 5:1. 
The loading buffer (80mM Tris (w/v; BDH), 5% P-mercaptoethanol (v/v; BDH), 
0.02% bromophenol blue (w/v), 10% glycerol (v/v), 2% SDS (w/v) with pH to 6.8 
with HC1) served the joint purpose of allowing easy visualisation of the samples 
and aided in protein denaturisation and the separation of disulphide bonds. 
Immediately prior to loading of the samples they were boiled at 99°C for 10 
minutes and then chilled on ice to ensure complete protein separation.
2.5.1.2.2 Protein separation
Separation of proteins was achieved by one-dimensional electrophoresis on 
denatured samples. SDS separation gels were made for each experiment, with the 
percentage content of acrylamide varied according to the protein of interest.
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Initially two glass plates were fitted into a customised clamp separated by 
0.75mm spacers and the bottom sealed with agarose. The components of the 
separating gel were mixed (acrylamide, 3M Tris (pH 8.8), 10% w/v SDS, water) 
and then TEMED (NNNN-tetramethylethylenediamine) and 10% w/v ammonium 
persulphate were added to set the material just prior to pouring between the plates, 
to approximately 2cm from the top. Diluted Tris (pH 8.8) was poured over the gel 
to prevent drying during the setting process.
After the separation gels had set, a stacking gel (4% acrylamide, with pH 6.8 3M 
Tris) was poured and a 0.75mm thick comb was inserted to produce ten channels. 
After this had also set the comb was removed and the wells cleaned of excess 
material. Two gels were produced at a time and they were then mounted as a pair 
within the clamping frame and electrode assembly and placed in the buffer 
chamber (Bio-Rad Laboratories, USA). The entire assembly was then immersed 
in running buffer (0.125M Tris base, 0.96M glycine, 0.5% w/v SDS, water, pH 
8.3).
One or more pre-stained protein ladders (Invitrogen, USA) and the samples for 
separation were added to the wells within the stacking gel. No more than 30pl of 
solution was added to any well to avoid overfilling and spillage into neighbouring 
channels. Gels were then run at a constant voltage of 200V in order to separate 
the proteins, the duration according to the molecular weight of interest.
Following separation the gels were removed from the tanks and sandwiched 
between six sheets of Whatman paper and a nitrocellulose membrane (Hybond-P,
114
Amersham, UK) to allow transfer of the samples. Gel orientation was designated 
by the removal of the top left hand comer. Whatman paper was soaked in transfer 
buffer (3.6g Tris base, 14.4g glycine, 200ml methanol made up with water to 
1000ml, pH 8.3) and nitrocellulose membrane activated with methanol prior to 
transfer. All air bubbles were removed and then a 200mA constant current passed 
across the sandwich for 30 minutes to achieve transfer. At all times the 
nitrocellulose membranes were handled as little as possible and with the use of 
gloves to avoid contamination.
Following transfer the nitrocellulose membranes were cut to size and transferred 
to clean baths and immersed in phosphate buffered saline with Tween (PBST; 1L 
of PBS made from tablets (Sigma) in sterile water and 1ml Tween 20 (Sigma)) 
containing milk powder (5%w/v, Marvel) and gently agitated. This milk solution 
acted to bind and block non-specific proteins and improve resolution of antibody 
identification.
Gels were stained for protein content with Coomassie, by initially immersing in 
staining solution (1 part acetic acid, 3 parts isopropanol, 6 parts water and 0.5% 
w/v Coomassie brilliant blue) for 1 hour before changing this to destaining 
solution (7% v/v acetic acid, 5% v/v methanol, 88% water) for 12 hours (changed 
3 times), before finally fixing with fixing solution (50% v/v methanol, 10% v/v 
acetic acid, 40% water) and drying.
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2,5.1.23 Protein identification
Protein identification was performed by a two-stage antibody technique involving 
the use of a specific primary antibody and then an enzyme-linked secondary 
antibody directed against the primary. The primary antibodies for eNOS and 
iNOS were obtained from a commercial source (rabbit anti-human eNOS (c-20) 
and rabbit anti-mouse iNOS (m-19)[Santa Cruz Biotechnology, California USA]), 
whereas the anti-GTPCH-1 anti-peptide antibody was developed for the 
department by Sigma using amino acids 17-45 from the human sequence in a 
rabbit and was polyclonal(456) .
Following at least 4 hours of blocking in milk solution this was washed off and 
changed to primary antibody solution (1:1000 antibody in PBST). This was then 
incubated overnight on a rotary agitator at 4°C. In the case of anti-GTPCH-1 the 
solution contained 5% milk to reduce non-specific binding. On completion of the 
overnight exposure excess primary antibody was removed by washing with 
agitation for 10 minutes in fresh PBST. This was repeated a total of six times. 
Secondary antibody exposure was performed for 2 hours at room temperature, 
before a final six further wash cycles. The secondary antibody was anti-rabbit 
IgG fused with horseradish peroxidase (Santa Cruz Biotechnology, California 
USA) diluted in PBST to a final concentration of 1:3000.
Development of the bound secondary antibody was achieved with the ECL plus 
system (Amesham, UK) that is based on the enzymatic production of an 
acridinium ester, by horseradish peroxidase, that emits light. The light produced 
was recorded onto photographic film exposed for increasing durations from 5
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seconds to 2 minutes. The exact durations were optimised for the individual 
assays. Localisation of individual bands was achieved by comparison to a known 
standard and relative to the pre-stained protein ladder.
Developed films were scanned onto a computer with a flat-bed scanner once 
appropriately labelled. Although a semi-quantitative technique, the intensity of 
the bands were compared with the aid of Scion imaging software (Scioncorp, 
USA) and averaged over three individual blots.
Membranes were Coomassie stained in the same way as gels, without the fixing 
step, and dried and also scanned onto a computer to allow quantification of the 
degree of protein transfer in each channel.
2.6 Biochemical techniques
2.6.1 Isolation of hum an C-reactive protein
2.6.1.1 Rationale
Although preparations of CRP are available from commercial sources they are 
primarily intended as standards to calibrate assays for serum CRP. As a 
consequence they include sodium azide to retard the growth of any contaminating 
bacteria, as it acts as a mitochondrial respiratory chain inhibitor(276;278). The 
presence of this metabolic poison therefore makes commercially available CRP 
unsuitable for functional experiments in cells or intact tissues. In addition, the 
purity of commercially available CRP has been questioned, particularly with 
regard to the presence of immunoglobulins(249). As a result, for these studies,
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collaboration was made with Professor M B Pepys’ group at the Centre for 
Amyloidosis and Acute Phase proteins at the Royal Free Hospital (specifically Dr 
G M Hirschfield) to obtain CRP purified from human ascitic fluid, which 
specifically did not contain sodium azide as part of its buffer. In addition all 
experiments were then performed with the buffer (0.01M Tris 0.138M NaCl 
0.002M CaCb, pH 8) used for the CRP as the negative control.
2.6.1.2 Protocol
Human CRP was purified from human ascites by affinity chromatography as 
previously described(457). Briefly, the ascites was filtered and then Sepharose- 
phosphoethanolamine beads were used to capture the human CRP, which was 
subsequently packed into a column and the CRP eluted off with TrisNaCl-Ca 
buffer containing ImM phosphocholine (pH 8). The CRP was then dialysed 
extensively into TrisNaCl-Ca buffer, containing no azide (pH8), to remove the 
phosphocholine (final concentration 2mg/ml). C-reactive protein was 
demonstrated to be in its native pentameric form by size exclusion 
chromatography, and functionality was confirmed by calcium dependent binding 
to immobilised phosphoethanolamine. SDS gel electrophoresis demonstrated a 
single band corresponding to an approximate size of 23K. CRP and its vehicle 
contained <0.5ng/ml bacterial lipopolysaccharide (LPS) by Limulus chromogenic 
assay (BioWhittaker Europe).
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2.6.2 Urine and blood sam pling
2.6.2.1 Rationale
Our group have previously shown that the inflammatory response to vaccination 
leads to endothelial dysfunction(50;324). Collection of samples following 
vaccination allows the investigation of the size and type of an inflammatory 
response, an exploration of changes in cardiovascular risk factors and an 
assessment of the temporal change in inflammatory markers and indices of 
endothelial function.
2.6.2.2 Protocol
During plethysmography studies, described in chapters 4 and 5, blood and urine 
samples were taken before and 2 hourly for 8 hours after vaccination for the 
measurement of serum albumin and plasma lipids and urinary protein. As a 
control, urine samples were taken at 4pm on a different day in the absence of 
vaccination. In the studies using ascorbic acid prior to vaccination (chapter 4) 
samples of blood only were collected on day 1, prior to vaccination and 4 and 8 
hours after. For FMD studies (chapter 3) blood samples were taken prior to each 
study and additionally just before vaccination and again 4 hours later.
Blood was collected into tubes containing lithium heparin, citrate and EDTA and 
plasma was obtained by centrifugation (3000g for 10 minutes), then aliquoted and 
stored at -20°C. Plasma was used to measure IL-6 and IL-IRa with a 
commercially available ELISA as detailed below (section 2.6.3) (R and D 
systems, Abingdon, Oxon). Plasma was analysed at baseline and 8 hours
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following vaccination for concentrations of total cholesterol, HDL and albumin by 
reflectance spectroscopy (Vitros multichannel analyser 250,700,750) by a hospital 
laboratory (Great Ormond Street) and for total anti-oxidant capacity as detailed 
below (section 2.6.4). Urine was collected in sterile containers and chilled and 
frozen at -20°C immediately. Samples at baseline and 8 hours after vaccination 
were analysed for urinary albumin by immunonephlometry (Behring BNII 
analyser) and creatinine concentrations by enzymic assay and chemiluminescence 
(Vitros 700, Ortho Clinical Diagnostics) by a hospital laboratory (Great Ormond 
Street).
In the study with pre-treatment by ascorbic acid samples were collected into plain 
tubes, EDTA and lithium heparin. Plain tubes were allowed to clot and then all 
samples were centrifuged (at 3000g for 10 minutes). A further EDTA treated 
sample of whole blood was frozen (-20°C) for analysis of red blood cell 
glutathione. Serum (500pL) was added to equal volume of fresh 10% 
metaphosphoric acid and recentrifuged and the supernatant frozen. Plasma with 
EDTA (1ml) was deproteinated with 30% perchloric acid (60pL) and the 
supernatant stored. The remainder of the samples were stored at -80°C for 
analysis of markers of oxidant stress as detailed below (section 2.6.4).
Analysis by ELISA was made of IL-6 , IL-IRa and neopterin and CRP by 
automated immunoassay as detailed below (section 2.6.3).
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2.6.3 Blood analysis by im m unoassay
2.6.3.1 Rationale
All the assays used employed the quantitative sandwich immunoassay technique 
whereby a relevant monoclonal antibody was pre-coated on to a multi-well plate. 
Samples, and standards, bind to this immobilised antibody and after removal of 
unbound substances a specific enzyme-linked antibody was added that binds to 
the immobilised protein. Following a further wash a substrate solution was added 
and the colour change quantitated to determine concentration.
IL-6, IL-IRa and TNFa were assayed, as they are inflammatory cytokines 
involved in the immune response to vaccination(324,458,459). They represent an 
early and sensitive marker of inflammation and IL-6 in particular is involved in 
the development of the acute phase response. CRP was measured as it is the 
classical acute phase protein and as described in the introduction is predictive of 
future cardiovascular complications (section 1.8.1). Neopterin, itself an acute 
phase protein, was assayed to reflect changes in the pterin pathway as it is also 
generated following upregulation of GTP cyclohydrolase-1 which is the rate 
limiting step for these products.
I performed the assays of the interleukins and neopterin, with the exception of the 
5 subjects in the first venous occlusion plethysmography protocol. A member of 
Dr Vidya Mohamed-Ali’s group performed the remainder of the IL-6/IL-lRa 
analysis and Ruth Gallimore in Professor MB Pepys’ laboratory performed the 
CRP assays.
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2.6.3.2 Protocols
2.6.3.2.1 Interleukin-6
Assays were performed using a pre-packaged kit (R and D Systems, Abingdon, 
Oxon) with all samples being studied in duplicate in a 96-well plate according to 
the manufacturer’s instructions. Assay diluent (lOOpL) and standards (over a 
range of 0.156 to lOpg/mL) or citrated plasma samples (lOOpL) were added to the 
plates coated with mouse monoclonal antibody against IL-6 and incubated on an 
orbital shaker for 2 hours. The plates were then washed six times with a non­
phosphate containing buffer before IL-6 conjugated to alkaline phosphatase was 
added (200pL), before incubation and agitation for a further 2 hours. A further 
six washes were performed before substrate solution (NADPH with stabilisers; 
50pL) was added to each well and the plate incubated for 60 minutes on the 
desktop. Amplification was performed for 30 minutes after addition of the 
relevant amplifier solution (alcohol dehydrogenase and diaphorase; 50pL). 
NADH, formed from NADPH by reaction with the fixed alkaline phosphatase in a 
dose dependent fashion, reduced a tetrazolium salt to produce a coloured 
formazan dye (and NAD+ then is recycled in the amplification step). The reaction 
was stopped by the addition of stop solution (2N sulfuric acid; 50pL) and the 
plates immediately read in a microplate reader at 490nm (with wavelength 
correction at 690nm). Samples were compared to the standard curve and a final 
concentration obtained, which was averaged over the duplicates. The 
manufacturer’s lower limit of detection of this assay was 0.039pg/mL, with an 
interassay coefficient of variation (CV) of 7.2% at 2.78pg/mL and 6.5% at 
5.65pg/mL.
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2.6.3.2.2 Interleukin-1 Ra
Assays were performed using a pre-packaged kit (R and D Systems, Abingdon, 
Oxon) with all samples being studied in duplicate in a 96-well plate according to 
the manufacturer’s instructions. Assay diluent (50pL) and standards (over a range 
of 46.9 to 3000pg/mL) or lithium heparin plasma samples (200pL) were added to 
the plates coated with mouse monoclonal antibody against IL-IRa and incubated 
on an orbital shaker for 2 hours. The plates were then washed four times with a 
non-phosphate containing buffer before IL-IRa conjugated to horseradish 
peroxidase was added (200pL), before incubation and agitation for a further 2 
hours. A further four washes were performed before substrate solution (hydrogen 
peroxide and tetramethylbenzidine with stabilisers; 200pL) was added to each 
well and the plate incubated for 20 minutes while protected from light while the 
colour developed. The reaction was stopped by the addition of stop solution (2N 
sulfuric acid; 50pL) and the plates immediately read in a microplate reader at 
450nm (with wavelength correction at 570nm). Samples were compared to the 
standard curve and a final concentration obtained, which was averaged over the 
duplicates. The manufacturer’s lower limit of detection of this assay was 
14pg/mL, with an interassay CV of 4.4% at 918pg/mL and 5.0% at 1851pg/mL.
2.6.3.2.3 Neopterin
Assays were performed using pre-packaged kits (Brahms, Hennigsdorf, Germany) 
with all samples being studied in duplicate in a 96-well plate according to the 
manufacturer’s instructions. Enzyme conjugate (neopterin/alkaline phosphatase; 
150pL) and citrated plasma samples, standards (2-250nmol/L) or known controls 
(50pL) were added to a 96 well clean plate and mixed. A portion (150pL) of this
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was transferred to a second plate coated with polyclonal sheep anti-neopterin 
antibodies and incubated in the dark for 2 hours. The enzyme conjugate and 
neopterin in the plasma samples compete for binding to the fixed antibody. 
Following incubation the plate was washed four times to remove all unbound 
components and 4-nitrophenyl phosphate (PNP; lOOpL) was added to each well. 
Bound alkaline phosphatase conjugate catalyses the cleavage of the phosphate 
from PNP to produce the yellow 4-nitrophenol. The intensity of the colour is 
inversely proportional to the amount of neopterin in the plasma. The reaction was 
stopped by the addition of sodium hydroxide (lOOpL) and optical density 
measured in a microplate photometer at 405nm (with correction at 630nm). 
Samples were compared to the standard curve and a final concentration obtained, 
which was averaged over the duplicates. Accuracy of the assay was determined 
with reference to the known high and low concentration control samples. The 
manufacturer’s lower limit of detection of this assay was 2nmol/L, with an 
interassay CV of 9.6% at 7.19nmol/L and 5.14% at 65.42nmol/L.
2.6.3.2.4 C-reactive protein
Plasma C-reactive protein values in the in vivo study were determined, with a 
standard laboratory technique, using a high sensitivity automated microparticle 
enhanced latex turbidimetric immunoassay (COBAS MIRA; Roche Diagnostics 
GmbH)(460). Serum collected in lithium heparin, as described previously (section 
2.6.2), was recentrifuged at 4000G for 10 minutes in a chilled centrifuge and the 
supernatant removed. A blinded operator measured samples in batches. The 
lower limit of detection of this assay was 0.2 mg/1, with a CV of 4.2% at 4 mg/1
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and 6.3% at 1 mg/1. The assay was standardised with the appropriate WHO 
reference standard(461).
2.6.3.2.5 Tumour necrosis factor a
Assays were performed using a pre-packaged kit (R and D Systems, Abingdon, 
Oxon) with all samples being studied in duplicate in a 96-well plate according to 
the manufacturer’s instructions. Assay diluent (50pL) and standards (over a range 
of 0.5 to 32pg/mL) or citrated plasma samples (200pL) were added to the plates 
coated with mouse monoclonal antibody against TNFa and incubated on an 
orbital shaker for 3 hours. The plates were then washed six times with a non­
phosphate containing buffer before TNFa conjugated to alkaline phosphatase was 
added (200pL), before incubation and agitation for a further 2 hours. A further 
six washes were performed before substrate solution (NADPH with stabilisers; 
50pL) was added to each well and the plate incubated for 60 minutes on the 
desktop. Amplification was performed for 30 minutes after addition of the 
relevant amplifier solution (alcohol dehydrogenase and diaphorase; 50pL). 
NADH, formed from NADPH by reaction with the fixed alkaline phosphatase in a 
dose dependent fashion, reduced a tetrazolium salt to produce a coloured 
formazan dye (and NAD+ then is recycled in the amplification step). The reaction 
was stopped by the addition of stop solution (2N sulfuric acid; 50pL) and the 
plates immediately read in a microplate reader at 490nm (with wavelength 
correction at 690nm). Samples were compared to the standard curve and a final 
concentration obtained, which was averaged over the duplicates. The 
manufacturer’s lower limit of detection of this assay was 0.12pg/mL, with an 
interassay CV of 12.6% at 6.7pg/mL and 10.8% at 13.5pg/mL.
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2.6.4 Biochemical a s se s s m e n t of oxidant s tre s s
A pro-oxidant environment can reduce NO bioavailability by directly breaking 
down the NO or oxidising BH4 as discussed in the introduction (section 1.10.1.2). 
This section describes the assays carried out to determine changes in the blood 
oxidant profile and concentrations of reduced ascorbic acid before and after 
vaccination.
2.6.4.1 Total Anti-Oxidant Status
These assays were performed in a blinded fashion with the assistance of Dr 
Jeffrey Stephens, who has validated this assay(462). Plasma Total Anti-Oxidant 
Status (TAOS) was measured with a photometric assay initially described by 
Laight et al and modified by Sampson et alf413:463). The assay depends on the 
capacity of plasma to inhibit the peroxidase-mediated formation of the 2 ,2-azino- 
bis-3-ethylbensthiazoline-6-sulfonic acid (ABTS+) radical and is compared to the 
amount of ABTS+ produced when phosphate buffered saline (PBS) is used as a 
control. The effects are detected by the colour change of horseradish peroxidase 
induced in a quantitative fashion by the ABTS+.
Although this technique is used as a non-specific assay of multiple anti-oxidant 
pathways within the blood the activity of catalase may be most important 
component. In support of its use in these studies TAOS has been found to be 
closely correlated with other markers of oxidant stress, in particular F2- 
isoprostanes(464).
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The assay was performed in a clean 96 well plate with all samples analysed in 
duplicate. Stock solutions were made prior to the assay. Plasma samples or PBS 
controls (2 .5pi) are added to all bar two wells, which are used as blanks, with two 
known positive controls. To each well 20pl ABTS (20mmol/L; Sigma), 20pl 
horseradish peroxidase (30mU/ml; Merck) and 37.5pl PBS was added prior to 
commencing the reaction with 20pl hydrogen peroxide (final concentration 
O.lmmol/L; Sigma). The reaction proceeded in the dark at 37°C for 10 minutes 
and was read at 405nm using a Labsystems Multiscan Ex microplate reader. The 
difference in absorbance (control absorbance minus test absorbance) divided by 
the control absorbance (expressed as a percentage) represents the degree of 
inhibition of the reaction, and therefore the total anti-oxidant status of the plasma 
samples.
2.6.4.2 Acorbic Acid concentration
Dr Chrissi Dunster at King’s College London performed these assays for this 
work in a blinded fashion on samples collected by myself. Venous samples were 
collected onto ice and centrifuged at 4°C (3000G for 10 minutes) before being 
mixed with equal volumes of chilled fresh 10% metaphosphoric acid and 
recentrifuged. The supernatant was drawn off and stored at -20°C and then 
transported to King’s College for further analysis.
Samples were defrosted and diluted 5:1 with metaphosphoric acid to produce a 
final volume of lmL and mixed. Heptane (200pL) was added and vortexed 
before centrifuging at 4°C for 5 minutes (13000rpm). The supernatant was 
collected and diluted with more heptane before repeated centrifugation, on two
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further occasions. The ascorbic acid concentration was determined with High 
Performance Liquid Chromatography (HPLC).
The HPLC was run with the following parameters:
Mobile phase = 0.2M K H 2 PO 4  / 0.25mM octane sulphonic acid, pH2.1 at lml/min 
Column = 250 x 4.6mm ApexII ODS 5micron column with 2cm Bio300 guard 
Glassy carbon electrode = 400 - 600m V potential for measurement of vitamin C. 
Range = 0.5 -  1.0 (ramps sensitivity
Samples were compared to standards made with ascorbic and uric acid dissolved 
in metaphosphoric acid at concentrations of 0, 3.125, 6.25, 12.5, 25, 50pM on 
each occasion.
2.6.5 Determination of NO production by G reiss a ssay
The Griess assay is a colorimetric technique for detecting nitrite concentrations by 
the azo coupling of diazonium, which is itself produced by the reaction of nitrite 
with sulphanilamide, with naphthylethylenediamine (NED). This produces a 
purple dye (wavelength 540nm) in a quantitative manner that is then detected with 
a plate colourimeter. In these experiments, in the interests of simplicity, no 
attempt was made to reduce nitrate to nitrite and therefore only the latter was 
measured.
A series of seven standards were produced in DMEM from 2-100pM of nitrite 
from a known 10'3M stock solution. These were added in duplicate (lOOpl per 
well) to the first three columns of wells on each plate with the last row being used
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for DMEM alone. The two Griess reagents were made; “A” consisting of 5% 
phosphoric acid and 1% sulphanilamide and “B” of 0.1% NED. These were 
mixed in equal volumes and lOOpl of the resultant solution added to each well. 
The plate was allowed to incubate on the desktop and then the absorbance read (at 
540nm) on a photometer. A standard curve was produced and the raw data 
converted into concentrations of nitrite by reference to this, having subtracted the 
effect of the DMEM blank. All results were then corrected for the protein 
concentration (producing a result as pM nitrite per pg protein) and averaged over 
the four identical treatments on each experiment.
2.6.6 Determination of pH by colourim etric assay
As DMEM contains the pH dependent dye phenol red it is possible to see changes 
in the pH of the solution by changes in this dye (from yellow for acidic to pink for 
alkali). In these experiments pH was determined by two methods, firstly the use 
of pH sensitive paper strips and secondly by taking advantage of the colour 
change to perform a colourimetric test.
The strips (pH-FIX; Sigma, UK) were chosen for their range of 6-9 units and 50pl 
of solution was added to each. The result was read from the colour standard 
provided with the strips.
In order to more accurately quantify the results a standard curve of 8 different pHs 
was generated over the range of 6-9 by the addition of increasing quantities of 
0.25M hydrochloric acid to a stock solution of DMEM. Initially the pH of the 
solution was determined with a pH meter (Hanna Instruments pH211 meter,
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Leighton Buzzard, UK) and lOOpl added in duplicate to the 96 well plate with the 
culture media samples. Hydrochloric acid was then added and the pH 
redetermined, aiming to produce a 0.5 unit fall in pH each time, and the resultant 
solution aliquoted into the 96 well plate. This was repeated to produce the 
standard curve and then the plate was read with a photometer (wavelength 
595nm).
Unknown samples were then transformed into pH by reference to the standard 
curve and averaged over the four identical treatments.
2.7 Data analysis
2.7.1 Data handling
2.7.1.1 In vitro studies
In organ bath studies concentration-response curves for vasoconstrictors were 
generated by firstly subtracting the baseline tone of the vessels (approximately 1 g 
for rat and 2g for human tissue) from the tone at each time point. Results were 
then plotted as active tone against drug concentration (on a log 10 scale) using the 
mean (± standard error of the mean (SEM)) for the multiple replicates of each 
experiment. In the case of vasorelaxants, which were initially pre-constricted 
with phenylephrine, the results were expressed as percentage relaxation from the 
maximal constriction after subtraction of the basal tone in all cases. Again data 
was plotted as mean (±SEM).
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Protein intensity blots were semi-quantified by intensity and expressed as mean 
(±SEM) over at least three groups. Other biochemical parameters were also 
expressed as mean (±SEM).
2.7.1.2 In vivo studies
In studies using plethysmography the slope of the steepest part of the MacLab 
recording from the strain gauges was determined for both arms for the last 4 
recordings of each dose of agent and baseline. Although this gives actual flow (in 
mL/lOOmL forearm/min) a ratio of active to inactive arm was calculated, to allow 
the inactive arm to control for changes in ambient conditions. The percentage 
change in the averaged active ratio compared to the baseline ratio was determined 
and this was plotted in each case. In addition the area under the curve for each 
individual dose-response was calculated and also plotted. In all cases the data was 
expressed as means (±SEM). For studies involving the assessment of flow 
mediated dilatation the data was analysed with an automated system. The 
resultant percentage changes were displayed as means (±SEM). In the case of 
biochemical data parameters with a Gaussian distribution were expressed as mean 
(±SEM), while skewed data was shown as medians with 95% confidence intervals 
or geometric mean (± approximate SD).
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2.7.2 Statistical analysis
2.7.2.1 Definition of significance
In all studies significance was defined as a a-value of less than 5%, indicating that 
the chance of the null hypothesis still being true even though the difference is 
greater than the critical value was less than 5%. In the case of studies where the 
means of more than two variables were compared by t-tests a Bonferroni 
correction was applied. This states that when 3 or more variables are considered 
the resultant “P value” was multiplied by all possible comparisons. For example, 
if 3 groups were used the outcome of A vs. B would be multiplied by 3 (as it 
would be possible to compare A:B, A:C and B:C) and only if  the result was still 
less than 5% it would be considered statistically significant.
2.7.2.2 In vitro models
In organ bath experiments with concentration-response curves, comparisons 
between treated and control vessels were made by 2-way ANOVA. For studies 
with only a single intervention, such as the effect of arginine on pre-constricted 
vessels, and in those involving intensity analysis comparison was made by paired 
t-test with post hoc correction if required.
2.7.2.3 In vivo models
For plethysmography, comparison of dose-response curves was performed by 2- 
way ANOVA. Secondly the area under the curve was calculated and means then 
compared by paired t-tests. Data from FMD studies were compared by one-way
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repeated measures ANOVA with post hoc Bonferroni analysis of all pairs of data. 
In the experiments with tetrahydrobiopterin the data was analysed by the repeated 
measures of covariance model (XTREG procedure in STATA8.2) to account for 
the change in basal flow caused by tetradydrobiopterin infusion. This analysis 
was performed by JP Casas within our group.
Normally distributed biochemical data were compared by paired t-tests, while 
non-parametric tests (Wilcoxon sign ranked test) were used for skewed data. For 
cytokine changes comparisons were performed using area under the curve 
transformations and a one-sample t test.
Correlation between changes in FMD and inflammatory markers and neopterin 
were made by linear regression, with appropriate log transformation of parameters 
that were not normally distributed.
All statistical tests were performed with commercially available software -  
GraphPad Prism (San Diego, California).
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3 Human in vivo model of the time course of 
inflammation on vascular function
3.1 Background
An acute inflammatory insult leads to the synthesis and release of a variety of 
inflammatory and anti-inflammatory mediators, including interleukins and CRP. 
Epidemiological data indicates an association between the concentration of CRP 
or inflammatory cytokines and the risk of future atherothrombotic 
events( ’ ’ ). Incident cardiovascular events have been shown to be predicted
Q 7 . Q 0
by the presence of endothelial dysfimction( ’ ). Cross-sectional studies have 
shown an inverse correlation between CRP concentration and endothelium- 
dependent vasodilatation(311,312), but in these studies it has not been possible to 
divorce the raised CRP from the inflammatory milieu in which it exists. CRP 
may be causal; it may be a marker of other causal inflammatory products or may 
be elevated as result of endothelial dysfunction or the atherosclerotic risk factors 
that produce it.
Previous work by our group has shown that the acute inflammatory response 
induced by typhoid vaccination is followed by the development of transient, 
substantial endothelial dysfunction(324). This model was discussed in section 2.3. 
This chapter describes experiments where this model was used to examine the 
temporal relationship between the vaccination, the circulating concentration of 
inflammatory mediators and the development of endothelial dysfunction.
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3.2 Protocols
3.2.1 Experimental inflammation study
After obtaining approval from the University College London Research ethics 
committee, 12 healthy non-smoking male volunteers aged 28 (± 6) years who 
gave written informed consent were studied. Four subjects underwent a repeat 
assessment in the absence of an inflammatory stimulus.
Number of subjects 12
Age (years) 28 (6)
Sex All male
Systolic Blood pressure (mmHg) 121 (11)
Diastolic Blood Pressure (mmHg) 73 (7)
Body mass index (kg/m2) 25.2 (3.2)
Medications Nil
Table 3.1 Baseline characteristics of subjects in experimental 
inflammation study (mean (SD))
Endothelial function was studied, blood sampled and haemodynamic data 
collected at the same time on 4 consecutive days in 12 healthy, non-obese, 
subjects. Salmonella typhi capsular polysaccharide vaccine 0.025mg (Typhim Vi,
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P a s t e u r  M e r ie u x  M S D )  w a s  i n j e c t e d  i n t o  t h e  g l u t e u s  m u s c l e  a t  8 a m  o n  t h e  
m o r n i n g  o f  t h e  s e c o n d  d a y  o f  t h e  s t u d y  ( s e c t i o n  2 .3 ) .  B l o o d  s a m p l e s  w e r e  t a k e n  
a t  4 p m  o n  e a c h  d a y  a n d  8 a m  a n d  1 2 p m  o n  d a y  2  a n d  a n a l y s e d  f o r  c y t o k i n e ,  C R P  
a n d  n e o p t e r in  r e s p o n s e s  a s  d e t a i l e d  in  s e c t i o n  2 .6 . E n d o t h e l i a l  f u n c t i o n  w a s  
m e a s u r e d  b y  f l o w - m e d i a t e d  d i l a t a t io n ,  a s  d e t a i l e d  in  s e c t i o n  2 .2 .2 , a t  4 p m  o n  e a c h  
o f  t h e  f o u r  d a y s .
V
CRP and Cytokine measurements
V V V V
4nm iInm 4 Inm 4 pm
1
V
F M D
Dayl
F M D
Vaccination
Day2
F M D
Day 3
F M D
Day 4
Figure 3-1: Time line of study protocol. Arrows from above indicate 
blood sampling, arrow from below indicates vaccination.
3.2.2 Statistical Analysis
D a t a  a r e  p r e s e n t e d  a s  m e a n  a n d  SEM u n l e s s  o t h e r w i s e  s t a t e d .  A s  t h e y  w e r e  n o t  
n o r m a l ly  d i s t r ib u t e d ,  C R P  c o n c e n t r a t i o n s  w e r e  l o g  t r a n s f o r m e d  a n d  w e r e  
p r e s e n t e d  a s  g e o m e t r i c  m e a n s  a n d  a p p r o x i m a t e  s t a n d a r d  d e v i a t i o n s  a n d  
h e a m o d y n a m ic  p a r a m e t e r s  w e r e  e x p r e s s e d  a s  m e d i a n s  w i t h  in t e r q u a r t i l e  r a n g e s .  
C o m p a r i s o n  w a s  m a d e  b y  r e p e a t e d  m e a s u r e s  o n e - w a y  A N O V A  w i t h  a  p o s t  h o c
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Bonferroni analysis of all matched pairs. Correlations were performed between 
the changes in the CRP and IL-6 concentrations against changes in FMD and then 
a linear regression analysis. Significance was taken as P<0.05.
3.3 Results
3.3.1 Increases in CRP concentration  coincide with recovery of 
endothelial function
Vaccination with Salmonella typhi capsular polysaccharide produced a significant 
reduction in FMD (7.7±0.8% pre- vs 6.0±0.9% 8h post-vaccination; p=0.008) 
(Figure 3-2). FMD recovered fully by 32 hours after vaccination and this was 
maintained at 56 hours.
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Figure 3-2: Time course of endothelial response to vaccination.
Significant reduction in FMD at 8 hours (P=0.01) relative to all other 
time points.
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At the time of maximal endothelial dysfunction, 8 hours after vaccination, CRP 
concentration was unchanged (0.89 [0.88] mg/L at baseline vs 1.06 [0.92] mg/L at 
8h; p=0.3). However, by 32 hours after vaccination, CRP concentration was 
elevated 3-fold (to 2.7 [1.8] mg/L; p<0.01 vs baseline) (Figure 3-3) and this 
increase in CRP coincided temporally with the recovery of endothelial function 
(Figure 3-4).
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Figure 3-3: Change in CRP concentration relative to time of
vaccination. Significant rise in CRP at 32 hours relative to baseline 
(P=0.01 by post hoc analysis of repeated measures ANOVA).
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Figure 3-4: Changes in vivo in flow mediated dilatation of the human 
brachial artery (■) and CRP (□) relative to Salmonella typhi 
vaccination. (N=12; P<0.01 by repeated measures ANOVA for both 
CRP and FMD).
3.3.2 C hanges in cytokine concen tra tions p recede the  
developm ent of endothelial dysfunction
In contrast, concentrations of IL-6 and IL-IRa were both significantly elevated by 
4 hours after vaccination, prior to the development of maximal endothelial 
dysfunction, and returned to baseline by 32 hours (IL-6 0.87±0.08pg/mL at 
baseline and 5.8±1.6pg/mL at 4 hours post-vaccination; and IL-IRa 265±49pg/mL 
at baseline and 363±101pg/mL at 4 hours post-vaccination; P<0.05 for both 
comparisons) (Figure 3-5).
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Figure 3-5: Changes in vivo in flow mediated dilatation of the human 
brachial artery (■), IL-6 (o) and IL-1Ra (A) relative to Salmonella typhi 
vaccination. (N=12; P<0.01 by one-way ANOVA for CRP and P<0.05 
for IL-6 and IL-1Ra).
3.3.3 Vaccination does not lead to an alteration in 
haem odynam ic param eters or the  re sp o n se  to GTN
Baseline vessel diameter, response to GTN and temperature, pulse and blood 
pressure did not change over the study period (Figures 3-6 and 3-7 respectively). 
The degree of reactive hyperaemia also did not alter at different time points 
(Figure 3-8). Neither CRP nor FMD varied during the time control studies (P=0.6 
and 0.5 respectively by repeated measures ANOVA) (Figure 3-9).
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Figure 3-6: Baseline vessel diameters for FMD analysis and the 
response to the control vasodilator GTN are not changed by 
vaccination.
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Figure 3-7: Haemodynamic changes relative to vaccination. No
significant change in temperature, pulse or blood pressure.
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Figure 3-8: Hyperaemic response does not alter significantly at 
different time points (P=0.3 by repeated measures ANOVA).
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Figure 3-9: Time control study. CRP and FMD do not alter
significantly over time in the absence of vaccination (P=0.5 for FMD 
and P=0.6 for CRP)
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3.3.4 IL-6, but not CRP, concen tra tions correlate with FMD 
resp o n ses
Analysis, of all the time points at which endothelial function was assessed, of the 
change in FMD from the proceeding day compared to the change in serum 
markers showed no correlation between CRP and FMD (N=36, r2=0.02, P=0.45) 
but an inverse relationship between IL-6 and FMD (N=36, r2=0.36, P<0.001) 
(Figure 3-10).
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Figure 3-10: Linear regression between the changes in endothelial 
function compared to the changes in IL-6 concentrations between 
each day of the study. (N=36, ^=0.365, P<0.001)
3.4 Discussion
CRP is well characterised as an acute phase reactant that may have an important 
role in host defence against infection. Measurement of CRP concentrations within 
the range found in health has been shown to be strongly predictive of future
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cardiovascular events. This has led to the proposal that CRP itself might play a 
role in atherogenesis, a proposal supported by data from a small number of studies 
that have described associations between CRP and the presence of endothelial 
dysfunction(311,312).
Work by other authors, conducted in vitro, suggests that CRP causes a reduction 
in nitric oxide bioavailability and would therefore be expected to be associated 
with endothelial dysfunction(298;299). This was studied in this model of 
inflammatory endothelial dysfunction in humans, in which impaired FMD of the 
brachial artery is observed 8 hours after intra-muscular administration of 
Salmonella typhi capsular polysaccharide vaccine. The reduction in FMD was 
preceded by increases in IL-6 and IL-IRa. Using a highly sensitive assay, no 
detectable changes in CRP concentration were found prior to the development of 
endothelial dysfunction. However, CRP values were significantly increased 
following this time point (from 1.5mg/L [0.4-2.0mg/L] at 8 hours to 2.8mg/L 
[1.9-3.8mg/L] at 32 hours; p<0.001) and were associated temporally with 
recovery, rather than further impairment, of endothelial function. Since FMD of 
the brachial artery, following this short hyperaemic response, is almost 
exclusively dependent on the release of endothelial NO, changes in FMD were 
taken to reflect alterations in NO bioavailability(452 465).
Although vaccination did lead to a change in endothelial function this was not 
accompanied by an alteration in haemodynamic parameters. Importantly there 
was not a significant change in the hyperaemic response following cuff inflation, 
measured by the velocity-time integral, which could have confounded the results.
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In fact there was a trend to a towards a smaller hyperaemic response at 32 hours 
that would if anything lead to an underestimation of the FMD at this point. As 
has been shown previously(324), there was no alteration in blood pressure with 
vaccination. This may be because the vessels studied were conduit and not 
resistance structures and therefore any changes seen may have a predominant 
effect in these arteries, or that the increased NO generation leads to acute reflex 
compensatory mechanisms that serve to maintain blood pressure.
In previous cross-sectional studies conducted in vivo, CRP concentrations have 
been shown to correlate inversely with NO-mediated endothelium-dependent 
vasodilation in patients with, or at-risk of, atherosclerosis(311;312), and this has 
been taken as evidence that CRP causes endothelial dysfunction. However, the 
correlation between CRP and endothelial function in cross-sectional studies is 
likely to be confounded by the presence in the circulation of elevated 
concentrations of cytokines and other pro-inflammatory factors, and does not 
therefore prove a causal link.
In this study differences in the time-course of induction of inflammatory 
cytokines and CRP revealed a temporal dissociation between the development of 
endothelial dysfunction and the induction of CRP synthesis. Following a sterile 
inflammatory stimulus induced by S.typhi capsular polysaccharide vaccination, 
increases in circulating CRP concentration occurred after the development of 
endothelial dysfunction which was preceded by increases in IL-IRa (a marker of 
IL-1 activation) and IL-6 . It is possible, therefore, that IL-1 or IL-6 , or their 
downstream effectors contribute to the development of endothelial dysfunction,
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while the later elevation of CRP plays a part in its resolution. These results are 
further supported by the observation that changes in IL-6 concentrations, but not 
CRP, are correlated with changes in FMD when the entire time course is 
considered.
Despite these likely explanations for the differences between our study and 
previous reports, we cannot completely discount the possibility that CRP has 
pleiotropic effects on the vasculature, that differ according to the time course of 
exposure, concentration achieved and the prevailing cytokine milieu. It is not 
possible to infer causality in the association between CRP concentration and 
changes in FMD, as it is possible that in the absence of a rise in CRP on the third 
day that the FMD response may have been even more marked and therefore the 
CRP is still acting to suppress NO release.
In summary, this study suggests that IL-6 and IL-IRa could be involved in the 
processes that lead to endothelial dysfunction following typhoid vaccination, but 
that CRP changes are too slow to be causal. This thesis will now go on to explore 
the mechanisms by which inflammation leads to endothelial dysfunction and to 
further explore, in vivo, the mechanisms by which CRP might lead to 
improvements in endothelial function.
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4 Determination of the effect of experimental 
inflammation upon the nitric oxide pathway in 
vivo
4.1 Background
The healthy vascular endothelium has vasodilator, anti-adhesive, anti­
inflammatory and anti-coagulant properties, through the production of mediators, 
including nitric oxide (NO). Endothelial dysfunction is an early event in the 
pathogenesis of atherosclerosis^ °8,466) and is characterised by reduced dilator 
function, increased inflammatory cell and platelet adhesion(467), and increased 
coagulant activity(468). Reduced bioavailability of NO makes a major 
contribution to endothelial dysfunction and may be the result of reduced NO 
synthesis, due to substrate or co-factor deficiency, or increased NO breakdown, 
due to chemical reaction with oxidant radicals.
One potential trigger for endothelial dysfunction is inflammation(23,149' 151,469,470). 
Inflammatory cytokines impair endothelial function in animal models(471) and 
isolated human veins( ). Previous work by our group has shown that acute 
systemic inflammation induced by vaccination leads to transient endothelial 
dysfunction, characterised by reduced response to the endothelium-dependent 
vasodilators bradykinin and acetylcholine in the forearm arterial bed(324). 
However, the precise mechanism of this effect has not been previously explored.
The aims of this chapter were to determine whether this experimental 
inflammatory stimulus also alters basal NO-mediated dilatation, to determine the
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mechanisms of the effects seen and to explore whether endothelial dysfunction is 
evident systemically.
4.2 Protocols
4.2.1 Subjects
Twenty-one male and female subjects aged 22 to 40 were studied. No subjects 
had received typhoid vaccination in the preceding 6 months. Individuals were 
studied at the same time of day on two consecutive afternoons.
Number of Subjects 21
Age (years) 29 (6)
Sex (male/female) 15/6
Systolic Blood Pressure (mmHg) 122 (12)
Diastolic Blood Pressure (mmHg) 72 (6)
Medications Nil
Table 4.1 Baseline characteristics of subjects in these studies (mean 
<SD))
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4.2.2 Generation of an inflam matory resp o n se
Salmonella typhi capsular polysaccharide vaccine 0.025mg (Typhim Vi, Pasteur 
Merieux MSD) was injected into the gluteus muscle at 8am on the morning of the 
second day of the study (section 2.3).
4.2.3 M easurem ent of cytokines, serum  total anti-oxidant 
sta tus, serum  albumin and lipids and urinary protein
Blood and urine samples were taken before and 2 hourly for 8 hours after 
vaccination for the measurement of serum albumin, plasma lipids and urinary 
protein. As a control in 8 subjects, urine samples were taken at 4pm on a different 
day in the absence of vaccination. In five subjects the plasma was assayed for 
interleukin-6 (IL-6) and interleukin-1 receptor antagonist (IL-IRa). Plasma from 
20 subjects (one was unsuitable) was assessed for total anti-oxidant status 
(TAOS). Urine was collected in sterile containers and frozen at -20°C 
immediately. Samples from only 17 subjects at baseline and 8 hours after 
vaccination were suitable (due to a storage failure) and therefore analysed for 
urinary albumin and creatinine concentrations. At a separate time samples were 
taken in 8 subjects at 8am and 4pm in the absence of vaccination to study urine 
albumin/creatinine ratios. Individual assays are described in section 2.6.
4.2.4 A ssessm en t of forearm  blood flow
Venous occlusion plethysmography was used to measure forearm blood flow 16 
hours before vaccination (control) and 8 hours following vaccination as described 
in section 2 .2 .1.
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4.2.4.1 Protocol 1: Effect of vaccination on NO-mediated dilatation
In five individuals, forearm blood flow in response to intra-arterial infusion of the 
vasodilators bradykinin (BK; 20, 40, 80pmol/min; each dose for 3 minutes) and 
glyceryl trinitrate (GTN; 8, 16 and 32 nmol/min; each dose for 3 minutes) and 
vasoconstrictors NG-monomethyl-L-arginine (L-NMMA; 1, 2, 4 pmol/min; each 
dose for 5 minutes) and norepinephrine (NE; 60, 120 and 240 pmol/min min; 
each dose for 5 minutes) were assessed before and after vaccination. The order of 
the infusions was randomised although, due to its long duration of action, L- 
NMMA was always infused last. Saline was infused for 15 minutes between drug 
infusions to allow restoration of baseline flow. In three subjects, time control 
studies were performed to determine variation in vasoconstrictor response over 
time. In these studies, forearm responses to L-NMMA and norepinephrine were 
determined 24 hours apart in the absence of typhoid vaccination.
4.2.4.2 Protocol 2; Effect of L-arginine on endothelial function after 
vaccination
In five individuals, forearm blood flow in response to BK (20, 40, 80pmol/min; 
each dose for 3 minutes) and GTN (8, 16 and 32 nmol/min; each dose for 3 
minutes) was assessed before and during co-infusion with L-arginine (50 
pmol/min; preinfused for 15 minutes). This protocol was repeated before and 
after vaccination as above.
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4.2A.3 Protocol 3: Effect of ascorbic acid on endothelial function
after vaccination
In eight individuals, forearm blood flow in response to BK (20, 40, 80pmol/min; 
each dose for 3 minutes) and GTN (8, 16 and 32 nmol/min; each dose for 3 
minutes) was assessed post-vaccination before and during co-infusion with 
ascorbic acid (25 mg/min; preinfused for 15 minutes).
4.2.5 Calculations and sta tistical analysis
The ratio of blood flow in the infused/non-infused (control) arm was calculated 
for each measurement period. Changes in flow were expressed as a percentage 
change in the ratio of forearm blood flow (infused/non-infused) relative to the 
immediately preceding baseline flow, as described in section 2.2.1. Results are 
expressed as mean ±SEM unless otherwise stated. Cumulative dose-response 
curves were constructed for all drugs and the area under the curve (AUC) 
calculated. Responses were compared by paired Student’s t-test. The Wilcoxon 
sign ranked test was used for non-parametric data. The time course of the 
cytokine response was expressed as the AUC and analysed by a one-sample t-test. 
Analysis of the effect of L-arginine and ascorbic acid was carried out by 
assessment of the AUC for each dose response curve with paired t tests followed 
by the Bonferroni correction for multiple comparisons. P<0.05 was considered 
statistically significant.
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4.2.6 Drugs
BK, NE and L-NMMA were obtained from Clinalfa AG; GTN from Faulding 
Pharmaceuticals and L-arginine and ascorbic acid from Medeva Pharma Ltd. All 
of the drugs were prepared as stock solutions and stored at -20°C until use.
4.3 Results
4.3.1 System ic inflammatory re sp o n se  to vaccination
Two to four hours following vaccination there was a progressive rise in the IL-6 
concentration from 1.6±0.27pg/mL at baseline to 5.6±1.3pg/mL at 8 hours (n=5, 
P=0.02). IL-IRa levels rose after 6 hours from 186±42pg/mL at baseline to a 
peak of 332±78pg/mL before starting to fall, 8 hours following vaccination (n=5, 
P=0.02; Figure 4-1).
i-------------1----------------- 1--------------- 1-------------r
0 2 4 6 8
Time following vaccination (hours)
Figure 4-1: IL-1Ra (o; left y axis) and IL-6 (■; right y axis) response in 
8 hours following vaccination. There was a significant increase in 
the AUC for both cytokines (P=0.02)
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In comparison to baseline there was an increase in urinary albumin (p=0.03) and 
urinary albumin/creatinine ratios (UAC; p=0.05; Figure 4-2) at 8 hours following 
vaccination. In the absence of vaccination there was no diurnal variation in the 
UAC (8am 0.42±0.07, 4pm 0.45±0.09 mg albumin/mmol creatinine; p=NS; N=8).
P=0.05
o> ®
Pre vaccine 
8 h post vaccine
Pre vaccine 8 h post vaccine 
Time following vaccination
Figure 4-2: Urinary albumin/creatinine ratio prior to and 8 hours 
following vaccination
There were no significant changes in the serum levels of total (pre vaccine 
4.56±0.15mmol/L, post vaccine 4.65±0.17mmol/L; p=0.07) or HDL cholesterol 
(pre vaccine 1.26±0.08mmol/L, post vaccine 1.28±0.09mmol/L; p=0.62) over this 
time course. Serum albumin increased following vaccination (42.5±0.5g/L pre­
vaccine, 44.5±0.5g/L post-vaccine; p<0.01). TAOS decreased significantly eight 
hours following vaccination (33.7±3.7% at baseline to 21.3±3.4% at 8 hours; 
P=0.01; Figure 4-3) indicating an increase in oxidant stress at this time.
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P=0.01
Pre vaccine  
8 h Post vaccine
N=20
Pre vaccine Post vaccine
Time following vaccina tion
Figure 4-3: Total anti-oxidant capacity of plasma prior to and 8 hours 
following vaccination expressed as a percentage of the saline control
4.3.2 Forearm blood flow re sp o n se s
Mean baseline blood flow did not change following vaccination 
(4.1±0.36ml/100ml forearm per minute before and 3.9±0.24ml/100ml forearm per 
minute 8 hours after). All subjects showed dose-dependent increases in blood 
flow in response to BK and GTN. Eight hours following vaccination the 
response to BK was significantly impaired (P=0.05 for AUC; Figure 4-4 A and B) 
while the response to GTN was unchanged (P=0.4 for AUC; Figure 4-5 A and B).
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Figure 4-4: Change in forearm blood flow in response to bradykinin 
before ( o )  and eight hours following vaccination (•) (A) and 
expressed as area under the curve (B) (n=5, P=0.05)
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Prior to vaccination, L-NMMA and NE caused dose-dependent reductions in 
forearm blood flow. Eight hours following vaccination there was a reduction in 
the vasoconstriction to L-NMMA (P=0.02 for AUC; Figure 4-6 A and B) with no 
change in the response to NE (P=0.83 for AUC; Figures 4-7 A and B). In control 
studies, conducted in the absence of vaccination, there were no time-dependent 
changes in the response to L-NMMA (AUC: pre-vaccine 105 arbitrary units (AU), 
post-vaccine 125AU; P=0.6) or NE (AUC: pre-vaccine 6142AU, post-vaccine 
3546AU; P=0.2) on consecutive days.
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Figure 4-6: Change in forearm blood flow in response to L-NMMA 
before ( o )  and eight hours following vaccination (•) (A) and 
expressed as area under the curve (B) (n=5, P=0.02 for AUC)
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Figure 4-7: Change in forearm blood flow in response to
norepinephrine before ( o )  and eight hours following vaccination (•) 
(A) and expressed as area under the curve (B) (n=5, P=NS for AUC)
Co-infusion of L-arginine (50pmol/min) had no effect on the response to 
bradykinin (Figure 4-8 A and B) or GTN before or after vaccination. However, 
infusion of ascorbic acid (25mg/min) after vaccination caused a partial restoration 
of the response to BK (AUC post vaccine 5004±1081 vs. post vaccine with 
ascorbic acid 7649±1124, P=0.04; Figure 4-9 A and B). Neither vaccination nor 
ascorbic acid had any effect upon the response to GTN (AUC pre-vaccine 
3677±471, post-vaccine 4023±514 and with ascorbic acid 3158±370; P=NS)
159
A£
o3<L>
V i
c  *.53 O 
<L> C3
2P ”0  § o 
- f l  o o
€
<L>o
V i 
<L>
Ph
100 -
o 50-
0 -
-o—Pre vaccine 
-•—Post vaccine 
•*— Post + Arginine
—i---------------------1--------------------- 1—
20 40 80
Bradykinin dose (pmol/min)
B
/j>00n
P=0.01
P  5000
L _□ Pre vaccine
I H  8hrs post vaccine
B83 Postvaccine 
+ar^inine
_ n=5
Prevaccine Postvaccine +Areinine
Figure 4-8: Changes in forearm blood flow in response to bradykinin, 
expressed as dose response (A) and area under the curve (B), before 
and eight hours after vaccination with and without the addition of L- 
arginine (50p mol/m in; n=5; P=NS for AUC). The response in the 
presence of arginine, prior to vaccination, is not shown.
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Figure 4-9: Changes in forearm blood flow in response to bradykinin, 
expressed as dose response (A) and area under the curve (B), before 
vaccination and eight hours after vaccination with and without the 
addition of ascorbic acid (n=8; P=0.02 for pre-vaccine vs. post­
vaccine, P=0.04 for post-vaccine with vs. without ascorbic acid)
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4.4 Discussion
These experiments confirm that inflammation caused by typhoid vaccination 
causes a pro-inflammatory cytokine response, and impairs forearm arterial 
endothelium-dependent dilatation. Vascular responses to L-NMMA were also 
diminished, indicating reduced basal NO bioavailability in the forearm ciculation. 
Urinary albumin excretion increased, which may be secondary to increased 
capillary permeability caused by endothelial dysfunction in the kidney and, by 
extrapolation, could indicate endothelial dysfunction in other organs and vascular 
beds. Despite the reduced NO bioactivity, supplementation with L-arginine 
50pmol/min, the substrate for NO synthesis, did not restore endothelial function 
whereas infusion of the anti-oxidant ascorbic acid (25mg/min) led to a partial 
restoration of endothelium-dependent vasodilator responses. Plasma TAOS was 
decreased at the time of maximal endothelial dysfunction indicating an increase in 
oxidant stress. These findings implicate production of reactive oxygen species in 
the genesis of inflammation induced-endothelial dysfunction in humans.
In animals and humans, bradykinin vasodilates in part by an NO-dependent 
mechanism, with a probable contribution from endothelium-derived 
hyperpolarizing factor(57,472). Previous work by our group has shown impaired 
bradykinin-induced vasodilatation following typhoid vaccination, with 
preservation of the response to the NO donor, GTN(50’324). Administration of a 
high dose of aspirin before vaccination prevented inflammation-induced 
endothelial dysfunction, probably by blocking part of the cytokine response to 
vaccination(50). In order to address specifically the role of the L-arginine:NO
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pathway in vaccine induced endothelial dysfunction and to determine whether the 
protective basal NO mediated effects are lost, the vasoconstrictor response to L- 
NMMA was measured. The response to L-NMMA was markedly reduced 
following vaccination, with preservation of the response to the endothelium- 
independent vasoconstrictor norepinephrine. These data indicate that 
inflammation causes reduced activity of the basal endothelial dilator NO pathway. 
This may be biologically significant, because in animal models reduced NO 
bioavailability enhances atherogenesis and is associated with increased vascular 
resistance even if the blood pressure does not rise(473 474).
Changes in NO bioavailability can be caused by a reduction in NO production or 
an increase in NO breakdown. Inhibition of NO synthesis with L-NMMA does 
not distinguish between these mechanisms. A reduction in smooth muscle 
sensitivity to NO was excluded given the normal vasodilatation observed to GTN 
not only in this study, but also in prior investigations^0’324). Other potential 
mechanisms to account for reduced endogenous NO availability include depletion 
of the NOS substrate L-arginine or increased generation of reactive oxygen 
species, which combine with NO and lead to its breakdown, both of which have 
been reported in the context of endothelial dysfunction in the presence of 
orthodox cardiovascular risk factors.
Failure of L-arginine to restore the response to BK in the current study suggests 
that a deficiency of the substrate for NO synthase does not account for the effect 
of inflammation on the NO pathway. The dose of L-arginine administered is 
sufficient to raise L-arginine concentration into the low millimolar range(475), and
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previous work has shown that this dose of L-arginine improves endothelial 
dysfunction in the resistance vasculature of patients with 
hypercholesterolemia(476), diabetes(115) and heart failure(477). Failure to respond 
to L-arginine supplementation suggests that the mechanism of endothelial 
dysfunction is not simply explained by acute L-arginine deficiency.
Ascorbic acid infused 8 hours following the inflammatory stimulus of vaccination 
partially restored the bradykinin response with no effect on the endothelium- 
independent vasodilator GTN. Ascorbic acid may exert antioxidant effects by 
direct quenching of reactive oxygen species(373) or by stabilising the NOS 
cofactor tetrahydrobiopterin(379). A significant fall in total anti-oxidant status of 
the plasma following vaccination may indicate an increase in free radical 
production with inflammation. However, concern has been raised as to which 
pathways are actually measured by this assay, and no specific assays of individual 
pathways were made to strengthen this association. That ascorbic acid partially 
reverses endothelial dysfunction supports a role for increased oxidant stress in 
inflammation-induced endothelial dysfunction. Similarly, ascorbic acid reversed 
endothelial dysfunction following administration of bacterial
7^7lipopolysacchamde( ). Taken together with the observation that aspirin prevents 
endothelial dysfunction in this model(50), it is possible that cyclo-oxygenase is a 
source of reactive oxygen species. Whether ascorbic acid acts to improve 
endothelial function by preventing oxidation of NO or promoting the stability of 
the B H 4  to increase NO generation(478) remains to be determined. Failure to 
entirely restore the BK response may also reflect additional effects of
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inflammation to reduce the activity of the NO pathway, including expressional 
changes in NOS.
Vaccination also caused increased UAC that was contemporaneous with changes 
in endothelial function and the rise in cytokines, and this may reflect transitory 
endothelial dysfunction in the kidney. In healthy volunteers there was a 
correlation between albuminuria and systemic endothelial function(479), and 
increased urinary albumin excretion is commonly seen in clinical conditions 
where endothelial dysfunction is present, including diabetes mellitus(480), 
hypertension(481) cardiopulmonary bypass(482) and sepsis(483). Whether the 
microalbuminuria observed following typhoid vaccination can be explained by a 
transient reduction in renal NO production or represents a more generalised 
endothelial abnormality remains to be seen. Nevertheless, this combination of 
endothelial dysfunction, microalbuminuria, increased oxidant stress and a 
cytokine response suggests that typhoid vaccination causes the temporary 
development of a high cardiovascular risk phenotype. If this model accurately 
reflects the pathology of systemic inflammation then this may indicate a 
mechanism by which inflammatory events may lead to a transient rise in the 
incidence of cardiovascular events.
The measured lipid parameters did not change during these studies, indicating that 
this is not the mechanism by which inflammation induces endothelial dysfunction. 
However, it is possible that there were changes in the make-up of the different 
lipid fractions or modified lipids, for example an increase in oxidised LDL or 
small dense LDL, which might influence endothelial reactivity.
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In summary, this study demonstrates that typhoid vaccination causes generalised 
endothelial dysfunction involving reduced NO bioavailability. This is not 
explained by substrate depletion but is partly dependent on increased oxidative 
stress. Naturally occurring infections and inflammatory stimuli may cause 
fluctuating endothelial dysfunction by similar means.
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5 The role of anti-oxidants in the vascular 
response to inflammation
5.1 Background
The preceding two chapters have shown that inflammation, caused by typhoid 
vaccination, leads to a transient reduction in endothelial function. This was 
associated with an increase in serum oxidant stress and was partially reversible by 
ascorbic acid. This indicates that the changes observed may be due to increased 
oxidant breakdown of nitric oxide. However, the role of tetrahydrobiopterin 
bioavailability has not been directly addressed. This may be important, as local 
tetrahydrobiopterin infusion corrects endothelial dysfunction in established 
atherosclerosis(369) or subjects at elevated cardiovascular risk(383,484). Moreover, 
mice with targeted overexpression of GTPCH-1, the rate limiting enzyme in B H 4  
synthesis, are protected from endothelial dysfunction that results from
ICQ
experimental diabetes( ).
During the pilot studies for the previous work examining the effects of ascorbic 
acid on the impaired vascular response following vaccination, it appeared that, as 
well as partially reversing endothelial dysfunction once established, pre-treatment 
with ascorbic acid prevented the development of endothelial dysfunction. 
Ascorbic acid could prevent NO breakdown by stopping the reaction of NO with 
oxidant radicals or prevent the oxidation and inactivation of the NOS co-factor 
tetrahydrobiopterin(378). BH4 is inactivated to BH2, which is ineffective as a NOS 
co-factor and in this state NOS enzyme itself synthesises oxygen radicals in 
preference to NO. As a result of these observations a series of experiments were
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performed to test the following hypotheses: (i) that systemic pre-treatment with 
ascorbic acid could prevent the development of inflammatory endothelial 
dysfunction, (ii) that tetrahydrobiopterin supplementation after vaccination could 
restore endothelial function and (iii) that the effect of tetrahydrobiopterin was 
altered by pre-treatment with ascorbic acid.
5.2 Protocols
5.2.1 Subjects
Twelve male and female subjects aged 22 to 40 were studied. No subjects had 
received typhoid vaccination in the preceding 6 months. Individuals were studied 
at the same time of day on two consecutive afternoons.
Ascorbic Acid 
Group
Control Group
Comparison 
P value
Number of Subjects 6 6
Age (years) 24(2) 26 (7) 0.4
Sex (male/female) 5/1 5/1
Systolic Blood 
Pressure (mmHg)
129(12) 123 (5)
0.3
Diastolic Blood 
Pressure (mmHg)
74(9) 74 (7) 0.9
Medications Nil Nil
Table 5.1 Baseline characteristics of subjects in pre-treatment study 
(expressed as mean (SD)) with comparison between groups showing 
no significant differences
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5.2.2 Generation of an inflam m atory resp o n se
Salmonella typhi capsular polysaccharide vaccine 0.025mg (Typhim Vi, Pasteur 
Merieux MSD) was injected into the gluteus muscle at 8am on the morning of the 
second day of the study (section 2.3).
5.2.3 A ssessm en t of forearm  blood flow
Venous occlusion plethysmography was used to measure forearm blood flow 16 
hours before vaccination (control) and 8 hours following vaccination (detailed in 
section 2 .2 .1).
Forearm blood flow in response to intra-arterial infusion of the vasodilators 
bradykinin (BK; 20, 40, 80pmol/min; each dose for 3 minutes) and glyceryl 
trinitrate (GTN; 8, 16 and 32 nmol/min; each dose for 3 minutes) were assessed 
16 hours before and 8 hours after vaccination. The order of the infusions was 
randomised. Saline was infused for 15 minutes between drug infusions to allow 
restoration of baseline flow.
On the first day, after the initial assessment of endothelial function, the intra- 
arterial needle was removed and a venous cannula inserted under local 
anaesthetic. Blood was taken for analysis and subjects were randomised, using a 
number table stratified by gender, to receive intravenously either ascorbic acid 
(1.5g, dissolved in 30ml of 0.9% saline) or 30ml of 0.9% saline alone over 20 
minutes in a double blinded fashion.
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On the second day, 8 hours after vaccination endothelial function was again 
assessed and then tetrahydrobiopterin (BH4; 500mcg/min) was infused intra- 
arterially for 15 minutes and the dose responses to BK and GTN were repeated.
In five individuals the effect of BH4 on basal blood flow was determined in the 
absence of an acute inflammatory stimulus (by Dr L Mayahi).
6 Subjects 6 Subjects
12 Healthy subjects
Assessment of endothelial function
Assessment of endothelial function
Intra-arterial tetrahydrobiopterin 
Reassessment of endothelial function
12 Subjects 
S.typhi vaccination
Day 1
1.5g Ascorbic Acid N Saline
Day 2
Figure 5-1: Flow diagram of protocol for the ascorbic acid pre­
treatment and tetrahydrobiopterin study
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5.2.4 M easurem ent of Cytokines, Serum  Total Anti-Oxidant 
S tatus and Serum  A scorbic Acid
Blood samples were taken on the first day and then before and at 4 and 8 hours 
after vaccination for the measurement of cytokines, total anti-oxidant status 
(TAOS) and ascorbic acid. In all subjects the plasma was used to measure 
interleukin-6 (IL-6), interleukin-1 receptor antagonist (IL-IRa), tumour necrosis 
factor a (TNFa) and TAOS. Ascorbic acid concentration was measured in 
samples pre-treated with metaphosphoric acid to stabilise the vitamin. Individual 
assays are described in section 2 .6 .
5.2.5 Calculations and statistical analysis
Analysis of forearm blood flow was performed as described in section 2.2.1. 
Results are expressed as mean ±SEM unless otherwise stated. Cumulative dose- 
response curves were constructed for all drugs and the area under the curve 
(AUC) calculated. Responses were compared by paired Student’s t-test. The 
Wilcoxon sign ranked test was used for non-parametric data. Due to the change 
in basal flow following BH4 infusion the post infusion data was compared by the 
repeated measures of covariance model (XTREG procedure in STATA8.2). Data 
was corrected for baseline flow in the control and active arms and the change in 
flow over the three doses of BK or GTN. The time course of the cytokine 
response was expressed as the AUC and analysed by a one-sample t test. 
Cytokine and ascorbic acid responses between groups were compared by 2-way 
ANOVA, while TAOS responses between groups were compared by unpaired 
Student’s t-test. P<0.05 was considered statistically significant.
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5.2.6 Drugs
B K  w a s  o b t a i n e d  f r o m  C l i n a l f a  A G ;  G T N  f r o m  F a u l d i n g  P h a r m a c e u t i c a l s ,  BH4 
f o r m  S c h r i c k s  L a b o r a t o r ie s  ( S w i t z e r l a n d )  a n d  a s c o r b i c  a c i d  f r o m  M e d e v a  P h a r m a  
L td .  A l l  o f  t h e  d r u g s  w e r e  p r e p a r e d  a s  s t o c k ,  s o l u t i o n s  a n d  s t o r e d  a t  - 2 0 ° C  u n t i l  
u s e .
5.3 Results
5.3.1 Vaccination leads to an inflam m atory  
independent of ascorbic acid treatm ent
response
A s  w i t h  p r e v io u s  s t u d i e s  v a c c i n a t i o n  l e d  t o  a n  i n c r e a s e  i n  t h e  c o n c e n t r a t i o n  o f  
c i r c u l a t i n g  c y t o k i n e s .  T h e r e  w a s  a  s i g n i f i c a n t  p e a k  o f  I L - 6  a t  4  h o u r s  
( 0 . 6 9 ± 0 . 2 p g / m l  a t  b a s e l i n e  v s .  5 . 5 ± 3 . 9 p g / m l  a t  4  h o u r s ;  P = 0 . 0 0 1 ,  N = 1 2 ) .  I n  
c o n t r a s t  t h e r e  w a s  l i t t l e  c h a n g e  i n  t h e  c o n c e n t r a t i o n  o f  T N F a  ( 6 . 3 ± 2 . 3 p g / m l  a t  
b a s e l i n e  v s .  6 . 3 ± 2 .3 p g / m l  a t  8  h o u r s ;  P = 0 . 9 ,  N = 1 2 ) .  T h e  c y t o k i n e  r e s p o n s e  t o  
v a c c i n a t i o n  w a s  n o t  a f f e c t e d  b y  p r e - t r e a t m e n t  w i t h  a s c o r b i c  a c id  ( F i g u r e  5 - 2  A  
a n d  B ) .
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Figure 5-2: Change in serum concentration of IL-6 (A) and TNFa (B) 
in the time following vaccination. Although there was a significant 
rise in IL-6 at 4 and 8 hours, ascorbic acid treatment did not modify 
the cytokine response (P=0.13 by 2-way ANOVA, P=0.17 by t test for 4 
hour time point)
T h e r e  w e r e  n o  s i g n i f i c a n t  d i f f e r e n c e s  i n  t h e  I L l - R a  r e s p o n s e s  b e t w e e n  g r o u p s  
( d a t a  n o t  s h o w n ) .
5.3.2 Ascorbic acid pre-treatm ent prevents the developm ent of 
endothelial dysfunction
A s  e x p e c t e d ,  t y p h o id  v a c c i n a t i o n  c a u s e d  a  r e d u c t io n  i n  t h e  v a s o d i l a t o r  r e s p o n s e  t o  
B K  in  i n d iv i d u a l s  p r e - t r e a t e d  w i t h  n o r m a l  s a l i n e  ( F ig u r e  5 - 3 ) ,  w i t h  n o  c h a n g e  i n  
t h e  r e s p o n s e  t o  G T N  ( F ig u r e  5 - 4 ) .
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Figure 5-3: Change in forearm blood flow in response to bradykinin 
before ( o )  and eight hours following vaccination (•) in the saline- 
treated control group (A), and expressed as AUC (B) (n=6, P<0.001)
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Figure 5-4: Change in forearm blood flow in response to GTN before 
( o )  and eight hours following vaccination (•) in the saline-treated 
control group (A), and expressed as AUC (B) (n=6, P=0.9)
In contrast, individuals who were pre-treated with ascorbic acid (1.5g IV) showed 
an augmentation rather than attenuation in vasodilator response to BK (Figure 5- 
5), with no change in response to GTN (Figure 5-6).
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Figure 5-5: Change in forearm blood flow in response to bradykinin 
before ( o )  and eight hours following vaccination (•) in the group pre­
treated with ascorbic acid (A), and expressed as AUC (B) (n=6, 
P<0.001)
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Figure 5-6: Change in forearm blood flow in response to GTN before 
( o )  and eight hours following vaccination (•) in the group pre-treated 
with ascorbic acid (A), and expressed as AUC (B) (n=6, P=0.6)
5.3.3 Vaccination alters 
tetrahydrobiopterin
the basal response to
Following vaccination the control subjects showed an increase in forearm blood 
flow following a 15-minute infusion of tetrahydrobiopterin (Figure 5-7; N=6 ,
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P=0.02). There was no significant change in flow in individuals pretreated with 
ascorbic acid (Figure 5-8) or those, in a separate set of experiments, infused with 
BH4 in the absence of vaccination (Figure 5-9).
2
1
N=6
0
Pre-BH4 infusion Post-BH4 infusion
Treatment
Figure 5-7: Increase in relative forearm flow (expressed as active [A] 
over control [C] arm) after infusion of BH4 (500mcg/min for 15 
minutes) in control group following vaccination (N=6, P=0.02)
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Figure 5-8: Absence of change in relative forearm flow (expressed as 
active [A] over control [C] arm) following infusion of BH4 
(500mcg/min for 15 minutes) following vaccination in group pre­
treated with ascorbic acid (N=6, P=0.4)
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Figure 5-9: Absence of change in basal flow (expressed as
percentage change from baseline) in individuals infused with BH4 in 
the absence of the vaccine inflammatory stimulus at 10, 20 and 30 
minutes.
The change in basal flow make interpretation of subsequent dose-response curves 
difficult as all the following assessments depend on the basal flow(449). To try 
and account for this a repeated measures of covariance model was applied and 
showed that following BH4 infusion there was an increased response to BK in 
only the group not pretreated with ascorbic acid (table 5.2). In contrast the GTN 
response was not affected by BH4, unless the vessel had been pretreated with 
ascorbic acid (table 5.2)
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Change in BK 
response after 
BH4 in 
untreated group
Change in GTN 
response after 
BH4 in 
untreated 
group
Change in BK 
response after 
BH4 in 
pretreated 
group
Change in GTN 
response after 
BH4 in 
pretreated 
group
P coefficient 0.18 0.091 0.058 0.15
95 % Cl 0.007 to 0.3 -0.2 to 0.2 -0.5 to 0.16 0.08 to 0.22
P value 0.002 0.1 0.3 <0.001
Table 5.2 Result of regression analysis indicating that BK vasodilates 
vessels more following BH4 infusion, though only in the group not 
pretreated with ascorbic acid. The reverse is true for GTN response.
5.3.4 C hanges in vascu lar re sp o n se s  due to asco rb ic  acid 
treatm ent are not m ediated by alterations in oxidant 
s tre ss
In all subjects TAOS decreased 8 hours following vaccination (Figure 5-10; 
N=12, P=0.03), though there was no significant difference in the reduction in 
TAOS between the ascorbic acid treated groups and controls (Figure 5-11; N=6 , 
P=0.35).
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Figure 5-10: Vaccination leads to a significant fall in total anti­
oxidant status at 8 hours after stimulus compared to before (N=12, 
P=0.03)
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Figure 5-11: The fall in total anti-oxidant status is not different
between individuals treated with ascorbic acid and controls (N=6, 
P=0.35)
In the subjects pre-treated with ascorbic acid their serum concentration increased 
significantly from baseline (-16 hours) to the time of vaccination (0 hours) (N=6 , 
P=0.01), and then returned to normal by the time of repeat vascular study, 8 hours 
later (N=6, P=0.14). Repeated measures ANOVA was significant (P<0.001 
overall) and by Bonferroni post-hoc analysis there was a significant increase in 
ascorbic acid concentration at the time of vaccination relative to baseline
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( P < 0 . 0 5 ) .  I n  t h e  c o n t r o l  g r o u p  a s c o r b i c  a c i d  c o n c e n t r a t i o n s  d i d  n o t  c h a n g e  a t  a n y  
p o in t  ( N = 6 ,  P = 0 . 2 3  f r o m  b a s e l i n e  t o  v a c c i n a t i o n  a n d  P = 0 . 9  f r o m  b a s e l i n e  t o  8  
h o u r s  a f t e r  v a c c i n a t i o n )  ( F ig u r e  5 - 1 2 ) .  I n  t h e  c o n t r o l  g r o u p  t h e  r e p e a t e d  m e a s u r e s  
A N O V A  w a s  n o t  s i g n i f i c a n t  ( P = 0 . 3 ) .
75-
25-
-16 0 4 8
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Figure 5-12: Serum concentration of ascorbic acid from before
infusion of ascorbic acid (-16 hours), prior to vaccination (0 hours) 
and 4 and 8 hours later (point of vascular study). There is a 
significant rise in concentration from baseline (-16 hours) to 
vaccination (0 hours) only in the ascorbic acid treated group (P=0.01, 
vs P=0.23 for control; * on graph) and even in that group this 
normalises by 8 hours (P=0.14) (N=6 in each group).
5.4 Discussion
In  t h i s  c h a p t e r  it  h a s  b e e n  s h o w n  t h a t  v a c c i n a t i o n - i n d u c e d  e n d o t h e l i a l  d y s f u n c t i o n  
c a n  b e  c o m p l e t e l y  p r e v e n t e d  b y  t h e  p r e - a d m i n i s t r a t io n  o f  a s c o r b i c  a c id .  T h i s  l e d
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to a significantly increased concentration of ascorbic acid at the time of the 
vaccination, which had normalised by the time endothelial function was 
reassessed. There was an equivalent fall in total anti-oxidant status of the serum, 
at the time of the repeated study of the endothelial function, irrespective of pre­
treatment. The mechanism by which the ascorbic acid acts to prevent 
inflammation-induced endothelial dysfunction in this context is not clear. It may 
be mediated by changes in intracellular anti-oxidant stores that then either directly 
prevent NO breakdown or act through changes in BH4. In support of a role for 
BH4, this study showed that eight hours following vaccination the control subjects 
showed an increase in basal blood flow and response to BK following BH4 
infusion. Ascorbic acid pre-treatment prevented this BH4-dependent change in 
basal flow and BK response and, in the absence of vaccination in a separate series 
of studies, BH4 had no effect on flow. This induction of BH4 dependence could 
represent a depletion of BH4 by oxidant stress.
Previous work by our group, and experiments detailed earlier (Chapter 4), have 
shown that vaccination leads to a reduction in the vasodilator response to 
bradykinin, indicating the development of endothelial dysfunction(50,324). In the 
last chapter this reduction in bradykinin response was shown to be partially 
reversible by the infusion of ascorbic acid 8 hours after the stimulus. This is in 
keeping with the observation that there is an increase in oxidant stress within the 
serum at 8 hours following vaccination (Figure 4-3). Ascorbic acid may produce 
its effects by directly quenching reactive oxidant species(425) or by stabilising the 
nitric oxide synthase cofactor BH4(379). In this chapter the pre-treatment with 
ascorbic acid completely prevented the development of endothelial dysfunction.
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These studies show that the protective effect of ascorbic acid is not mediated by a 
reduction in the measured cytokine response, as occurred in the studies with anti­
inflammatory dose aspirin pre-treatment(50). It was possible that there was an 
alteration in cytokine responses that were not directly measured, or alternatively 
inadequate numbers were studied leading to a type II error. This is in contrast to a 
clinical study of inflammation in acute pancreatitis, in which high dose ascorbic 
acid led to a reduction in all inflammatory cytokines (including IL-6)(485). The 
difference may be a dose and duration effect, as the clinical pancreatitis study 
employed lOg/day for a sustained period as opposed to a single 1.5g dose in this 
work.
Previous chapters have shown that vaccination leads to a detectable fall in the 
total anti-oxidant capacity of the blood at 8 hours after vaccination, the point at 
which endothelial dysfunction is reassessed. One potential explanation for the 
effects of pre-treatment with ascorbic acid was that it produces a prolonged 
increased concentration of this anti-oxidant in the serum and that this leads to a 
prevention of the fall in TAOS. This was not borne out in this work, as there was 
neither a sustained increase in ascorbic acid concentration nor a difference in the 
development of “oxidant stress” in the ascorbate treatment group when measured 
at 8 hours. It must be noted that at the time of vaccination the ascorbic acid 
concentration in pre-treated subjects was higher than that of controls and it is 
possible that this alters the response to the inflammatory stimulus, perhaps by 
intra-cellular changes, such as supplementing intra-cellular anti-oxidant stores that
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could locally prevent degradation of BH4, that cannot be measured by the 
techniques employed in this work.
During these experiments the basal peripheral vascular tone, as shown by basal 
flow prior to the dose-response curves, appears to become B H 4  dependent 
following vaccination. This is shown by the increase in flow following the 
infusion of B H 4  alone. By contrast, in the control non-vaccinated subjects and 
published studies(100), B H 4  has no effect on the basal tone of “healthy” vessels. In 
individuals with traditional cardiac risk factors, such as diabetes(384), smoking(380) 
and hypercholesterolaemia(383), and established coronary heart disease(382), 
infusion of B H 4  improves the response to endothelial-dependent vasodilators, 
though it did not alter basal flow. These results suggest that an acute 
inflammatory stimulus acts to deplete or deactivate B H 4 , or render the 
endothelium resistant to B H 4  making it possible for supplementation now to alter 
basal tone. Although not directly tested in these experiments supplementation is 
thought to act by altering the balance of NO to superoxide production by NOS in 
favour of the vasodilator. It cannot be discounted that B H 4  may be acting directly 
as an anti-oxidant and reducing NO breakdown, perhaps as well as augmenting its 
production.
Pre-infusion with ascorbic acid avoids the development of B H 4  dependence by the 
forearm vasculature. As such there is no change in the basal forearm flow after 
infusion of B H 4 . It has been shown that ascorbic acid can increase the efficiency 
of NOS by the stabilisation of the essential co-factor B H 4 ( 378’478) .  This may be 
particularly relevant in this situation as it is known that when oxidised B H 4  loses
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its ability to dimerise NOS it actually tends to favour the production of further 
oxygen ffee-radicals( ’ ’ ). It is therefore possible that pre-treatment with
ascorbic acid has its beneficial effects through an alteration in BH4 bioavailability 
that is sustained to up to 8 hours following vaccination. Whether this occurs at 
the time of ascorbic acid infusion or later is not clear and exactly how it acts is 
also not apparent.
In a similar way there appeared to be an increase in the response to BK following 
BH4, though only in the group not pretreated with ascorbic acid. This supports the 
concept of developing BH4 dependence. The failure of BH4 to increase flow 
following ascorbic acid pre-treatment could be due to maximal flow in these 
vessels prior to the infusion of the pterin, or that ascorbic acid prevented BH4- 
dependence developing. Although regression analysis has been applied 
previously to situations where basal flow has altered(100) this must be treated with 
caution. It is possible that changes in basal tone may make any subsequent 
responses to stimulants uninterpretable(449). It is not clear why ascorbic acid pre­
treatment increased the response to GTN following BH4 infusion and this needs 
further investigation.
In animals and humans, bradykinin vasodilates in part by an NO-dependent 
mechanism, with a probable contribution from endothelium-derived 
hyperpolarizing factor(57,472). It is therefore possible for the ascorbic acid pre­
treatment to be acting by improving availability of NO or EDHF post-vaccination. 
As indicated above this does not seem to be by a direct effect on oxidant stress at 
the time of the plethysmography study. An EDHF dependent effect is not
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explored in these studies. The data on the changes in effect of BH4 suggest that at 
least in part the ascorbic acid acts on the NO pathway. Ascorbic acid in these 
experiments was given systemically by intravenous injection 16 hours before the 
stimulus. Further experiments would be needed to determine the duration of 
effect of this dose and the outcome if the anti-oxidant was given either orally or 
locally. Similarly the effect of other anti-oxidants, such as vitamin E, or a 
combination of agents is not clear.
In conclusion the experiments in this chapter suggest that inflammation may in 
part act through alteration in BH4 bioavailability and that this can be prevented by 
pre-treatment with ascorbic acid. Further experiments are needed to determine the 
applicability of these observations to other inflammatory stimuli, the duration of 
the effect and their importance to the development of unstable vascular disease.
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6 Determination of the direct vascular effects of C- 
reactive protein in vitro
6.1 Background
The introduction to this thesis describes the effects of infection and inflammation 
on vascular function. Acute sepsis may be accompanied by profound 
vasodilatation and hypotension(486) and, following the resolution of acute 
infection, there is a transient increase in the risk of atherothrombotic events(149' 
151). Chronic, sub-clinical infection or inflammation may also contribute to 
atherogenesis( ), since a variety of inflammatory markers( ’ ), persistent
1 1 • 170 1 S’)infection( ’ ), and chronic autoimmune disorders( ) are all associated with an 
increase in the rate of clinical cardiovascular disease. The mechanisms that 
underlie these observations are incompletely understood, but it is possible that 
products of the inflammatory response contribute both to the vasodilatation of 
sepsis, and modulate the development and stability of atheromatous plaques, by 
altering the release of vasoactive mediators such as nitric oxide (NO) by the 
vascular endothelium(23;104;109).
It has been known for many years that the concentration of CRP, a member of the 
pentraxin family, in plasma increases during acute infective or inflammatory 
episodes, as part of the innate immune response. More recently, it has also been 
shown that the baseline level of CRP is predictive of future cardiovascular events. 
Whilst the role of CRP in host defence, and as a clinically useful marker of 
infectious disease and inflammation is well established, the possible biological 
effects of CRP on the cardiovascular system are less clear.
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The in vivo model used in the previous chapters suggests that products of the 
inflammatory response could act through oxidant stress and the availability of 
B H 4  to produce endothelial dysfunction. Given the strong link between CRP and 
vascular events in epidemiological studies, and the published evidence for a 
proatherogenic role for CRP, the direct effects of CRP on vascular function were 
investigated in the experiments described in this chapter.
As no specific inhibitor of CRP for use in vivo as yet exists these studies were 
carried out ex vivo. Concerns exist as to the purity of commercially available 
CRP, and specifically the presence of preservatives that may directly influence 
cellular function. As a result these studies were performed with highly purified 
CRP that was not stored with any preservatives.
6.2 Protocols
6.2.1 Isolation and purification of hum an CRP
Human CRP was purified from human ascites by Dr M Pepys’ group at the Royal 
Free Hospital as previously described in section 2.6.1.2(457). SDS gel 
electrophoresis demonstrated a single band corresponding to an approximate size 
of 23K. CRP and its vehicle contained <0.5ng/ml bacterial lipopolysaccharide 
(LPS) by Limulus chromogenic assay (BioWhittaker Europe).
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6.2.2 Commercially available hum an CRP
CRP is available commercially from Calbiochem (Beeston, Nottingham, UK) and 
is shipped at a concentration of lmg/mL in solution containing 140mM NaCl, 
20mM Tris-HCl, 2mM CaCh and 0.05% sodium azide (pH 7.5).
In experiments where commercial CRP was used it was first dialysed three times 
against a large volume of buffered solution of the same contents as detailed above 
with the exception that it did not contain sodium azide. Final concentrations were 
confirmed to not be significantly changed. These procedures were performed by 
Dr G Hirschfield at the Royal Free Hospital London.
6.2.3 Organ bath stud ies
Endothelium-intact or denuded rings of thoracic aorta from male Sprague-Dawley 
rats or human internal mammary artery were incubated in 0.5mL serum-free 
Dulbecco’s modified Eagle’s medium containing human CRP (2-200mg/L) or 
buffer in 95% 02/5% CO2 at 37°C for 4 hours. Following incubation, tissues were 
mounted in an organ bath containing Krebs solution as described in section 2.1.2.
Tissues were maximally contracted with KC1 (4.8x 10' M) and then washed for 30 
minutes before endothelial integrity was assessed by contraction with 
phenylephrine (PE; 10'7M) and subsequent relaxation with acetylcholine (ACh; 
10'6M) as described in section 2.1.2.2. Rings were considered to have intact 
endothelium if ACh caused a greater than 50% reversal of PE contraction. Rings 
in which the endothelium was removed by gentle rubbing exhibited < 1% 
relaxation to ACh.
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Following incubation with CRP or vehicle, concentration-response curves to PE 
(10'9 -  10'5M) were constructed, and rings were then submaximally (80%) pre­
contracted with PE before construction of concentration-response curves to ACh 
or sodium nitroprusside (SNP) (10'9 -  10'5M).
Following incubation with CRP or vehicle, vessels were pre-incubated with nitro- 
L-arginine methyl ester (L-NAME; 3xlO’4M for 30 minutes) or 1400W (N-(3- 
(Aminomethyl)benzyl)acetamidine; 10'5M for 30 minutes) to block NO synthesis, 
actinomycin D (10'5M, for 4 hours) to block protein synthesis, 
methoxyacetylserotonin (lO^M for 30 minutes) to block tetrahydrobiopterin 
synthesis, polymixin (lOpg/ml) to bind LPS, or RMM (8.69mM) a novel low 
molecular weight inhibitor of CRP binding (Pepys MB et al. personal 
communication). In a further set of experiments the relaxant effect of D- or L- 
arginine (3x1 O^M) on vessels contracted submaximally with PE was ascertained. 
In all experiments the tissue rings were weighed at the end of the protocol and 
shown to be the same across all groups.
6.2.4 Protein expression  stud ies
Aortic rings were incubated for 4 hours with buffer, CRP (200mg/L) or LPS 
(-Salmonella typhosa; 500ng/ml) at 37 C and then protein expression of eNOS, 
iNOS and GTPCH-1 was determined as described in section 2.5.1.
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6.2.5 Endothelial cell culture
Passage five human coronary aortic endothelial cells (HCAECs; Promocell, 
Heidelberg, Germany) were grown to 80% confluence and then treated as 
described in section 2.4.1.1 with various formulations of CRP or vehicle. Cells 
were then harvested and protein expression determined (see section 2.5.1). In 
separate experiments cell viability following incubation was determined with the 
thiazolyl blue tetrazolium blue (MTT) assay (see section 2.4.1.3).
6.2.6 Protein expression  by W estern blotting
Protein expression was determined with the following primary antibodies: rabbit 
anti-human eNOS (c-20) and rabbit anti-mouse iNOS (m-19)(Santa Cruz 
Biotechnology, California USA) and GTPCH-1 anti-peptide antibody (raised 
against amino acids 17-45 from human sequence). According to the methods 
described in section 2.5.1. Coomassie staining of gels and membranes was used 
to confirm equal protein transfer.
6.2.7 Determination of NO production and pH in a m ouse  
endothelial cell line
As described in the methods section 2.4.2, experiments were performed using a 
mouse cell line that over-expressed GTP cyclohydrolase-1 feedback regulatory 
protein (GFRP). The rationale was to determine whether transgenic inhibition of 
GTPCH-1 activity would abolish the effect of CRP. Two experiments were 
conducted in this model. Firstly NO production was measured with a Griess 
assay, and secondly, the effect of different CRP preparations upon the pH of the
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culture medium was investigated. The first aim of these experiments was to 
investigate whether CRP increased NO production, and to test whether this was 
mediated through GTPCH-1 expression. The second was to determine whether 
the pH of the culture media, during experimental conditions, was altered by the 
sodium azide component of commercial CRP preparations.
The two assays are described in detail in the methods section (2.6.6 and 2.6.7). 
The Griess assay was used in all cells, whereas the colorimetric assay of pH was 
only performed on the untransfected group. Treatment groups consisted of 
control, pure isolated human CRP (50mg/L), CRP sourced from Calbiochem 
(50mg/L), Calbiochem CRP that had been dialysed against buffer to remove all 
sodium azide (50mg/L) and a positive control of lOng/ml TNFa, lOOunit/ml 
interferon y and 5pg/ml LPS.
In the pH experiments only a further positive control in the form of 1% and 0.1% 
myxothiazole (a respiratory chain inhibitor) was added. All incubations were 
performed for 24 hours.
6.2.8 Cohort study
Plasma samples from 579 healthy middle-aged male participants from the 
Northwick Park Heart Study II, a prospective cohort study of cardiovascular risk 
factors, were used to study correlations between plasma neopterin concentration 
(as an index of pterin pathway activation) and plasma CRP concentration. Details
a o n
of the design, recruitment and follow-up have been described elsewhere( ). C- 
reactive protein was measured on a BN Prospec (Dade Behring, Milton Keynes,
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UK). Inter-assay and intra-assay coefficients of variation were <4% and <2% 
respectively with a detection limit of 0.20 mg/1. Plasma neopterin was measured 
by commercially available ELISA (Brahms, Hennigsdorf, Germany). The 
manufacturer’s lower limit of detection of this assay was 2nmol/L, with an 
interassay CV of 9.6% at 7.19nmol/L and 5.14% at 65.42nmol/L. The statistician 
attached to the Northwick Park Heart Study, Jackie Cooper, performed the 
analysis.
6.3 Results
6.3.1 Purified, azide-free hum an CRP c a u se s  hyporeactivity in 
vascular rings through an endo thelium -dependent 
m echanism
Human CRP (200mg/L) produced marked hyporeactivity to PE in rat aortic rings 
similar to that observed with Salmonella typhosa lipopolysaccharide (50ng/ml) 
(Figure 6-1: P<0.0001, 2-way ANOVA for CRP vs control). This effect was also 
seen in rings of human internal mammary artery (Figure 6-2; P<0.0001, 2-way 
ANOVA). Similar effects were seen at concentrations of CRP observed in health 
(2mg/L) or mild inflammation (20 mg/L) (Figure 6-3).
194
Control
CRP (200mg/L) 
LPS (50ng/ml)
P<0.0001
89 7 6 5
Phenylephrine concentration (logM) N=6
Figure 6-1: Concentration response curve to PE in rat aortic rings; 
CRP (200mg/L for 4h; •) and LPS (50ng/ml for 4h; A) induce 
hyporeactivity compared to control (o) (N=6; P<0.0001 for CRP vs 
Control).
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Figure 6-2: Concentration response curve to PE in internal mammary 
artery rings; CRP (200mg/L for 4h; •) induced hyporeactivity 
compared to control (o) (N=6; P<0.0001 for CRP vs Control).
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Figure 6*3: Concentration response curve to PE in rat aortic rings; 
CRP at three concentrations (• 200mg/L, ▼ 20mg/L,A2mg/L) induced 
hyporeactivity compared to control (o)(N=7; P<0.05 for CRP 2mg/L vs 
Control).
The effects were specific to the presence of CRP since they were abolished by 
preabsorption of CRP by Sepharose-phosphoethanolamine (Figure 6-4), and were 
blocked by RMM (a low molecular weight inhibitor of CRP binding) (Figure 6-5). 
The effects of CRP were not explained by the presence of LPS since the stock 
CRP solution and its solvent buffer contained <0.5ng/ml LPS, and pre-incubation 
with polymixin to bind LPS did not alter the effect of CRP (Figure 6-6).
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Figure 6-4: Concentration response curve for rat aortic rings
showing hyporeactivity to phenylephrine induced by CRP (•) relative 
to control (o) is abolished by pre-absorption of CRP with sepharose- 
phosphoethanolamine (•) (N=8; P=0.13 for depleted CRP vs Control).
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Figure 6-5: Concentration response curve for rat aortic rings
showing hyporeactivity to phenylephrine induced by CRP (•) relative 
to control (o) is abolished by treatment with specific inhibitor RMM(«) 
(N=7; P=0.1 for RMM and CRP vs Control).
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Figure 6-6: Concentration response curve for rat aortic rings
showing hyporeactivity to phenylephrine induced by CRP (•) relative 
to control ( o )  is not abolished by co-incubation with polymixin 
(10pg/ml) (N=7; P<0.0001 for CRP in the presence of polymixin vs 
polymixin only control). Contemporaneous positive and negative 
controls have been removed for clarity (P=0.02 for CRP vs control 
without polymixin).
Endothelial denudation prior to CRP incubation (Figure 6-7), or non-isoform 
selective NOS inhibition with L-nitroarginine methyl ester (L-NAME) (Figure 6- 
8) after CRP incubation, prevented the effects of CRP, suggesting the PE 
hyporeactivity is mediated through physiological antagonism by endothelium- 
derived NO. Actinomycin D, which prevents protein synthesis, (Figure 6-9) 
blocked CRP-induced hyporeactivity to PE, indicating further that this action of 
CRP relies on new protein synthesis.
198
3
c.2
COca>
0
Denuded
3  P=0.5Denuded +CRP (200nrg/L)
2
1
0
9 8 7 6 5
Phenylephrine concentration (logM) N=6
Figure 6-7: Concentration response curve for rat aortic rings
showing hyporeactivity to phenylephrine induced by CRP (•) relative 
to control (o) is abolished by endothelial denudation (N=6; P=0.5 for 
CRP vs Control). Contemporaneous positive and negative controls 
have been removed for clarity (P<0.001 for CRP vs control with intact 
endothelium).
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Figure 6-8: Concentration response curve for rat aortic rings
showing hyporeactivity to phenylephrine induced by CRP (•) relative 
to control (o) is abolished by incubation with L-NAME (3x10 M) (N=8; 
P=0.15 for CRP vs Control). Contemporaneous positive and negative 
controls have been removed for clarity (P<0.001 for CRP vs control 
without L-NAME).
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Figure 6-9: Concentration response curve for rat aortic rings
showing hyporeactivity to phenylephrine induced by CRP (•) relative 
to control (o) is abolished by incubation with actinomycin D (10'5M) 
(N=7; P=0.7 for CRP vs Control). Contemporaneous positive and 
negative controls have been removed for clarity (P=0.002 for CRP vs 
control without actinomycin).
6.3.2 CRP augments NO availability in the absence of iNOS 
induction
To exclude a contribution from iNOS-derived NO additional studies were 
performed with 1400W, a specific inhibitor of iNOS. In contrast to L-NAME, 
1400W failed to reverse the PE hyporeactivity induced by CRP (Figure 6-10).
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Figure 6-10: Concentration response curve for rat aortic rings
showing hyporeactivity to phenylephrine induced by CRP (•) relative 
to control (o) is preserved after incubation with 1400W (10 M) (N=13; 
P<0.0001 for CRP vs Control). Contemporaneous positive and 
negative controls have been removed for clarity (P<0.001 for CRP vs 
control without 1400W).
In keeping with an iNOS-independent mechanism, in rings pre-contracted with 
phenylephrine, there was no difference in the relaxation to L-arginine (or its 
control D-arginine) in CRP-treated vessels compared to those left untreated 
(Figure 6-11).
Response to L-arginine
SB 10
Response to D-arginine
CRP Control CRP Control
N=8
P=NS
Figure 6-11: Percentage relaxation to L-arginine (A) and D-arginine 
(B) in partially pre-constricted vessel rings is not effected by pre­
treatment (N=8, P=NS).
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In control experiments 1400W entirely reversed the hyporeactivity to PE induced 
by incubation with lipopolysaccharide, which is known to be iNOS-dependent. In 
vessels that were not pre-incubated for 4 hours 1400W treatment did not lead an 
increase in the response to PE. This indicates that 1400W can inhibit the expected 
iNOS dependent response of LPS and that the incubation process leads to a small 
degree of iNOS induction independent to the treatment group.
6.3.3 CRP augm ents NO availability a s  a result of increased  
syn thesis of te trahydrobiopterin
In rat aortic rings incubated with CRP and pre-contracted with PE, there was a 
small but significant increase in the sensitivity to the endothelium-dependent 
vasodilator ACh (Figure 6-12: P<0.0001) with no change in the response to the 
endothelium-independent vasodilator SNP (Figure 6-13), consistent with 
increased NO availability.
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Figure 6-12: Concentration response curve for rat aortic rings
showing increased sensitivity to acetylcholine induced by CRP (•) 
relative to control ( o )  (N=12; P<0.0001 for CRP vs Control).
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Figure 6-13: Concentration response curve for rat aortic rings
showing similar sensitivity to sodium nitroprusside with CRP (•)  
treatment and control (o) (N=6; P=0.1 for CRP vs Control).
D e s p i t e  t h e  f u n c t i o n a l  i n c r e a s e  in  N O  a v a i l a b i l i t y  a n d  t h e  r e q u i r e m e n t  f o r  n e w  
p r o t e in  s y n t h e s i s ,  C R P  d id  n o t  a l t e r  e N O S  e x p r e s s i o n  in  r a t  a o r t ic  r i n g s  ( n o t  
s h o w n )  o r  H C A E C s  in  c u l t u r e  ( F ig u r e  6 - 1 4 ) .
C o n t r o l  C R P
~  /
Coomassie
Figure 6-14: Western blot of eNOS expression by human coronary 
artery endothelial cells incubated with CRP (50mg/L, chosen for 
reasons of dilution) or control for 24 hours showing no difference. 
Coomassie stain shows equal protein transfer.
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NO availability can be increased in the absence of transcriptional induction of 
eNOS by increased generation of the NOS cofactor B H 4 ( 323;376) .  Therefore the 
effect of co-incubation with methoxyacetylserotonin (MAS), an inhibitor of 
sepiapterin reductase, the terminal enzyme in B H 4  biosynthesis, was investigated. 
MAS (lOOpM for 4h) prevented CRP-mediated hyporeactivity to PE (Figure 6- 
15). CRP up-regulated expression of GTPCH1 (the rate-limiting enzyme in B H 4  
synthesis) in rat aortic rings and HCAEC (Figure 6-16).
Control
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Figure 6-15: Concentration response curve for rat aortic rings
showing hyporeactivity to phenylephrine induced by CRP (•) relative 
to control (o) is abolished after incubation with 
methylacetylserotonin (•)(10‘4M) (N=8; P<0.0001 for CRP vs Control).
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Figure 6-16: A) Western blot of GTPCH1 expression by human 
coronary artery endothelial cells incubated with CRP (50mg/L) or 
control for 24 hours showing upregulation in the CRP treated cells. 
Positive control of porcine kidney. Coomassie stain shows equal 
protein transfer.
B) Western blot for GTPCH1 expression in rat tissue after incubation 
with 200mg/L CRP for 4 hours against control. Coomassie stain 
assessment of transfer equal (not shown).
6.3.4 Effect of CRP in mouse endothelial cell model
In  t h e s e  e x p e r i m e n t s ,  i n v o l v i n g  i n c u b a t i o n  o f  G F R P  o v e r e x p r e s s i n g  m o u s e  
e n d o t h e l i a l  c e l l s  w i t h  v a r io u s  C R P  p r e p a r a t io n s ,  o n l y  t r e a t m e n t  w i t h  t h e  p o s i t i v e  
c o n t r o l  o f  L P S ,  I L - I R a  a n d  T N F  l e d  t o  a n y  s i g n i f i c a n t  c h a n g e  in  N O  p r o d u c t i o n .  
In  t h e  c a s e  o f  t h i s  p o s i t i v e  c o n t r o l  N O  p r o d u c t i o n  w a s  r e d u c e d  in  G F R P  o v e r ­
e x p r e s s i n g  c e l l s ,  w i t h  n o  s i g n i f i c a n t  e f f e c t  s e e n  in  o t h e r  g r o u p s .  I n  t h e  
e x p e r i m e n t s  t o  d e t e c t  t h e  e f f e c t  o f  i n c u b a t i o n  w i t h  d i f f e r e n t  C R P  p r e p a r a t io n s  
u p o n  p H  t h e r e  w a s  n o  d i f f e r e n c e  b e t w e e n  c o n t r o l  a n d  a z i d e - f r e e  C R P  ( C o n t r o l  p H
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7.4, CRP pH 7.1; N=3 P=0.5). However there was a significant reduction in pH in 
cells incubated with commercial CRP (Control pH 7.4, Calbiochem CRP pH 6.6; 
N=3 P=0.05), which was abolished by removal of the azide by dialysis (Control 
pH 7.4, Dialysed CRP pH 7.2; N=3 P=0.8) (Figure 6-17). A similar degree of 
change in pH was seen with the control metabolic poison myxothiazole (pH 6.3 
for 1% and pH 6.9 for 0.1%).
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Figure 6-17: Changes in pH of culture media following incubation 
with different CRP preparations for 24 hours. There is a significant 
reduction in the pH of Calbiochem CRP treated cells compared to 
control that is abolished by removal of sodium azide.
6.3.5 Plasm a concentrations of CRP correlate with th o se  of 
neopterin in the ab sen ce  of clinically ap p aren t 
inflammation
In 579 healthy middle-aged men from the Northwick Park Heart Study evaluated 
in the absence of clinically apparent infection or inflammation, plasma CRP 
concentration was correlated with plasma neopterin, an index of pterin pathway 
activation (1^=0.012, P=0.007) (Figure 6-18).
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Figure 6-18: Correlation between log plasma neopterin and logCRP 
concentrations in a large cohort of healthy males from the Northwick 
Park Heart Study. (N=579, ^=0.012, P=0.007)
6.4 Discussion
CRP is well characterised as an acute phase reactant that may have an important 
role in host defence against infection. Measurement of CRP has been widely used 
in clinical practice to assess the severity and monitor the progress of infective or 
inflammatory disorders but, more recently, CRP concentrations within the range 
found in health have been shown to be strongly predictive of future cardiovascular 
events. This has led to the proposal that CRP might itself play a role in 
atherogenesis, a proposal supported by data from a small number of studies that 
have indicated that CRP might contribute to the development of endothelial 
dysfunction(311;312).
This study investigated the direct effects of CRP on vascular cells and tissues and, 
contrary to several previous reports(298:299) , showed that CRP increases rather
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than decreases NO-bioavailability in blood vessels. This is indicated, in the first 
instance, by the impairment in contractility to PE. This was in the form of 
“functional antagonism”, that is a reduction in vasoconstriction being caused by 
an excess of vasodilators. That the excess vasodilator was nitric oxide is indicated 
by the ability of L-NAME, a non-specific NOS inhibitor, to restore PE-induced 
vasoconstriction to normal. The ability of NOS inhibition to return the vessel to 
normal contractility also indicated that there was no intrinsic abnormality in the 
vascular response to the vasoconstrictor, supporting the concept of functional 
antagonism.
NO can be generated from three NOS isoforms and in models of sepsis a similar 
hyporeactivity to PE was observed due to iNOS induction by LPS(488). In 
contrast, in these experiments the source of the additional NO appeared to be 
eNOS. This was supported by the prevention of hyporeactivity by endothelial 
denudation, the failure of the iNOS-specific inhibitor 1400W to abolish the effect 
and the failure of L-arginine to cause significant relaxation (which does occur 
with iNOS induction). Importantly eNOS was also implicated by the enhanced 
relaxation seen to the endothelial dependent vasodilator (ACh), with no parallel 
increase in response to the NO donor SNP. These effects of CRP were seen in 
human and rat blood vessels, over a range of physiological and pathophysiological 
concentrations of CRP.
Though requiring new protein synthesis, as indicated by the prevention of 
hyporeactivity when new protein synthesis was prevented by incubation with 
actinomycin, these actions of CRP were independent of increased eNOS
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expression by western blotting. Instead, CRP led to an induction in the expression 
of G TPC H -1, the rate-limiting enzyme in the synthesis of B H 4 . The functional 
importance of this increase in B H 4  was demonstrated by the amelioration of the 
PE hyporeactivity after incubation with the pterin pathway inhibitor MAS. 
Similarly in the epidemiological human data there was an association between 
CRP and neopterin concentrations, though this needs to be treated with caution, as 
neopterin is itself acute phase reactant and therefore the association between CRP  
and neopterin could be confounded.
Our group, and others, have shown previously that increases in the concentration
373 37 f \of BH 4  mediated by inflammatory cytokines( ), or estrogens( ), can lead to 
increases in NO synthesis from eNOS, independent of changes in enzyme 
expression. Failure to show any effect on NO production in the mouse cell 
culture model could reflect a number of points. Firstly the mouse cells may not 
respond in the same way to human CRP, due to a cross-species effect, and 
secondly the degree of NO production upregulation may not be adequate to be 
detected by the relatively insensitive Greiss assay.
In contrast to the current findings, previous cell culture studies have identified 
increased endothelial cell adhesion molecule expression and down-regulation of 
eNOS expression and activity following incubation with CRP, in line with a pro-
708*700atherogenic rather than a protective role( ’ ). How can this difference be
reconciled? While it is possible that differences in the concentrations of CRP 
studied, or the time course of exposure may play a part in the in vitro experiments, 
one important difference is the source of CRP.
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In many previous studies, CRP has been obtained from commercial
7on*90Rsources( ’ ). Such preparations usually contain significant concentrations of 
sodium azide (0.05%w/v; final concentration 370pM), which is known to have 
important vasoactive effects by the generation of nitric oxide from its catalase- 
dependent breakdown(276'278). This exogenous production of NO could then lead 
to down-regulation of NO production by eNOS(489). A recent paper with CRP 
preparations in which the azide had been removed by dialysis indicated that the 
acute vasodilator effect of commercially sourced CRP is by way of this direct 
NO-donor effect(300). Sodium azide also alters cell metabolism by inhibiting the 
mitochondrial respiratory chain and therefore will favour anaerobic respiration 
and the development of an acidosis(278). This can be seen in the experiments with 
mouse cell lines where incubation with commercial CRP lead to a significant fall 
in pH of the culture medium. To overcome this problem, CRP was prepared to a 
high degree of purity, free from sodium azide.
A number of previous studies have failed also to confirm the specificity of 
observed effects by the use of appropriate controls. In the current study, the 
vascular effects of CRP were abolished by pre-absorption of the CRP with 
phosphocholine-coated sepharose beads and then incubation of the resultant 
solution in a blinded fashion. Further, a specific inhibitor of CRP- 
phosphocholine-ligand binding (RMM) abolished the CRP-induced PE 
hyporeactivity. Finally, it was confirmed that the effects observed could not be 
explained by contamination of solutions by bacterial endotoxin. As such this 
work has attempted to show an effect that is robustly attributable to CRP and not
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contaminants. Caution must be applied to the effects of one species of CRP on 
another species vessel, in particular because CRP has different background levels 
and immunological effects across species. This was addressed by repeating some 
of the experiments in isolated human vessels and human cells lines.
Although these experiments have explored the effects of CRP on NO 
bioavailability in some detail alternative modes of action cannot be excluded. 
CRP could act multifactorially to alter substrate availability, though in this case an 
effect on L-arginine supplementation would be expected. Alternatively it might 
alter ADMA concentrations or activity, influence to generation of reactive oxygen 
species, or alter post-translation enzymic structure (for instance by 
phosphorylation). These areas have not been specifically addressed in this work.
In summary, short-term exposure of vascular cells or tissues to highly purified 
human CRP results in induction of NO synthesis from eNOS, probably via 
increased provision of the NOS co-factor B H 4 . These actions point to a 
potentially protective role for CRP in the resolution of endothelial dysfunction 
that may follow acute sepsis or inflammation, or during the low-grade 
inflammation that exists during the long pre-clinical phase of atherosclerosis. 
Interestingly this ties in with the data in the first chapter that shows the time 
course of the development of a significant CRP concentration coincides with the 
resolution, rather than development, of endothelial dysfunction. It is important to 
note that these observations do not undermine the utility of CRP measurement in 
the prediction of future disease, which is based on the demonstration of a strong 
association in many large epidemiological studies. The development of selective
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inhibitors of CRP binding will aid future studies addressing the physiological and 
pathological properties of CRP.
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7 Conclusion
This thesis has explored the effects of inflammation of vascular function in vivo 
and in vitro. A number of themes have been developed and this section will bring 
these together.
7.1 Methodological issues
There is an increasingly large literature on the direct vascular effects of CRP. 
Almost all of this uses the commercially sourced CRP, which is intended as a 
reference standard for assaying the accuracy of diagnostic tests. An important 
aspect of this thesis has been the appreciation of the biological importance of the 
agents added to this CRP. In particular, sodium azide is included to prevent the 
growth of bacterial contaminants, as it is a mitochondrial chain inhibitor, to 
prevent contamination of the agents. However the direct effects of the sodium 
azide on the biological system itself cannot be ignored. In the experiments 
described in section 6 not only was a highly purified CRP used, free from 
bacteriostatic agents, but also experiments were also performed to address the 
issue of specificity. As a result one can be confident that the effects demonstrated 
are as a result of the actions of the CRP and not any other agent in which it is 
dissolved.
Another important methodological issue addressed in this research is the 
difference between cross-sectional and longitudinal studies. Previous publications 
looking at an association between the serum concentration of CRP and the
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presence of endothelial dysfunction failed to take into account the inflammatory 
milieu in which the CRP exists. Importantly in a cross-sectional study it is not 
possible to determine which of the various raised inflammatory mediators is 
important to the observed biological effects. This work used a time-course model 
to tease out the impact of some of the different mediators, particularly that the rise 
in CRP following an inflammatory stimulus is temporally dissociated from the 
induced endothelial dysfunction in this model. Although this alone does not allow 
for the attribution of causality it is more suggestive than is possible from a cross- 
sectional analysis alone.
7.2 Inflammation as a cause of endothelial dysfunction
The introduction developed the idea that endothelial dysfunction is important as a 
mediator of traditional risk factors in the development of atherosclerotic plaques 
and also their destabilisation to produce clinical events. Previous work by our 
group, and others, has suggested that inflammation may in a similar way be 
important in atherosclerosis, again by an action mediated through endothelial 
dysfunction. This work has taken these concepts further, by exploring the role an 
acute inflammatory stimulus has over a longer time period and the changes it 
produces in nitric oxide bioavailability.
Following vaccination there is a transient reduction in the bioavailability of NO, 
seen both in terms of a reduced effect of NOS inhibition and impairment in the 
flow-mediated response (thought largely to be NO mediated). These effects can 
be related to both the conduit (FMD) and resistance (L-NMMA effect) 
vasculature of the forearm and certainly in the case of FMD lasts less than 36
214
hours. All these studies were performed in healthy individuals and as such it is 
not possible to say whether these effects would be more marked or reduced in the 
presence of other risk factors.
How these changes appear to be mediated is discussed below. Although 
vaccination leads to the development of a reproducible cytokine response (IL-IRa 
-  IL6 -  CRP) it is not clear as yet exactly which component is involved in the 
changes described. In contrast to some previous literature CRP does not appear to 
be the casual agent as its biological dynamics mean that it does not increase in 
level until after the development and recovery of the endothelial abnormality. To 
explore the impact of each individual mediator would require the use of specific 
inhibitors and the determination of whether each one alters the vascular responses. 
One of the ways in which inflammation, endothelial dysfunction and 
atherosclerosis has been linked is the association between CRP concentrations and 
future atherothrombotic events. This work however does not support the 
proposed causal role for CRP -  does this nullify these previous associations? 
Probably not, as CRP can be viewed as a summative inflammatory mediator that 
reflects the presence of other, potentially causal, mediators. The biology of CRP 
makes it a very effective barometer of other inflammatory markers, which are 
often too transient to monitor. As such this work does not contradict the utility of 
the observation that CRP predicts future vascular events, just that it is unlikely to 
be causal.
215
7.3 Importance of reactive oxygen species to 
inflammation-induced endothelial dysfunction
Two of the data sections in this work look at the impact of inflammation on the 
degree of oxidant stress within the circulation. Reactive oxygen species have 
been implicated, by a number of authors, in the development and progression of 
atherosclerosis. This work has shown that a mild inflammatory insult can lead to 
the development of increased oxidant stress within the circulation. Further, this 
work indicates that reversal of this pro-oxidant state has different effects 
depending upon the point at which it is performed. After the development of 
endothelial dysfunction ascorbic acid is only partially effective. However, pre­
treatment entirely avoids the development of vascular abnormalities. This raises 
the possibility that either ascorbic acid has different effects at different times, 
perhaps acting as a direct free radical scavenger acutely while a pre-exposure 
allows an action through other pathways (for instance B H 4 ).
It is not clear from this work exactly how oxidant stress is implicated in the 
development of endothelial dysfunction. Free radicals can directly breakdown 
NO and thereby reduce its bioavailability. However if this were the entire effect it 
would be expected that adequate quantities of ascorbic acid given at any point 
would entirely restore endothelial function. As this is not the case it increases the 
likelihood that the effect is at least in part mediated by an indirect mechanism. 
This would explain the partial effect of delayed asorbic acid and brings to the fore 
the role of NOS co-factors, in particular B H 4 .
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Interestingly the failure of delayed ascorbic acid to fully reverse the effects of 
inflammation on endothelial dysfunction may have implications for our 
understanding of clinical trials of vitamin supplementation in secondary 
prevention. If a similar effect is seen it may be that the supplements are given 
“too late” in the natural history of atherosclerosis to be effective. As such an early 
intervention study, most probably by dietary alteration, may produce a more 
favourable outcome.
7.4 Importance of tetrahvdrobiopterin to the 
bioavailabilitv of nitric oxide
In both the vaccine and in vitro CRP studies tetrahydrobiopterin assumes a central 
role. Vaccination leads to the development of relative BH4 deficiency, indicated 
by the development of a dependence on BH4 in the basal flow within the forearm 
vasculature. This effect is abolished by the pre-infusion of ascorbic acid, 
suggesting that inflammation may act to reduce BH4 bioavailability by its 
oxidation to BH2. The consequence of this would be a reduction in NO 
bioavailability and a further increase in oxidant stress. Changes in BH4 are 
therefore the potential common pathway for the effects of inflammation on 
vascular function.
How does CRP fit into this model? Two observations from this work are 
important -  firstly CRP appears to increase the production of BH4 by means of an 
increase in the levels of the rate-limiting production enzyme (GTPCH-1) and 
secondly the rise in CRP concentration appears to coincide with the recovery of 
NO-dependent vascular responses. Perhaps CRP is not involved in the
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development of endothelial dysfunction, as suggested by other authors, but rather 
implicated in the restoration of vascular intergrity following an inflammatory 
insult. This may be important in host defences as it allows the increase in flow to 
the damaged area that is required for effective healing.
7.5 Future work
This thesis has thrown up almost as many questions as it has attempted to answer. 
Some of the important ones are explored below, grouped according to 
methodology.
7.5.1 Vaccination studies
All of the work using this model has so far concentrated on healthy volunteers. 
However, the population most at risk of vascular events possess a number of 
conditions known to predispose to cardiovascular disease. It would be 
informative to study the impact of these risk factors (for instance smoking) on the 
magnitude and time course of the endothelial dysfunction to see if co-existant 
pathologies augment or diminish the observed effects.
This work has implicated changes in IL-6 and ILl-Ra in the development of the 
effects seen and this could be further detailed by selective antibody inhibition of 
these mediators. The role of tetrahydrobiopterin needs further exploration, 
particularly the relative importance of the different redox states of the co-factor. 
With the development of a robust assay the changes in B H 4 /B H 2  ratios over the 
time course of the vascular effects following vaccination could be quantified.
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Although the L-NMMA studies indicate that there is a reduction in basal nitric 
oxide bioavailability following vaccination, they do not confirm that the reduction 
in response to bradykinin is only mediated through a NO-dependent mechanism. 
Bradykinin may cause vasodilitation by changes in prostaglandins or EDHFs. 
The relative importance of each potential pathway could be explored by 
generating bradykinin dose response curves in the presence of basal NOS 
inhibition (with L-NMMA) and separately prostaglandin inhibition (with 
indomethacin).
7.5.2 Clinical studies
The work described in this thesis used a model of inflammation to explore the 
possible mechanisms by which endothelial dysfunction is induced. The rationale 
for this approach is that there is an increase in cardiovascular events following 
intercurrent illnesses and that endothelial dysfunction may act as the link between 
these observations. All models have their limitations and it would be extremely 
interesting to explore the effects of a clinically relevant inflammatory stimulus 
(such as surgery). This could be achieved by measuring FMD responses in the 
forearm of patients undergoing abdominal surgery, before, during and for a period 
after the operation and comparing this to changes in inflammatory mediators.
Having established this clinical model the mechanism of any changes seen could 
be explored. In particular it would be useful to see if pre-treatment with ascorbic 
acid in any way protected the individual. The route of administration of ascorbic 
acid could be varied to determine whether it needs to be given systemically. In an
219
adequately powered study the patients could be followed up to determine whether 
the frequency o f clinical vascular complications following the surgery correlate 
with the extent of changes in endothelial function. In an intervention study it 
could also be seen whether pre-treatment of surgical patients with anti-oxidants, 
or perhaps BH 4 , altered the frequency of cardiovascular events.
The studies in this work explore changes in vascular reactivity in the peripheral 
circulation and assume, as other studies indicate, that these act as an effective 
model for coronary and cerebral vascular responses. It would be of interest, 
though practically difficult, to determine the actual changes in coronary 
vasculature following an inflammatory insult. Although this could be performed 
in a cross-sectional way with correlations made to measured inflammatory 
indices, it would be preferable to measure the vascular reactivity at two time 
points, one acute and one following recovery from the index event. There are 
obviously practical and ethical issues surrounding repeated invasive studies and 
this type of work would best be added onto another study that already requires 
serial measurements.
7.5.3 In vitro studies
In the in vitro studies in this thesis it was assumed that any effect of CRP on 
vascular function would take a time to occur. This was supported by the 
observation that new protein synthesis is required for the changes in vascular 
responses to develop. However, to date it is not clear exactly the duration of 
incubation needed to produce an effect and whether there may be different effects 
dependent on the time for which tissues are exposed to CRP. This could be
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explored in two ways, either organ bath experiments could be performed after a 
series of different incubation periods (for example 1 hour, 2 hours, 4 hours, 8 
hours and 16 hours) or the CRP could be added to tonically contracted vessels 
already mounted in the organ bath and monitor the time to vessel relaxation. At 
the end of this experiment the addition of NOS inhibitors could show that the 
effect seen is NO-dependent.
From the work in this thesis it seems possible that CRP exerts its cardiovascular 
effects by changes in BFL* or the BH4/BH2 ratio. It would be informative to 
directly measure the impact of CRP on the concentration of these co-factors both 
in in vitro and in vivo experiments. As part of this it would be interesting to 
determine the effect of instilling highly purified CRP into human vessels in vivo. 
This would best be achieved with a hand vein model where the vein is isolated 
from the circulation before the CRP is instilled and its vascular responses 
determined. Similar experiments using cytokines have been previously performed 
by our group(323).
7.6 Final comment
This thesis describes a body of work aiming to explore the mechanisms by which 
inflammation can lead to endothelial dysfunction. The studies have shown the 
importance of oxidant stress in this process and the potentially central role of 
tetrahydrobiopterin. The vascular effects of the acute phase protein CRP have 
been explored in great detail, both in vivo and in vitro. During this process I have 
learnt a large amount about the design, execution and interpretation of well- 
controlled scientific experiments. Further studies, indicated in the section above, 
will hopefully allow the application of these observations to clinically relevant
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inflammatory insults and ultimately lead to the development of novel therapeutic 
strategies to reduce morbidity and mortality.
222
Reference List
1. Magnus P, Beaglehole R. The real contribution of the major risk factors to 
the coronary epidemics: time to end the "only-50%" myth. Arch Intern 
Med. 2001;161:2657-2660.
2. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P et al. Myocardial infarction 
and coronary deaths in the World Health Organization MONICA Project. 
Registration procedures, event rates, and case-fatality rates in 38 
populations from 21 countries in four continents. Circulation. 
1994;90:583-612.
3. Stary HC. Evolution and progression of atherosclerotic lesions in coronary 
arteries of children and young adults. Arteriosclerosis. 1989;9:119-132.
4. Kruth HS. The fate of lipoprotein cholesterol entering the arterial wall. 
Curr Opin Lipidol. 1997;8:246-252.
5. Stary HC. The sequence of cell and matrix changes in atherosclerotic 
lesions of coronary arteries in the first forty years of life. Eur Heart J. 
1990; 11 Suppl E:3-19.
6 . Stary HC, Chandler AB, Dinsmore RE et al. A definition of advanced 
types of atherosclerotic lesions and a histological classification of 
atherosclerosis. A report from the Committee on Vascular Lesions of the 
Council on Arteriosclerosis, American Heart Association. Circulation. 
1995;92:1355-1374.
7. Glagov S, Weisenberg E, Zarins CK et al. Compensatory enlargement of 
human atherosclerotic coronary arteries. N  Engl J  Med. 1987;316:1371- 
1375.
8. Vamava AM, Mills PG, Davies MJ. Relationship between coronary artery 
remodeling and plaque vulnerability. Circulation. 2002;105:939-943.
9. Vamava AM, Davies MJ. Relation between coronary artery remodelling 
(compensatory dilatation) and stenosis in human native coronary arteries. 
Heart. 2001;86:207-211.
10. Schoenhagen P, Ziada KM, Kapadia SR et al. Extent and direction of 
arterial remodeling in stable versus unstable coronary syndromes : an 
intravascular ultrasound study. Circulation. 2000;101:598-603.
11. Mann J, Davies MJ. Mechanisms of progression in native coronary artery 
disease: role of healed plaque disruption. Heart. 1999;82:265-268.
12. Alderman EL, Corley SD, Fisher LD et al. Five-year angiographic follow- 
up of factors associated with progression of coronary artery disease in the 
Coronary Artery Surgery Study (CASS). CASS Participating Investigators 
and Staff. J  Am Coll Cardiol. 1993;22:1141-1154.
223
13. McGill HC, Jr., Strong JP, Tracy RE et al. Relation of a postmortem renal 
index of hypertension to atherosclerosis in youth. The Pathobiological 
Determinants of Atherosclerosis in Youth (PDAY) Research Group. 
Arterioscler Thromb Vase Biol. 1995;15:2222-2228.
14. Tuzcu EM, Kapadia SR, Tutar E et al. High prevalence of coronary 
atherosclerosis in asymptomatic teenagers and young adults: evidence 
from intravascular ultrasound. Circulation. 2001;103:2705-2710.
15. Alfonso F, Macaya C, Goicolea J et al. Intravascular ultrasound imaging 
of angiographically normal coronary segments in patients with coronary 
artery disease. Am Heart J. 1994;127:536-544.
16. Virchow R. Phlogese und thrombose in gefassystem. Gesammelte 
Abhandlungen Zur Wissenschaftlichen Medicin (ed by R Virchow). 
1856;458.
17. von Rikatansky C. A Manual of Pathological Anatomy. The Sydneham 
Society, London. 1852.
18. Benditt EP, Benditt JM. Evidence for a monoclonal origin of human 
atherosclerotic plaques. Proc Natl Acad Sci USA.  1973;70:1753-1756.
19. Schwartz SM, Majesky MW, Murry CE. The intima: development and 
monoclonal responses to injury. Atherosclerosis. 1995;118 Suppl:S125- 
S140.
20. Chung IM, Schwartz SM, Murry CE. Clonal architecture of normal and 
atherosclerotic aorta: implications for atherogenesis and vascular 
development. Am J  Pathol. 1998;152:913-923.
21. Williams KJ, Tabas I. The response-to-retention hypothesis of 
atherogenesis reinforced. Curr Opin Lipidol. 1998;9:471-474.
22. Ross R, Glomset J, Harker L. Response to injury and atherogenesis. Am J  
Pathol. 1977;86:675-684.
23. Ross R. Atherosclerosis—an inflammatory disease. N  Engl J  Med. 
1999;340:115-126.
24. Venema RC, Sayegh HS, Amal JF et al. Role of the enzyme calmodulin- 
binding domain in membrane association and phospholipid inhibition of 
endothelial nitric oxide synthase. J  Biol Chem. 1995;270:14705-14711.
25. Sessa WC, Harrison JK, Barber CM et al. Molecular cloning and 
expression of a cDNA encoding endothelial cell nitric oxide synthase. J  
Biol Chem. 1992;267:15274-15276.
26. Salerno JC, Harris DE, Irizarry K et al. An autoinhibitory control element 
defines calcium-regulated isoforms of nitric oxide synthase. J  Biol Chem. 
1997;272:29769-29777.
224
27. Fleming I, Busse R. Signal transduction of eNOS activation. Cardiovasc 
Res. 1999;43:532-541.
28. Abu-Soud HM, Stuehr DJ. Nitric oxide synthases reveal a role for 
calmodulin in controlling electron transfer. Proc Natl Acad Sci USA.  
1993;90:10769-10772.
29. Hevel JM, Marietta MA. Macrophage nitric oxide synthase: relationship 
between enzyme-bound tetrahydrobiopterin and synthase activity. 
Biochemistry. 1992;31:7160-7165.
30. Scott-Burden T. Regulation of nitric oxide production by 
tetrahydrobiopterin. Circulation. 1995;91:248-250.
31. Vasquez-Vivar J, Kalyanaraman B, Martasek P et al. Superoxide 
generation by endothelial nitric oxide synthase: the influence of cofactors. 
Proc Natl Acad Sci US A .  1998;95:9220-9225.
32. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits 
human platelet adhesion to vascular endothelium. Lancet. 1987;2:1057- 
1058.
33. Felmeden DC, Blann AD, Lip GY. Angiogenesis: basic pathophysiology 
and implications for disease. Eur Heart J. 2003;24:586-603.
34. Ignarro LJ, Adams JB, Horwitz PM et al. Activation of soluble guanylate 
cyclase by NO-hemoproteins involves NO-heme exchange. Comparison of 
heme-containing and heme-deficient enzyme forms. J  Biol Chem. 
1986;261:4997-5002.
35. Kosarikov DN, Lee JM, Uversky VN et al. Role of conformational 
changes in the heme-dependent regulation of human soluble guanylate 
cyclase. J  Inorg Biochem. 2001;87:267-276.
36. Furukawa K, Tawada Y, Shigekawa M. Regulation of the plasma 
membrane Ca2+ pump by cyclic nucleotides in cultured vascular smooth 
muscle cells. J  Biol Chem. 1988;263:8058-8065.
37. Haynes WG, Noon JP, Walker BR et al. Inhibition of nitric oxide 
synthesis increases blood pressure in healthy humans. J  Hypertens. 
1993;11:1375-1380.
38. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric 
oxide on peripheral arteriolar tone in man. Lancet. 1989;2:997-1000.
39. Quyyumi AA, Dakak N, Andrews NP et al. Contribution of nitric oxide to 
metabolic coronary vasodilation in the human heart. Circulation. 
1995;92:320-326.
40. Stamler JS, Loh E, Roddy MA et al. Nitric oxide regulates basal systemic 
and pulmonary vascular resistance in healthy humans. Circulation. 
1994;89:2035-2040.
225
41. Davidge ST. Prostaglandin H synthase and vascular function. Circ Res. 
2001;89:650-660.
42. Landino LM, Crews BC, Timmons MD et al. Peroxynitrite, the coupling 
product of nitric oxide and superoxide, activates prostaglandin 
biosynthesis. Proc Natl Acad Sci US A .  1996;93:15069-15074.
43. Dembinska-Kiec A, Rucker W, Schonhofer PS. Effects of PGI2 and PGI 
analogues on cAMP levels in cultured endothelial and smooth muscle cells 
derived from bovine arteries. Naunyn Schmiedebergs Arch Pharmacol. 
1980;311:67-70.
44. Adelstein RS, Hathaway DR. Role of calcium and cyclic adenosine 3':5’ 
monophosphate in regulating smooth muscle contraction. Mechanisms of 
excitation-contraction coupling in smooth muscle. Am J  Cardiol. 
1979;44:783-787.
45. Zmuda A, Dembinska-Kiec A, Chytkowski A et al. Experimental 
atherosclerosis in rabbits: platelet aggregation, thromboxane A2 
generation and anti-aggregatory potency of prostacyclin. Prostaglandins. 
1977;14:1035-1042.
46. Smith EF, III, Lefer AM, Nicolaou KC. Mechanism of coronary 
vasoconstriction induced by carbocyclic thromboxane A2. Am J  Physiol.
1981 ;240:H493-H497.
47. Wolin MS. Interactions o f oxidants with vascular signaling systems. 
Arterioscler Thromb Vase Biol. 2000;20:1430-1442.
48. Duffy SJ, Tran BT, New G et al. Continuous release of vasodilator 
prostanoids contributes to regulation of resting forearm blood flow in 
humans. Am J  Physiol. 1998;274:H 1174-H1183.
49. Duffy SJ, Castle SF, Harper RW et al. Contribution of vasodilator 
prostanoids and nitric oxide to resting flow, metabolic vasodilation, and 
flow-mediated dilation in human coronary circulation. Circulation. 
1999;100:1951-1957.
50. Kharbanda RK, Walton B, Allen M et al. Prevention of inflammation- 
induced endothelial dysfunction: a novel vasculo-protective action of 
aspirin. Circulation. 2002;105:2600-2604.
51. Busse R, Edwards G, Feletou M et al. EDHF: bringing the concepts 
together. Trends Pharmacol Sci. 2002;23:374-380.
52. Chauhan SD, Nilsson H, Ahluwalia A et al. Release of C-type natriuretic 
peptide accounts for the biological activity of endothelium-derived 
hyperpolarizing factor. Proc Natl Acad Sci US A .  2003;100:1426-1431.
53. Shimokawa H, Yasutake H, Fujii K et al. The importance of the 
hyperpolarizing mechanism increases as the vessel size decreases in
226
endothelium-dependent relaxations in rat mesenteric circulation. J  
Cardiovasc Pharmacol. 1996;28:703-711.
54. Sandow SL, Hill CE. Incidence of myoendothelial gap junctions in the 
proximal and distal mesenteric arteries of the rat is suggestive of a role in 
endothelium-derived hyperpolarizing factor-mediated responses. Circ Res. 
2000;86:341-346.
55. Dawes M, Sieniawska C, Delves T et al. Barium reduces resting blood 
flow and inhibits potassium-induced vasodilation in the human forearm. 
Circulation. 2002;105:1323-1328.
56. Halcox JP, Narayanan S, Cramer-Joyce L et al. Characterization of 
endothelium-derived hyperpolarizing factor in the human forearm 
microcirculation. Am J  Physiol Heart Circ Physiol. 2001;280:H2470- 
H2477.
57. Taddei S, Ghiadoni L, Virdis A et al. Vasodilation to bradykinin is 
mediated by an ouabain-sensitive pathway as a compensatory mechanism 
for impaired nitric oxide availability in essential hypertensive patients. 
Circulation. 1999;100:1400-1405.
58. Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease. 
Am JHypertens. 2001;14:83S-89S.
59. de Nucci G, Thomas R, D'Orleans-Juste P et al. Pressor effects of 
circulating endothelin are limited by its removal in the pulmonary 
circulation and by the release o f prostacyclin and endothelium-derived 
relaxing factor. Proc Natl Acad Sci US A .  1988;85:9797-9800.
60. Warner TD, Mitchell JA, de Nucci G et al. Endothelin-1 and endothelin-3 
release EDRF from isolated perfused arterial vessels of the rat and rabbit. 
J  Cardiovasc Pharmacol. 1989; 13 Suppl 5:S85-S88.
61. Clarke JG, Benjamin N, Larkin SW et al. Endothelin is a potent long- 
lasting vasoconstrictor in men. Am J  Physiol. 1989;257:H2033-H2035.
62. Haynes WG, Webb DJ. Contribution of endogenous generation of 
endothelin-1 to basal vascular tone. Lancet. 1994;344:852-854.
63. Kyriakides ZS, Kremastinos DT, Bofilis E et al. Endogenous endothelin 
maintains coronary artery tone by endothelin type A receptor stimulation 
in patients undergoing coronary arteriography. Heart. 2000;84:176-182.
64. Cardillo C, Kilcoyne CM, Waclawiw M et al. Role of endothelin in the 
increased vascular tone o f patients with essential hypertension. 
Hypertension. 1999;33:753-758.
65. Haynes WG, Hand MF, Johnstone HA et al. Direct and sympathetically 
mediated venoconstriction in essential hypertension. Enhanced responses 
to endothelin-1. J  Clin Invest. 1994;94:1359-1364.
227
66 . Griendling KK, Alexander RW. Endothelial control of the cardiovascular 
system: recent advances. FASEBJ. 1996;10:283-292.
67. Lerman A, Edwards BS, Hallett JW et al. Circulating and tissue endothelin 
immunoreactivity in advanced atherosclerosis. N  Engl J  Med. 
1991;325:997-1001.
68. Lerman A, Holmes DR, Jr., Bell MR et al. Endothelin in coronary 
endothelial dysfunction and early atherosclerosis in humans. Circulation. 
1995;92:2426-2431.
69. McEver RP, Cummings RD. Role of PSGL-1 binding to selectins in 
leukocyte recruitment. J  Clin Invest. 1997;100:S97-103.
70. Bevilacqua MP, Pober JS, Wheeler ME et al. Interleukin 1 acts on cultured 
human vascular endothelium to increase the adhesion of 
polymorphonuclear leukocytes, monocytes, and related leukocyte cell 
lines. JC lin Invest. 1985;76:2003-2011.
71. McEver RP, Beckstead JH, Moore KL et al. GMP-140, a platelet alpha- 
granule membrane protein, is also synthesized by vascular endothelial 
cells and is localized in Weibel-Palade bodies. J  Clin Invest. 1989;84:92-
99.
72. Tedder TF, Penta AC, Levine HB et al. Expression of the human 
leukocyte adhesion molecule, LAM1. Identity with the TQ1 and Leu-8 
differentiation antigens. J  Immunol. 1990;144:532-540.
73. Hynes RO. Integrins: versatility, modulation, and signaling in cell 
adhesion. Cell. 1992;69:11-25.
74. Diamond MS, Springer TA. The dynamic regulation of integrin 
adhesiveness. Curr Biol. 1994;4:506-517.
75. Pober JS, Gimbrone MA, Jr., Lapierre LA et al. Overlapping patterns of 
activation of human endothelial cells by interleukin 1, tumor necrosis 
factor, and immune interferon. J  Immunol. 1986;137:1893-1896.
76. Erl W, Weber PC, Weber C. Monocytic cell adhesion to endothelial cells 
stimulated by oxidized low density lipoprotein is mediated by distinct 
endothelial ligands. Atherosclerosis. 1998;136:297-303.
77. Li H, Cybulsky MI, Gimbrone MA, Jr. et al. An atherogenic diet rapidly 
induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion 
molecule, in rabbit aortic endothelium. Arterioscler Thromb. 1993;13:197-
204.
78. Cybulsky MI, Iiyama K, Li H et al. A major role for VCAM-1, but not 
ICAM-1, in early atherosclerosis. J  Clin Invest. 2001;107:1255-1262.
228
79. Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin- 
antithrombin complex formation in rat hindquarters via heparinlike 
molecules bound to the endothelium. JClin Invest. 1984;74:341-350.
80. Stem DM, Kaiser E, Nawroth PP. Regulation of the coagulation system by 
vascular endothelial cells. Haemostasis. 1988;18:202-214.
81. Sagripanti A, Carpi A. Antithrombotic and prothrombotic activities of the 
vascular endothelium. Biomed Pharmacother. 2000;54:107-111.
82. Prydz H, Pettersen KS. Synthesis of thromboplastin (tissue factor) by 
endothelial cells. Haemostasis. 1988;18:215-223.
83. van Hinsbergh VW, Nieuw Amerongen GP. Intracellular signalling 
involved in modulating human endothelial barrier function. JAnat. 
2002;200:549-560.
84. Nieuw Amerongen GP, Draijer R, Vermeer MA et al. Transient and 
prolonged increase in endothelial permeability induced by histamine and 
thrombin: role of protein kinases, calcium, and RhoA. Circ Res. 
1998;83:1115-1123.
85. Moy AB, Bodmer JE, Blackwell K et al. cAMP protects endothelial 
barrier function independent of inhibiting MLC20-dependent tension 
development. Am J  Physiol. 1998;274:L1024-L1029.
86. Verbeuren TJ, Jordaens FH, Van Hove CE et al. Release and vascular 
activity of endothelium-derived relaxing factor in atherosclerotic rabbit 
aorta. Eur J  Pharmacol. 1990;191:173-184.
87. Bonthu S, Heistad DD, Chappell DA et al. Atherosclerosis, vascular 
remodeling, and impairment of endothelium- dependent relaxation in 
genetically altered hyperlipidemic mice. Arterioscler Thromb Vase Biol. 
1997;17:2333-2340.
88. Jayakody L, Senaratne M, Thomson A et al. Endothelium-dependent 
relaxation in experimental atherosclerosis in the rabbit. Circ Res. 
1987;60:251-264.
89. Bossaller C, Yamamoto H, Lichtlen PR et al. Impaired cholinergic 
vasodilation in the cholesterol-fed rabbit in vivo. Basic Res Cardiol. 
1987;82:396-404.
90. Osborne JA, Siegman MJ, Sedar AW et al. Lack of endothelium- 
dependent relaxation in coronary resistance arteries of cholesterol-fed 
rabbits. Am J  Physiol. 1989;256:C591-C597.
91. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apo E. 
Evaluation of lesional development and progression. Arterioscler Thromb. 
1994;14:141-147.
229
92. Limas C, Westrum B, Limas CJ. The evolution of vascular changes in the 
spontaneously hypertensive rat. Am J  Pathol. 1980;98:357-384.
93. Kwon HM, Kim D, Hong BK et al. Ultrastructural changes of the internal 
elastic lamina in experimental hypercholesterolemic porcine coronary 
arteries. J  Korean Med Sci. 1998; 13:603-611.
94. Bolande RP, Leistikow EA, Wartman FS, III et al. The development of 
preatherosclerotic coronary artery lesions in perinatal piglets. Biol 
Neonate. 1996;69:109-118.
95. Halcox JP, Schenke WH, Zalos G et al. Prognostic value of coronary 
vascular endothelial dysfunction. Circulation. 2002;106:653-658.
96. Suwaidi JA, Hamasaki S, Higano ST et al. Long-term follow-up of 
patients with mild coronary artery disease and endothelial dysfunction. 
Circulation. 2000; 101:948-954.
97. Gokce N, Keaney JF, Jr., Hunter LM et al. Predictive value of 
noninvasively determined endothelial dysfunction for long-term 
cardiovascular events in patients with peripheral vascular disease. J  Am 
Coll Cardiol. 2003;41:1769-1775.
98. Perticone F, Ceravolo R, Pujia A et al. Prognostic significance of 
endothelial dysfunction in hypertensive patients. Circulation. 
2001;104:191-196.
99. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary 
vasodilator dysfunction on adverse long-term outcome of coronary heart 
disease. Circulation. 2000;101:1899-1906.
100. Chan NN, Colhoun HM, Vallance P. Cardiovascular risk factors as 
determinants of endothelium-dependent and endothelium-independent 
vascular reactivity in the general population. J  Am Coll Cardiol. 
2001;38:1814-1820.
101. Reddy KG, Nair RN, Sheehan HM et al. Evidence that selective 
endothelial dysfunction may occur in the absence of angiographic or 
ultrasound atherosclerosis in patients with risk factors for atherosclerosis. 
J  Am Coll Cardiol. 1994;23:833-843.
102. Anderson TJ, Uehata A, Gerhard MD et al. Close relation of endothelial 
function in the human coronary and peripheral circulations. J  Am Coll 
Cardiol. 1995;26:1235-1241.
103. Takase B, Uehata A, Akima T et al. Endothelium-dependent flow- 
mediated vasodilation in coronary and brachial arteries in suspected 
coronary artery disease. Am J  Cardiol. 1998;82:1535-1538.
104. Clarkson P, Celermajer DS, Donald AE et al. Impaired vascular reactivity 
in insulin-dependent diabetes mellitus is related to disease duration and
230
low density lipoprotein cholesterol levels. J  Am Coll Cardiol. 
1996;28:573-579.
105. Clarkson P, Celermajer DS, Powe AJ et al. Endothelium-dependent 
dilatation is impaired in young healthy subjects with a family history of 
premature coronary disease. Circulation. 1997;96:3378-3383.
106. Clarkson P, Adams MR, Powe AJ et al. Oral L-arginine improves 
endothelium-dependent dilation in hypercholesterolemic young adults. J  
Clin Invest. 1996;97:1989-1994.
107. Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of 
endothelial dysfunction in children and adults at risk of atherosclerosis. 
Lancet. 1992;340:1111-1115.
108. Creager MA, Cooke JP, Mendelsohn ME et al. Impaired vasodilation of 
forearm resistance vessels in hypercholesterolemic humans. J  Clin Invest. 
1990;86:228-234.
109. Chowienczyk PJ, Watts GF, Cockcroft JR et al. Impaired endothelium- 
dependent vasodilation o f forearm resistance vessels in 
hypercholesterolaemia [see comments]. Lancet. 1992;340:1430-1432.
110. Johnstone MT, Creager SJ, Scales KM et al. Impaired endothelium- 
dependent vasodilation in patients with insulin-dependent diabetes 
mellitus. Circulation. 1993;88:2510-2516.
111. Linder L, Kiowski W, Buhler FR et al. Indirect evidence for release of 
endothelium-derived relaxing factor in human forearm circulation in vivo. 
Blunted response in essential hypertension. Circulation. 1990;81:1762- 
1767.
112. Tamai O, Matsuoka H, Itabe H et al. Single LDL apheresis improves 
endothelium-dependent vasodilatation in hypercholesterolemic humans. 
Circulation. 1997;95:76-82.
113. Alonso R, Mata P, De Andres R et al. Sustained long-term improvement 
of arterial endothelial function in heterozygous familial 
hypercholesterolemia patients treated with simvastatin. Atherosclerosis. 
2001;157:423-429.
114. Mancini GB, Henry GC, Macaya C et al. Angiotensin-converting enzyme 
inhibition with quinapril improves endothelial vasomotor dysfunction in 
patients with coronary artery disease. The TREND (Trial on Reversing 
ENdothelial Dysfunction) Study. Circulation. 1996;94:258-265.
115. Creager MA, Gallagher SJ, Girerd XJ et al. L-arginine improves 
endothelium-dependent vasodilation in hypercholesterolemic humans. J  
Clin Invest. 1992;90:1248-1253.
231
116. Calver A, Collier J, Moncada S et al. Effect of local intra-arterial NG- 
monomethyl-L-arginine in patients with hypertension: the nitric oxide 
dilator mechanism appears abnormal. J  Hypertens. 1992;10:1025-1031.
117. McFadden EP, Clarke JG, Davies GJ et al. Effect of intracoronary 
serotonin on coronary vessels in patients with stable angina and patients 
with variant angina. N  Engl J  Med. 1991;324:648-654.
118. Quyyumi AA, Dakak N, Andrews NP et al. Nitric oxide activity in the 
human coronary circulation. Impact of risk factors for coronary 
atherosclerosis. J  Clin Invest. 1995;95:1747-1755.
119. Lefroy DC, Crake T, Uren NG et al. Effect of inhibition of nitric oxide 
synthesis on epicardial coronary artery caliber and coronary blood flow in 
humans. Circulation. 1993;88:43-54.
120. Ludmer PL, Selwyn AP, Shook TL et al. Paradoxical vasoconstriction 
induced by acetylcholine in atherosclerotic coronary arteries. N  Engl J  
Med. 1986;315:1046-1051.
121. Bossaller C, Hehlert-Friedrich C, Jost S et al. Angiographic assessment of 
human coronary artery endothelial function by measurement of 
endothelium-dependent vasodilation. Eur Heart J. 1989; 10 Suppl F:44-48.
122. Nabel EG, Selwyn AP, Ganz P. Large coronary arteries in humans are 
responsive to changing blood flow: an endothelium-dependent mechanism 
that fails in patients with atherosclerosis. J  Am Coll Cardiol. 1990; 16:349- 
356.
123. Drexler H, Zeiher AM. Progression of coronary endothelial dysfunction in 
man and its potential clinical significance. Basic Res Cardiol. 1991 ;86 
Suppl 2:223-232.
124. Gertler JP, Abbott WM. Prothrombotic and fibrinolytic function of normal 
and perturbed endothelium. JSurg  Res. 1992;52:89-95.
125. Thambyrajah J, Landray MJ, McGlynn FJ et al. Abnormalities of 
endothelial function in patients with predialysis renal failure. Heart. 
2000;83:205-209.
126. Felmeden DC, Spencer CG, Blann AD et al. Physical activity in relation to 
indices of endothelial function and angiogenesis factors in hypertension: a 
substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J  
Intern Med. 2003;253:81-91.
127. Blann AD, de Romeuf C, Mazurier C et al. Circulating von Willebrand 
factor antigen II in atherosclerosis: a comparison with von Willebrand 
factor and soluble thrombomodulin. Blood Coagul Fibrinolysis. 
1998;9:261-266.
128. Blann AD, Lip GY, Fijnheer R. Significance of soluble P-selectin, von 
Willebrand factor, and other adhesion molecules in hypercholesterolemia
232
and peripheral artery disease [letter; comment]. Circulation. 
1999;99:2478-2479.
129. Ikeda H, Takajo Y, Ichiki K et al. Increased soluble form of P-selectin in 
patients with unstable angina. Circulation. 1995;92:1693-1696.
130. Blann AD, Lip GY. Raised levels of intercellular adhesion molecule-1 and 
vascular cell adhesion molecule- 1 in the plasma of patients with ischaemic 
heart disease and hyperlipidaemia [letter; comment]. Atherosclerosis. 
1998;141:177-178.
131. Fowler S, Shio H, Haley NJ. Characterization of lipid-laden aortic cells 
from cholesterol-fed rabbits. IV. Investigation of macrophage-like 
properties of aortic cell populations. Lab Invest. 1979;41:372-378.
132. Boring L, Gosling J, Cleary M et al. Decreased lesion formation in CCR2- 
/- mice reveals a role for chemokines in the initiation of atherosclerosis. 
Nature. 1998;394:894-897.
133. Smith JD, Trogan E, Ginsberg M et al. Decreased atherosclerosis in mice 
deficient in both macrophage colony-stimulating factor (op) and 
apolipoprotein E. Proc Natl Acad Sci US A.  1995;92:8264-8268.
134. Schonbeck U, Sukhova GK, Shimizu K et al. Inhibition of CD40 signaling 
limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci 
USA.  2000;97:7458-7463.
135. Fabricant CG, Fabricant J. Atherosclerosis induced by infection with 
Marek's disease herpesvirus in chickens. Am Heart J. 1999;138:S465- 
S468.
136. Fong IW, Chiu B, Viira E et al. De Novo induction of atherosclerosis by 
Chlamydia pneumoniae in a rabbit model. Infect Immun. 1999;67:6048- 
6055.
137. Muhlestein JB, Anderson JL, Hammond EH et al. Infection with 
Chlamydia pneumoniae accelerates the development of atherosclerosis and 
treatment with azithromycin prevents it in a rabbit model. Circulation. 
1998;97:633-636.
138. Kalayoglu MV, Byrne GI. A Chlamydia pneumoniae component that 
induces macrophage foam cell formation is chlamydial lipopolysaccharide. 
Infect Immun. 1998;66:5067-5072.
139. Alber DG, Powell KL, Vallance P et al. Herpesvirus infection accelerates 
atherosclerosis in the apolipoprotein E-deficient mouse. Circulation. 
2000;102:779-785.
140. Hsich E, Zhou YF, Paigen B et al. Cytomegalovirus infection increases 
development of atherosclerosis in Apolipoprotein-E knockout mice. 
Atherosclerosis. 2001; 156:23-28.
233
141. Lehr HA, Sagban TA, Ihling C et al. Immunopathogenesis of 
atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on 
hypercholesterolemic diet. Circulation. 2001;104:914-920.
142. Rothstein NM, Quinn TC, Madico G et al. Effect of azithromycin on 
murine arteriosclerosis exacerbated by Chlamydia pneumoniae. J  Infect 
Dis. 2001;183:232-238.
143. Caligiuri G, Rottenberg M, Nicoletti A et al. Chlamydia pneumoniae 
infection does not induce or modify atherosclerosis in mice. Circulation. 
2001;103:2834-2838.
144. Zhou X, Nicoletti A, Elhage R et al. Transfer of CD4(+) T cells aggravates 
atherosclerosis in immunodeficient apolipoprotein E knockout mice. 
Circulation. 2000; 102:2919-2922.
145. George J, Afek A, Gilburd B et al. Induction of early atherosclerosis in 
LDL-receptor-deficient mice immunized with beta2-glycoprotein I. 
Circulation. 1998;98:1108-1115.
146. George J, Shoenfeld Y, Afek A et al. Enhanced fatty streak formation in 
C57BL/6J mice by immunization with heat shock protein-65. Arterioscler 
Thromb Vase Biol. 1999;19:505-510.
147. Xu Q, Dietrich H, Steiner HJ et al. Induction of arteriosclerosis in 
normocholesterolemic rabbits by immunization with heat shock protein 
65 .Arterioscler Thromb. 1992;12:789-799.
148. Xu Q, Kleindienst R, Waitz W et al. Increased expression of heat shock 
protein 65 coincides with a population of infiltrating T lymphocytes in 
atherosclerotic lesions o f rabbits specifically responding to heat shock 
protein 65. JClin Invest. 1993;91:2693-2702.
149. Mamode N, Cobbe S, Pollock JG. Infarcts after surgery. BMJ. 
1995;310:1215-1216.
150. Quartin AA, Schein RM, Kett DH et al. Magnitude and duration of the 
effect of sepsis on survival. Department of Veterans Affairs Systemic 
Sepsis Cooperative Studies Group. JAMA. 1997;277:1058-1063.
151. Meier CR, Jick SS, Derby LE et al. Acute respiratory-tract infections and 
risk of first-time acute myocardial infarction. Lancet. 1998;351:1467- 
1471.
152. Biasucci LM, Liuzzo G, Fantuzzi G et al. Increasing levels of interleukin 
(IL)-lRa and IL-6 during the first 2 days of hospitalization in unstable 
angina are associated with increased risk of in-hospital coronary events. 
Circulation. 1999;99:2079-2084.
153. Meuwissen M, Piek JJ, van der Wal AC et al. Recurrent unstable angina 
after directional coronary atherectomy is related to the extent of initial 
coronary plaque inflammation. J  Am Coll Cardiol. 2001;37:1271-1276.
234
154. Liuba P, Persson J, Luoma J et al. Acute infections in children are 
accompanied by oxidative modification of LDL and decrease of HDL 
cholesterol, and are followed by thickening of carotid intima-media. Eur 
Heart J. 2003;24:515-521.
155. Held C, Hjemdahl P, Rehnqvist N et al. Haemostatic markers, 
inflammatory parameters and lipids in male and female patients in the 
Angina Prognosis Study in Stockholm (APSIS). A comparison with 
healthy controls. J  Intern Med. 1997;241:59-69.
156. Bouwman JJ, Visseren FL, Bosch MC et al. Procoagulant and 
inflammatory response of virus-infected monocytes. Eur J  Clin Invest. 
2002;32:759-766.
157. Meyers DG. Myocardial infarction, stroke, and sudden cardiac death may 
be prevented by influenza vaccination. Curr Atheroscler Rep. 2003;5:146-
149.
158. Jackson LA, Yu O, Heckbert SR et al. Influenza vaccination is not 
associated with a reduction in the risk of recurrent coronary events. Am J  
Epidemiol. 2002;156:634-640.
159. Nichol KL, Nordin J, Mullooly J et al. Influenza vaccination and reduction 
in hospitalizations for cardiac disease and stroke among the elderly. N  
Engl J  Med. 2003;348:1322-1332.
160. Pesonen E, Paakkari I, Rapola J. Infection-associated intimal thickening in 
the coronary arteries of children. Atherosclerosis. 1999;142:425-429.
161. Saikku P, Leinonen M, Mattila K et al. Serological evidence of an 
association of a novel Chlamydia, TWAR, with chronic coronary heart 
disease and acute myocardial infarction. Lancet. 1988;2:983-986.
162. Nicholson AC, Hajjar DP. Herpesvirus in atherosclerosis and thrombosis: 
etiologic agents or ubiquitous bystanders? Arterioscler Thromb Vase Biol. 
1998;18:339-348.
163. Danesh J, Wong Y, Ward M et al. Chronic infection with Helicobacter 
pylori, Chlamydia pneumoniae, or cytomegalovirus: population based 
study of coronary heart disease. Heart. 1999;81:245-247.
164. Danesh J, Whincup P, Walker M et al. Low grade inflammation and 
coronary heart disease: prospective study and updated meta-analyses.
BMJ. 2000;321:199-204.
165. Kuo CC, Shor A, Campbell LA et al. Demonstration of Chlamydia 
pneumoniae in atherosclerotic lesions of coronary arteries. J  Infect Dis. 
1993;167:841-849.
166. Ameriso SF, Fridman EA, Leiguarda RC et al. Detection of Helicobacter 
pylori in human carotid atherosclerotic plaques. Stroke. 2001;32:385-391.
235
167. Haraszthy VI, Zambon JJ, Trevisan M et al. Identification of periodontal 
pathogens in atheromatous plaques. J  Periodontol. 2000;71:1554-1560.
168. Parchure N, Zouridakis EG, Kaski JC. Effect of azithromycin treatment on 
endothelial function in patients with coronary artery disease and evidence 
of Chlamydia pneumoniae infection. Circulation. 2002;105:1298-1303.
169. Cercek B, Shah PK, Noc M et al. Effect of short-term treatment with 
azithromycin on recurrent ischaemic events in patients with acute coronary 
syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) 
trial: a randomised controlled trial. Lancet. 2003;361:809-813.
170. Gurfinkel E, Bozovich G, Beck E et al. Treatment with the antibiotic 
roxithromycin in patients with acute non- Q-wave coronary syndromes. 
The final report of the ROXIS Study. Eur Heart J. 1999;20:121-127.
171. Zahn R, Schneider S, Frilling B et al. Antibiotic therapy after acute 
myocardial infarction: a prospective randomized study. Circulation. 
2003;107:1253-1259.
172. Muhlestein JB, Anderson JL, Carlquist JF et al. Randomized secondary 
prevention trial of azithromycin in patients with coronary artery disease: 
primary clinical results of the ACADEMIC study. Circulation. 
2000;102:1755-1760.
173. Sinisalo J, Mattila K, Valtonen V et al. Effect of 3 months of antimicrobial 
treatment with clarithromycin in acute non-q-wave coronary syndrome. 
Circulation. 2002;105:1555-1560.
174. Grayston JT. Antibiotic treatment o f atherosclerotic cardiovascular 
disease. Circulation. 2003;107:1228-1230.
175. Mattila KJ, Nieminen MS, Valtonen VV et al. Association between dental 
health and acute myocardial infarction. BMJ. 1989;298:779-781.
176. Beck J, Garcia R, Heiss G et al. Periodontal disease and cardiovascular 
disease. J  Periodontol. 1996;67:1123-1137.
177. Lalla E, Lamster IB, Hofmann MA et al. Oral infection with a periodontal 
pathogen accelerates early atherosclerosis in apolipoprotein e-null mice. 
Arterioscler Thromb Vase Biol. 2003;23:1405-1411.
178. Amar S, Gokce N, Morgan S et al. Periodontal disease is associated with 
brachial artery endothelial dysfunction and systemic inflammation. 
Arterioscler Thromb Vase Biol. 2003;23:1245-1249.
179. Zhu J, Nieto FJ, Home BD et al. Prospective study of pathogen burden and 
risk of myocardial infarction or death. Circulation. 2001;103:45-51.
180. Zhu J, Shearer GM, Norman JE et al. Host response to cytomegalovirus 
infection as a determinant of susceptibility to coronary artery disease : sex-
236
based differences in inflammation and type of immune response [In 
Process Citation]. Circulation. 2000;102:2491-2496.
181. Hubacek JA, Rothe G, Pit'ha J et al. C(-260)~>T polymorphism in the 
promoter of the CD 14 monocyte receptor gene as a risk factor for 
myocardial infarction. Circulation. 1999;99:3218-3220.
182. Liang MH, Mandl LA, Costenbader K et al. Atherosclerotic vascular 
disease in systemic lupus erythematosus. J  Natl Med Assoc. 2002;94:813- 
819.
183. Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid 
arthritis. Circulation. 1999;100:2124-2126.
184. Svenungsson E, Fei GZ, Jensen-Urstad K et al. TNF-alpha: a link between 
hypertriglyceridaemia and inflammation in SLE patients with 
cardiovascular disease. Lupus. 2003;12:454-461.
185. Hurlimann D, Forster A, Noll G et al. Anti-tumor necrosis factor-alpha 
treatment improves endothelial function in patients with rheumatoid 
arthritis. Circulation. 2002;106:2184-2187.
186. Svenungsson E, Jensen-Urstad K, Heimburger M et al. Risk factors for 
cardiovascular disease in systemic lupus erythematosus. Circulation. 
2001;104:1887-1893.
187. Matsuura E, Kobayashi K, Kasahara J et al. Anti-beta 2-glycoprotein I 
autoantibodies and atherosclerosis. Int Rev Immunol. 2002;21:51-66.
188. Nuttall SL, Heaton S, Piper MK et al. Cardiovascular risk in systemic 
lupus erythematosus—evidence of increased oxidative stress and 
dyslipidaemia. Rheumatology (Oxford). 2003;42:758-762.
189. Russell Al, Cunninghame Graham DS, Shepherd C et al. Polymorphism at 
the C-reactive protein locus influences gene expression and predisposes to 
systemic lupus erythematosus. Hum Mol Genet. 2003.
190. Hemandez-Rodriguez J, Segarra M, Vilardell C et al. Elevated Production 
of Interleukin-6 Is Associated With a Lower Incidence of Disease-Related 
Ischemic Events in Patients With Giant-Cell Arteritis. Angiogenic Activity 
of Interleukin-6 as a Potential Protective Mechanism. Circulation. 2003.
191. Ridker PM. Plasma Concentration of Endogenous Tissue Plasminogen 
Activator and the Occurrence of Future Cardiovascular Events. J  Thromb 
Thrombolysis. 1994;1:35-40.
192. Ridker PM, Hennekens CH, Stampfer MJ et al. Prospective study of 
herpes simplex virus, cytomegalovirus, and the risk of future myocardial 
infarction and stroke. Circulation. 1998;98:2796-2799.
193. Ridker PM, Hennekens CH, Roitman-Johnson B et al. Plasma 
concentration of soluble intercellular adhesion molecule 1 and risks of
237
future myocardial infarction in apparently healthy men. Lancet. 
1998;351:88-92.
194. Ridker PM, Buring JE, Shih J et al. Prospective study of C-reactive protein 
and the risk of future cardiovascular events among apparently healthy 
women. Circulation. 1998;98:731-733.
195. Ridker PM. Role of inflammatory biomarkers in prediction of coronary 
heart disease. Lancet. 2001;358:946-948.
196. Naruko T, Ueda M, Haze K et al. Neutrophil infiltration of culprit lesions 
in acute coronary syndromes. Circulation. 2002;106:2894-2900.
197. Uzui H, Harpf A, Liu M et al. Increased expression of membrane type 3- 
matrix metalloproteinase in human atherosclerotic plaque: role of activated 
macrophages and inflammatory cytokines. Circulation. 2002; 106:3024- 
3030.
198. Greaves DR, Channon KM. Inflammation and immune responses in 
atherosclerosis. Trends Immunol. 2002;23:535-541.
199. Buffon A, Biasucci LM, Liuzzo G et al. Widespread coronary 
inflammation in unstable angina. N  Engl JM ed. 2002;347:5-12.
200. Rudd JH, Warburton EA, Fryer TD et al. Imaging atherosclerotic plaque 
inflammation with [18F]- fluorodeoxyglucose positron emission 
tomography. Circulation. 2002;105:2708-2711.
201. Stefanadis C, Toutouzas K, Tsiamis E et al. Increased local temperature in 
human coronary atherosclerotic plaques: an independent predictor of 
clinical outcome in patients undergoing a percutaneous coronary 
intervention. JA m  Coll Cardiol. 2001;37:1277-1283.
202. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither 
among 17,187 cases of suspected acute myocardial infarction: ISIS-2. 
ISIS-2 (Second International Study of Infarct Survival) Collaborative 
Group. Lancet. 1988;2:349-360.
203. Ikonomidis I, Andreotti F, Economou E et al. Increased proinflammatory 
cytokines in patients with chronic stable angina and their reduction by 
aspirin. Circulation. 1999;100:793-798.
204. Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the 
risk of cardiovascular disease in apparently healthy men [published 
erratum appears in N Engl J Med 1997 Jul 31;337(5):356] [see comments]. 
N  Engl JM ed. 1997;336:973-979.
205. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease 
with pravastatin in men with hypercholesterolemia. West of Scotland 
Coronary Prevention Study Group. N  Engl J  Med. 1995;333:1301-1307.
238
206. Swedberg K, Held P, Kjekshus J et al. Effects of the early administration 
o f enalapril on mortality in patients with acute myocardial infarction. 
Results of the Cooperative New Scandinavian Enalapril Survival Study II 
(CONSENSUS II). N Engl JM ed. 1992;327:678-684.
207. Crisby M, Nordin-Fredriksson G, Shah PK et al. Pravastatin treatment 
increases collagen content and decreases lipid content, inflammation, 
metalloproteinases, and cell death in human carotid plaques: implications 
for plaque stabilization. Circulation. 2001;103:926-933.
208. Linz W, Wohlfart P, Scholkens BA et al. Interactions among ACE, kinins 
and NO. Cardiovasc Res. 1999;43:549-561.
209. Schieffer B, Schieffer E, Hilfiker-Kleiner D et al. Expression of 
angiotensin II and interleukin 6 in human coronary atherosclerotic 
plaques: potential implications for inflammation and plaque instability. 
Circulation. 2000;101:1372-1378.
210. Haffner SM, Greenberg AS, Weston WM et al. Effect of rosiglitazone 
treatment on nontraditional markers of cardiovascular disease in patients 
with type 2 diabetes mellitus. Circulation. 2002;106:679-684.
211. Robins SJ, Collins D, Wittes JT et al. Relation of gemfibrozil treatment 
and lipid levels with major coronary events: VA-HIT: a randomized 
controlled trial. JAMA. 2001;285:1585-1591.
212. Kleemann R, Verschuren L, de Rooij BJ et al. Evidence for anti­
inflammatory activity of statins and PPARalpha activators in human C- 
reactive protein transgenic mice in vivo and in cultured human hepatocytes 
in vitro. Blood. 2004;103:4188-4194.
213. Koenig W, Sund M, Frohlich M et al. C-Reactive protein, a sensitive 
marker of inflammation, predicts future risk of coronary heart disease in 
initially healthy middle-aged men: results from the MONICA (Monitoring 
Trends and Determinants in Cardiovascular Disease) Augsburg Cohort 
Study, 1984 to 1992. Circulation. 1999;99:237-242.
214. Ridker PM, Cushman M, Stampfer MJ et al. Plasma concentration of C- 
reactive protein and risk of developing peripheral vascular disease [see 
comments]. Circulation. 1998;97:425-428.
215. Garcia-Moll X, Zouridakis E, Cole D et al. C-reactive protein in patients 
with chronic stable angina: differences in baseline serum concentration 
between women and men. Eur Heart J. 2000;21:1598-1606.
216. Lindahl B, Toss H, Siegbahn A et al. Markers of myocardial damage and 
inflammation in relation to long-term mortality in unstable coronary artery 
disease. FRISC Study Group. Fragmin during Instability in Coronary 
Artery Disease [see comments]. N  Engl J  Med. 2000;343:1139-1147.
239
217. de Winter RJ, Bholasingh R, Lijmer JG et al. Independent prognostic 
value of C-reactive protein and troponin I in patients with unstable angina 
or non-Q-wave myocardial infarction. Cardiovasc Res. 1999;42:240-245.
218. Pietila KO, Harmoinen AP, Jokiniitty J et al. Serum C-reactive protein 
concentration in acute myocardial infarction and its relationship to 
mortality during 24 months of follow-up in patients under thrombolytic 
treatment. Eur Heart J. 1996; 17:1345-1349.
219. Chew DP, Bhatt DL, Robbins MA et al. Incremental prognostic value of 
elevated baseline C-reactive protein among established markers of risk in 
percutaneous coronary intervention. Circulation. 2001;104:992-997.
220. Liuzzo G, Buffon A, Biasucci LM et al. Enhanced inflammatory response 
to coronary angioplasty in patients with severe unstable angina. 
Circulation. 1998;98:2370-2376.
221. Lincoff AM, Kereiakes DJ, Mascelli MA et al. Abciximab suppresses the 
rise in levels of circulating inflammatory markers after percutaneous 
coronary revascularization. Circulation. 2001; 104:163-167.
222. Gaudino M, Nasso G, Andreotti F et al. Preoperative C-reactive protein 
level and outcome following coronary surgery. Eur J  Cardiothorac Surg. 
2002;22:521-526.
223. Milazzo D, Biasucci LM, Luciani N et al. Elevated levels of C-reactive 
protein before coronary artery bypass grafting predict recurrence of 
ischemic events. Am J  Cardiol. 1999;84:459-61, A9.
224. Sano T, Tanaka A, Namba M et al. C-reactive protein and lesion 
morphology in patients with acute myocardial infarction. Circulation. 
2003;108:282-285.
225. Ridker PM, Rifai N, Rose L et al. Comparison of C-reactive protein and 
low-density lipoprotein cholesterol levels in the prediction of first 
cardiovascular events. N  Engl J  Med. 2002;347:1557-1565.
226. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other 
circulating markers of inflammation in the prediction of coronary heart 
disease. N  Engl JM ed. 2004;350:1387-1397.
227. Duncan BB, Schmidt MI, Pankow JS et al. Low-grade systemic 
inflammation and the development of type 2 diabetes: the atherosclerosis 
risk in communities study. Diabetes. 2003;52:1799-1805.
228. Chul SK, Suh JY, Kim BS et al. High sensitivity c-reactive protein as an 
independent risk factor for essential hypertension. Am J  Hypertens. 
2003;16:429-433.
229. Sesso HD, Buring JE, Rifai N et al. C-reactive protein and the risk of 
developing hypertension. JAMA. 2003;290:2945-2951.
240
230. Reilly MP, Wolfe ML, Localio AR et al. C-Reactive Protein and Coronary 
Artery Calcification. The Study of Inherited Risk of Coronary 
Atherosclerosis (SIRCA). Arterioscler Thromb Vase Biol. 2003.
231. MacGregor AJ, Gallimore JR, Spector TD et al. Genetic Effects on 
Baseline Values of C-Reactive Protein and Serum Amyloid A Protein: A 
Comparison of Monozygotic and Dizygotic Twins. Clin Chem. 2003.
232. Szalai AJ, McCrory MA, Cooper GS et al. Association between baseline 
levels of C-reactive protein (CRP) and a dinucleotide repeat 
polymorphism in the intron of the CRP gene. Genes Immun. 2002;3:14-19.
233. Brull DJ, Serrano N, Zito F et al. Human CRP Gene Polymorphism 
Influences CRP Levels. Implications for the Prediction and Pathogenesis 
of Coronary Heart Disease. Arterioscler Thromb Vase Biol. 2003.
234. Vickers MA, Green FR, Terry C et al. Genotype at a promoter 
polymorphism of the interleukin-6 gene is associated with baseline levels 
of plasma C-reactive protein. Cardiovasc Res. 2002;53:1029-1034.
235. Berger P, McConnell JP, Nunn M et al. C-reactive protein levels are 
influenced by common IL-1 gene variations. Cytokine. 2002;17:171-174.
236. Zee RY, Ridker PM. Polymorphism in the human C-reactive protein 
(CRP) gene, plasma concentrations of CRP, and the risk of future arterial 
thrombosis. Atherosclerosis. 2002;162:217-219.
237. Koenig W, Sund M, Frohlich M et al. Refinement of the association of 
serum C-reactive protein concentration and coronary heart disease risk by 
correction for within-subject variation over time: the MONICA Augsburg 
studies, 1984 and 1987. Am J  Epidemiol. 2003;158:357-364.
238. Ridker PM, Rifai N, Stampfer MJ et al. Plasma concentration of 
interleukin-6 and the risk of future myocardial infarction among 
apparently healthy men. Circulation. 2000;101:1767-1772.
239. Brevetti G, Piscione F, Silvestro A et al. Increased inflammatory status 
and higher prevalence of three-vessel coronary artery disease in patients 
with concomitant coronary and peripheral atherosclerosis. Thromb 
Haemost. 2003;89:1058-1063.
240. Patti G, D'Ambrosio A, Dobrina A et al. Interleukin-1 receptor antagonist: 
a sensitive marker of instability in patients with coronary artery disease. J  
Thromb Thrombolysis. 2002;14:139-143.
241. Ridker PM, Rifai N, Pfeffer M et al. Elevation of tumor necrosis factor- 
alpha and increased risk of recurrent coronary events after myocardial 
infarction. Circulation. 2000; 101:2149-2153.
242. Blankenberg S, Tiret L, Bickel C et al. Interleukin-18 is a strong predictor 
of cardiovascular death in stable and unstable angina. Circulation. 
2002;106:24-30.
241
243. Kofoed SC, Wittrup HH, Sillesen H et al. Fibrinogen predicts ischaemic 
stroke and advanced atherosclerosis but not echolucent, rupture-prone 
carotid plaques: the Copenhagen City Heart Study. Eur Heart J. 
2003;24:567-576.
244. Morrow DA, Rifai N, Antman EM et al. Serum amyloid A predicts early 
mortality in acute coronary syndromes: A T IM I11A substudy. J  Am Coll 
Cardiol 2000;35:358-362.
245. de Lemos JA, Morrow DA, Sabatine MS et al. Association between 
plasma levels of monocyte chemoattractant protein-1 and long-term 
clinical outcomes in patients with acute coronary syndromes. Circulation. 
2003;107:690-695.
246. Blankenberg S, Rupprecht HJ, Bickel C et al. Circulating cell adhesion 
molecules and death in patients with coronary artery disease. Circulation. 
2001;104:1336-1342.
247. Malik I, Danesh J, Whincup P et al. Soluble adhesion molecules and 
prediction of coronary heart disease: a prospective study and meta­
analysis. Lancet. 2001;358:971-976.
248. Tillet W, Francis TJr. Serological reactions in pneumonia with a 
nonprotein fraction from pneumococcus. J  Exp Med. 1930;52:561-571.
249. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J  Clin 
Invest. 2003;111:1805-1812.
250. Thompson D, Pepys MB, Wood SP. The physiological structure of human 
C-reactive protein and its complex with phosphocholine. Structure Fold 
Des. 1999;7:169-177.
251. de Beer FC, Baltz ML, Munn EA et al. Isolation and characterization of C- 
reactive protein and serum amyloid P component in the rat. Immunology. 
1982;45:55-70.
252. Baltz ML, de Beer FC, Feinstein A et al. Phylogenetic aspects of C- 
reactive protein and related proteins. Ann N  Y Acad Sci. 1982;389:49-75.
253. Oliveira EB, Gotschlich EC, Liu TY. Comparative studies on the binding 
properties of human and rabbit C-reactive proteins. J  Immunol. 
1980;124:1396-1402.
254. Castell JV, Gomez-Lechon MJ, David M et al. Interleukin-6 is the major 
regulator of acute phase protein synthesis in adult human hepatocytes. 
FEBS Lett. 1989;242:237-239.
255. Darlington GJ, Wilson DR, Lachman LB. Monocyte-conditioned medium, 
interleukin-1, and tumor necrosis factor stimulate the acute phase response 
in human hepatoma cells in vitro. J  Cell Biol. 1986;103:787-793.
242
256. de Maat MP, Kluft C. Determinants of C-reactive protein concentration in 
blood. Ital Heart J. 2001;2:189-195.
257. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic 
studies of radioiodinated human C-reactive protein in health and disease. J  
Clin Invest. 1993;91:1351-1357.
258. Agrawal A, Cha-Molstad H, Samols D et al. Transactivation of C-reactive 
protein by IL-6 requires synergistic interaction of CCAAT/enhancer 
binding protein beta (C/EBP beta) and Rel p50. J  Immunol. 
2001;166:2378-2384.
259. Agrawal A, Cha-Molstad H, Samols D et al. Overexpressed nuclear factor- 
kappaB can participate in endogenous C-reactive protein induction, and 
enhances the effects of C/EBPbeta and signal transducer and activator of 
transcription-3. Immunology. 2003;108:539-547.
260. Yue CC, Muller-Greven J, Dailey P et al. Identification of a C-reactive 
protein binding site in two hepatic carboxylesterases capable of retaining 
C-reactive protein within the endoplasmic reticulum. J  Biol Chem. 
1996;271:22245-22250.
261. Meier-Ewert HK, Ridker PM, Rifai N et al. Absence of diurnal variation 
of C-reactive protein concentrations in healthy human subjects. Clin 
Chem. 2001;47:426-430.
262. Sothem RB, Roitman-Johnson B, Kanabrocki EL et al. Circadian 
characteristics of interleukin-6 in blood and urine of clinically healthy 
men. In Vivo. 1995;9:331-339.
263. Spath-Schwalbe E, Hansen K, Schmidt F et al. Acute effects of 
recombinant human interleukin-6 on endocrine and central nervous sleep 
functions in healthy men . J  Clin Endocrinol Metab. 1998;83:1573-1579.
264. Chang MK, Binder CJ, Torzewski M et al. C-reactive protein binds to both 
oxidized LDL and apoptotic cells through recognition of a common 
ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci 
USA.  2002;99:13043-13048.
265. Du Clos TW. C-reactive protein reacts with the U 1 small nuclear 
ribonucleoprotein. J  Immunol. 1989;143:2553-2559.
266. Volanakis JE. Complement activation by C-reactive protein complexes. 
Ann N Y  Acad Sci. 1982;389:235-250.
267. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by 
C-reactive protein. Immunopharmacology. 1999;42:23-30.
268. Diaz PN, Bleeker WK, Lubbers Y et al. Rat C-reactive protein activates 
the autologous complement system. Immunology. 2003;109:564-571.
243
269. Stein MP, Edberg JC, Kimberly RP et al. C-reactive protein binding to 
FcgammaRIIa on human monocytes and neutrophils is allele-specific. J  
Clin Invest. 2000;105:369-376.
270. Saeland E, van Royen A, Hendriksen K et al. Human C-reactive protein 
does not bind to FcgammaRIIa on phagocytic cells. J  Clin Invest. 
2001;107:641-643.
271. Hundt M, Zielinska-Skowronek M, Schmidt RE. Lack of specific 
receptors for C-reactive protein on white blood cells. Eur J  Immunol. 
2001;31:3475-3483.
272. Xia D, Samols D. Transgenic mice expressing rabbit C-reactive protein are 
resistant to endotoxemia. Proc Natl Acad Sci US A.  1997;94:2575-2580.
273. Mold C, Nakayama S, Holzer TJ et al. C-reactive protein is protective 
against Streptococcus pneumoniae infection in mice. J  Exp Med. 
1981;154:1703-1708.
274. Szalai AJ, VanCott JL, McGhee JR et al. Human C-reactive protein is 
protective against fatal Salmonella enterica serovar typhimurium infection 
in transgenic mice. Infect Immun. 2000;68:5652-5656.
275. Mold C, Rodic-Polic B, Du Clos TW. Protection from Streptococcus 
pneumoniae infection by C-reactive protein and natural antibody requires 
complement but not Fc gamma receptors. J  Immunol. 2002; 168:6375- 
6381.
276. Farber SA, Slack BE, Blusztajn JK. Acceleration of phosphatidylcholine 
synthesis and breakdown by inhibitors of mitochondrial function in 
neuronal cells: a model of the membrane defect of Alzheimer's disease. 
FASEBJ. 2000;14:2198-2206.
277. Mian KB, Martin W. The inhibitory effect of 3-amino-1,2,4-triazole on 
relaxation induced by hydroxylamine and sodium azide but not hydrogen 
peroxide or glyceryl trinitrate in rat aorta. Br J  Pharmacol. 
1995;116:3302-3308.
278. Sies H, Brauser B, Bucher T. On the state of mitochondria in perfused 
liver: Action of sodium azide on respiratory carriers and respiration. FEBS 
Lett. 1969;5:319-323.
279. van den Berg CW, Taylor KE, Lang D. C-reactive protein-induced in vitro 
vasorelaxation is an artefact caused by the presence of sodium azide in 
commercial preparations. Arterioscler Thromb Vase Biol. 2004;24:el68- 
el 71.
280. Swafford AN, Bratz IN, Knudson JD et al. C-Reactive Protein Does Not 
Relax Vascular Smooth Muscle: Effects Mediated by Sodium Azide in 
Commercially Available Preparations. Am J  Physiol Heart Circ Physiol. 
2004.
244
281. Griselli M, Herbert J, Hutchinson WL et al. C-reactive protein and 
complement are important mediators of tissue damage in acute myocardial 
infarction. J  Exp Med. 1999; 190:1733-1740.
282. Du Clos TW, Zlock LT, Hicks PS et al. Decreased autoantibody levels and 
enhanced survival of (NZB x NZW) FI mice treated with C-reactive 
protein. Clin Immunol Immunopathol. 1994;70:22-27.
283. Szalai AJ, Weaver CT, McCrory MA et al. Delayed lupus onset in (NZB x 
NZW)F1 mice expressing a human C-reactive protein transgene. Arthritis 
Rheum. 2003;48:1602-1611.
284. Danenberg HD, Szalai AJ, Swaminathan RV et al. Increased thrombosis 
after arterial injury in human C-reactive protein-transgenic mice. 
Circulation. 2003;108:512-515.
285. Torzewski J, Torzewski M, Bowyer DE et al. C-reactive protein frequently 
colocalizes with the terminal complement complex in the intima of early 
atherosclerotic lesions of human coronary arteries. Arterioscler Thromb 
Vase Biol. 1998;18:1386-1392.
286. Zhang YX, Cliff WJ, Schoefl GI et al. Coronary C-reactive protein 
distribution: its relation to development of atherosclerosis.
Atherosclerosis. 1999; 145:375-379.
287. Kobayashi S, Inoue N, Ohashi Y et al. Interaction of oxidative stress and 
inflammatory response in coronary plaque instability: important role of C- 
reactive protein. Arterioscler Thromb Vase Biol. 2003;23:1398-1404.
288. Nijmeijer R, Lagrand WK, Lubbers YT et al. C-reactive protein activates 
complement in infarcted human myocardium. Am J  Pathol. 2003; 163:269-
275.
289. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen 
activator inhibitor-1 expression and activity in human aortic endothelial 
cells: implications for the metabolic syndrome and atherothrombosis. 
Circulation. 2003;107:398-404.
290. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C- 
reactive protein on human endothelial cells [In Process Citation]. 
Circulation. 2000; 102:2165-2168.
291. Verma S, Wang CH, Weisel RD et al. Hyperglycemia potentiates the 
proatherogenic effects of C-reactive protein: reversal with rosiglitazone. J  
Mol Cell Cardiol. 2003;35:417-419.
292. Verma S, Li SH, Badiwala MV et al. Endothelin antagonism and 
interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive 
protein. Circulation. 2002;105:1890-1896.
245
293. Cermak J, Key NS, Bach RR et al. C-reactive protein induces human 
peripheral blood monocytes to synthesize tissue factor. Blood. 
1993;82:513-520.
294. Nakagomi A, Freedman SB, Geczy CL. Interferon-gamma and 
lipopolysaccharide potentiate monocyte tissue factor induction by C- 
reactive protein: relationship with age, sex, and hormone replacement 
treatment. Circulation. 2000;101:1785-1791.
295. Torzewski M, Rist C, Mortensen RF et al. C-reactive protein in the arterial 
intima: role of C-reactive protein receptor-dependent monocyte 
recruitment in atherogenesis. Arterioscler Thromb Vase Biol. 
2000;20:2094-2099.
296. Robey FA, Ohura K, Futaki S et al. Proteolysis of human C-reactive 
protein produces peptides with potent immunomodulating activity. J  Biol 
Chem. 1987;262:7053-7057.
297. Wang CH, Li SH, Weisel RD et al. C-reactive protein upregulates 
angiotensin type 1 receptors in vascular smooth muscle. Circulation. 
2003;107:1783-1790.
298. Verma S, Wang CH, Li SH et al. A self-fulfilling prophecy: C-reactive 
protein attenuates nitric oxide production and inhibits angiogenesis. 
Circulation. 2002; 106:913-919.
299. Venugopal SK, Devaraj S, Yuhanna I et al. Demonstration that C-reactive 
protein decreases eNOS expression and bioactivity in human aortic 
endothelial cells. Circulation. 2002;106:1439-1441.
300. Stemik L, Samee S, SchaffHV et al. C-reactive protein relaxes human 
vessels in vitro. Arterioscler Thromb Vase Biol. 2002;22:1865-1868.
301. Wylam ME, Metkus AP, Umans JG. Nitric oxide dependent and 
independent effects of in vitro incubation or endotoxin on vascular 
reactivity in rat aorta. Life Sci. 2001;69:455-467.
302. Ho KH, Kwan CY, Bourreau JP. Hyporesponsiveness to Ca2+ of aortic 
smooth muscle in endotoxin-treated rats: no-dependent and -independent 
in vitro mechanisms. Res Commun Mol Pathol Pharmacol. 1996;92:275-
284.
303. Wylam ME, Samsel RW, Umans JG et al. Endotoxin in vivo impairs 
endothelium-dependent relaxation of canine arteries in vitro. Am Rev 
RespirDis. 1990;142:1263-1267.
304. Myers PR, Parker JL, Tanner MA et al. Effects of cytokines tumor 
necrosis factor alpha and interleukin 1 beta on endotoxin-mediated 
inhibition of endothelium-derived relaxing factor bioactivity and nitric 
oxide production in vascular endothelium. Shock. 1994;1:73-78.
246
305. Parker JL, Adams HR. Selective inhibition of endothelium-dependent 
vasodilator capacity by Escherichia coli endotoxemia. Circ Res. 
1993;72:539-551.
306. Julou-Schaeffer G, Gray GA, Fleming I et al. Loss of vascular 
responsiveness induced by endotoxin involves L- arginine pathway. Am J  
Physiol 1990;259:H 1038-H1043.
307. Chauhan SD, Seggara G, Vo PA et al. Protection against 
lipopolysaccharide-induced endothelial dysfunction in resistance and 
conduit vasculature of iNOS knockout mice. FASEBJ. 2003;17:773-775.
308. Wang P, Ba ZF, Chaudry IH. Administration of tumor necrosis factor- 
alpha in vivo depresses endothelium-dependent relaxation. Am J  Physiol. 
1994;266:H2535-H2541.
309. Greenberg S, Xie J, Wang Y et al. Tumor necrosis factor-alpha inhibits 
endothelium-dependent relaxation. JA ppl Physiol. 1993;74:2394-2403.
310. Anderson HD, Rahmutula D, Gardner DG. Tumor necrosis factor-alpha 
inhibits endothelial nitric-oxide synthase gene promoter activity in bovine 
aortic endothelial cells. J  Biol Chem. 2004;279:963-969.
311. Fichtlscherer S, Rosenberger G, Walter DH et al. Elevated C-reactive 
protein levels and impaired endothelial vasoreactivity in patients with 
coronary artery disease. Circulation. 2000;102:1000-1006.
312. Cleland SJ, Sattar N, Petrie JR et al. Endothelial dysfunction as a possible 
link between C-reactive protein levels and cardiovascular disease. Clin Sci 
(Colch). 2000;98:531-535.
313. Brevetti G, Silvestro A, Di Giacomo S et al. Endothelial dysfunction in 
peripheral arterial disease is related to increase in plasma markers of 
inflammation and severity of peripheral circulatory impairment but not to 
classic risk factors and atherosclerotic burden. J  Vase Surg. 2003;38:374-
379.
314. Jarvisalo MJ, Harmoinen A, Hakanen M et al. Elevated serum C-reactive 
protein levels and early arterial changes in healthy children. Arterioscler 
Thromb Vase Biol. 2002;22:1323-1328.
315. Kang SM, Chung N, Kim JY et al. Relation of vasodilator response of the 
brachial artery to inflammatory markers in patients with coronary artery 
disease. Echocardiography. 2002;19:661-667.
316. Tomai F, Crea F, Gaspardone A et al. Unstable angina and elevated c- 
reactive protein levels predict enhanced vasoreactivity of the culprit lesion. 
Circulation. 2001; 104:1471 -1476.
317. Zeiher AM, Drexler H, Wollschlaeger H et al. Coronary vasomotion in 
response to sympathetic stimulation in humans: importance of the
247
functional integrity of the endothelium. J  Am Coll Cardiol. 1989;14:1181- 
1190.
318. van Haelst PL, van Doormaal JJ, Asselbergs FW et al. Correlates of 
endothelial function and their relationship with inflammation in patients 
with familial hypercholesterolaemia. Clin Sci (Lond). 2003;104:627-632.
319. Grahame-Clarke C, Chan NN, Andrew D et al. Human cytomegalovirus 
seropositivity is associated with impaired vascular function. Circulation. 
2003;108:678-683.
320. Khairy P, Rinfret S, Tardif JC et al. Absence of association between 
infectious agents and endothelial function in healthy young men. 
Circulation. 2003; 107:1966-1971.
321. Bhagat K, Collier J, Vallance P. Local venous responses to endotoxin in 
humans. Circulation. 1996;94:490-497.
322. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium- 
dependent dilatation in human veins in vivo. Circulation. 1997;96:3042- 
3047.
323. Bhagat K, Hingorani AD, Palacios M et al. Cytokine-induced 
venodilatation in humans in vivo: eNOS masquerading as iNOS. 
Cardiovasc Res. 1999;41:754-764.
324. Hingorani AD, Cross J, Kharbanda RK et al. Acute systemic inflammation 
impairs endothelium-dependent dilatation in humans. Circulation. 
2000;102:994-999.
325. Chia S, Ludlam CA, Fox KA et al. Acute systemic inflammation enhances 
endothelium-dependent tissue plasminogen activator release in men. J  Am 
Coll Cardiol. 2003;41:333-339.
326. Pleiner J, Heere-Ress E, Langenberger H et al. Adrenoceptor 
hyporeactivity is responsible for Escherichia coli endotoxin-induced acute 
vascular dysfunction in humans. Arterioscler Thromb Vase Biol. 
2002;22:95-100.
327. Pleiner J, Mittermayer F, Schaller G et al. High doses of vitamin C reverse 
Escherichia coli endotoxin-induced hyporeactivity to acetylcholine in the 
human forearm. Circulation. 2002;106:1460-1464.
328. Naruse K, Shimizu K, Muramatsu M et al. Long-term inhibition of NO 
synthesis promotes atherosclerosis in the hypercholesterolemic rabbit 
thoracic aorta. PGH2 does not contribute to impaired endothelium- 
dependent relaxation. Arterioscler Thromb. 1994;14:746-752.
329. Cayatte AJ, Palacino JJ, Horten K et al. Chronic inhibition of nitric oxide 
production accelerates neointima formation and impairs endothelial 
function in hypercholesterolemic rabbits. Arterioscler Thromb. 
1994;14:753-759.
248
330. Forte P, Copland M, Smith LM et al. Basal nitric oxide synthesis in 
essential hypertension. Lancet. 1997;349:837-842.
331. Cooke JP, Singer AH, Tsao P et al. Antiatherogenic effects of L-arginine 
in the hypercholesterolemic rabbit. J  Clin Invest. 1992;90:1168-1172.
332. Wang BY, Singer AH, Tsao PS et al. Dietary arginine prevents 
atherogenesis in the coronary artery of the hypercholesterolemic rabbit. J  
Am Coll Cardiol. 1994;23:452-458.
333. Yu XJ, Li YJ, Xiong Y. Increase of an endogenous inhibitor of nitric oxide 
synthesis in serum of high cholesterol fed rabbits. Life Sci. 1994;54:753- 
758.
334. Bode-Boger SM, Boger RH, Kienke S et al. Elevated L- 
arginine/dimethylarginine ratio contributes to enhanced systemic NO 
production by dietary L-arginine in hypercholesterolemic rabbits. Biochem 
Biophys Res Commun. 1996;219:598-603.
335. Gardiner SM, Kemp PA, Bennett T et al. Regional and cardiac 
haemodynamic effects of NG, NG,dimethyl-L-arginine and their 
reversibility by vasodilators in conscious rats. Br J  Pharmacol. 
1993;110:1457-1464.
336. Matsuoka H, Itoh S, Kimoto M et al. Asymmetrical dimethylarginine, an 
endogenous nitric oxide synthase inhibitor, in experimental hypertension. 
Hypertension. 1997;29:242-247.
337. Chen PY, Sanders PW. L-arginine abrogates salt-sensitive hypertension in 
Dahl/Rapp rats. J  Clin Invest. 1991;88:1559-1567.
338. McDonald KK, Zharikov S, Block ER et al. A caveolar complex between 
the cationic amino acid transporter 1 and endothelial nitric-oxide synthase 
may explain the "arginine paradox". J  Biol Chem. 1997;272:31213-31216.
339. Hardy TA, May JM. Coordinate regulation of L-arginine uptake and nitric 
oxide synthase activity in cultured endothelial cells. Free Radic Biol Med. 
2002;32:122-131.
340. Buga GM, Singh R, Pervin S et al. Arginase activity in endothelial cells: 
inhibition by NG-hydroxy-L- arginine during high-output NO production. 
Am J  Physiol. 1996;271 :H 1988-H1998.
341. Campisi R, Czemin J, Schoder H et al. L-Arginine normalizes coronary 
vasomotion in long-term smokers. Circulation. 1999;99:491-497.
342. Lekakis JP, Papathanassiou S, Papaioannou TG et al. Oral L-arginine 
improves endothelial dysfunction in patients with essential hypertension. 
IntJCardiol. 2002;86:317-323.
249
343. Wascher TC, Graier WF, Dittrich P et al. Effects of low-dose L-arginine 
on insulin-mediated vasodilatation and insulin sensitivity. Eur J  Clin 
Invest. 1997;27:690-695.
344. Panza JA, Casino PR, Badar DM et al. Effect of increased availability of 
endothelium-derived nitric oxide precursor on endothelium-dependent 
vascular relaxation in normal subjects and in patients with essential 
hypertension. Circulation. 1993;87:1475-1481.
345. Mullen MJ, Wright D, Donald AE et al. Atorvastatin but not L-arginine 
improves endothelial function in type I diabetes mellitus: a double-blind 
study. J  Am Coll Cardiol. 2000;36:410-416.
346. Chin-Dusting JP, Alexander CT, Arnold PJ et al. Effects of in vivo and in 
vitro L-arginine supplementation on healthy human vessels. J  Cardiovasc 
Pharmacol. 1996;28:158-166.
347. Adams MR, Forsyth CJ, Jessup W et al. Oral L-arginine inhibits platelet 
aggregation but does not enhance endothelium-dependent dilation in 
healthy young men. J  Am Coll Cardiol. 1995;26:1054-1061.
348. Miyazaki H, Matsuoka H, Cooke JP et al. Endogenous nitric oxide 
synthase inhibitor: a novel marker of atherosclerosis. Circulation. 
1999;99:1141-1146.
349. Boger RH, Bode-Boger SM, Szuba A et al. Asymmetric dimethylarginine 
(ADMA): a novel risk factor for endothelial dysfunction: its role in 
hypercholesterolemia. Circulation. 1998;98:1842-1847.
350. Surdacki A, Nowicki M, Sandmann J et al. Reduced urinary excretion of 
nitric oxide metabolites and increased plasma levels of asymmetric 
dimethylarginine in men with essential hypertension.
351. Calver A, Collier J, Leone A et al. Effect of local intra-arterial asymmetric 
dimethylarginine (ADMA) on the forearm arteriolar bed of healthy 
volunteers. J  Hum Hypertens. 1993;7:193-194.
352. Achan V, Broadhead M, Malaki M et al. Asymmetric dimethylarginine 
causes hypertension and cardiac dysfunction in humans and is actively 
metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler 
Thromb Vase Biol. 2003;23:1455-1459.
353. Kielstein JT, Impraim B, Simmel S et al. Cardiovascular effects of 
systemic nitric oxide synthase inhibition with asymmetrical 
dimethylarginine in humans. Circulation. 2004;109:172-177.
354. Kayanoki Y, Kawata S, Yamasaki E et al. Reduced nitric oxide production 
by L-arginine deficiency in lysinuric protein intolerance exacerbates 
intravascular coagulation. Metabolism. 1999;48:1136-1140.
250
355. Torrents D, Mykkanen J, Pineda M et al. Identification of SLC7A7, 
encoding y+LAT-1, as the lysinuric protein intolerance gene. Nat Genet. 
1999;21:293-296.
356. Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ et al. Increased expression of 
arginase II in human diabetic corpus cavemosum: in diabetic-associated 
erectile dysfunction. Biochem Biophys Res Commun. 2001;283:923-927.
357. Tsutsui M, Milstien S, Katusic ZS. Effect of tetrahydrobiopterin on 
endothelial function in canine middle cerebral arteries. Circ Res. 
1996;79:336-342.
358. Werner ER, Wemer-Felmayer G, Fuchs D et al. Biochemistry and 
function of pteridine synthesis in human and murine macrophages. 
Pathobiology. 1991;59:276-279.
359. Alp NJ, Mussa S, Khoo J et al. Tetrahydrobiopterin-dependent 
preservation of nitric oxide-mediated endothelial function in diabetes by 
targeted transgenic GTP-cyclohydrolase I overexpression. J  Clin Invest. 
2003;112:725-735.
360. Giovanelli J, Campos KL, Kaufman S. Tetrahydrobiopterin, a cofactor for 
rat cerebellar nitric oxide synthase, does not function as a reactant in the 
oxygenation of arginine. Proc Natl Acad Sci US A .  1991;88:7091-7095.
361. Vodovotz Y, Bogdan C, Paik J et al. Mechanisms of suppression of 
macrophage nitric oxide release by transforming growth factor beta. J  Exp 
Med. 1993;178:605-613.
362. Scott-Burden T, Elizondo E, Ge T et al. Simultaneous activation of 
adenylyl cyclase and protein kinase C induces production of nitric oxide 
by vascular smooth muscle cells. Mol Pharmacol. 1994;46:274-282.
363. Kuzkaya N, Weissmann N, Harrison DG et al. Interactions of 
peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications 
for uncoupling endothelial nitric-oxide synthase. J  Biol Chem. 
2003;278:22546-22554.
364. Pieper GM. Acute amelioration of diabetic endothelial dysfunction with a 
derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J  
Cardiovasc Pharmacol. 1997;29:8 -15.
365. Pannirselvam M, Verma S, Anderson TJ et al. Cellular basis of endothelial 
dysfunction in small mesenteric arteries from spontaneously diabetic 
(db/db -/-) mice: role of decreased tetrahydrobiopterin bioavailability. B rJ  
Pharmacol. 2002;136:255-263.
366. Meininger CJ, Marinos RS, Hatakeyama K et al. Impaired nitric oxide 
production in coronary endothelial cells of the spontaneously diabetic BB 
rat is due to tetrahydrobiopterin deficiency. Biochem J. 2000;349:353-356.
251
367. Vasquez-Vivar J, Duquaine D, Whitsett J et al. Altered tetrahydrobiopterin 
metabolism in atherosclerosis: implications for use of oxidized 
tetrahydrobiopterin analogues and thiol antioxidants. Arterioscler Thromb 
Vase Biol. 2002;22:1655-1661.
368. Tiefenbacher CP, Chilian WM, Mitchell M et al. Restoration of 
endothelium-dependent vasodilation after reperfusion injury by 
tetrahydrobiopterin. Circulation. 1996;94:1423-1429.
369. Tiefenbacher CP, Bleeke T, Vahl C et al. Endothelial dysfunction of 
coronary resistance arteries is improved by tetrahydrobiopterin in 
atherosclerosis. Circulation. 2000;102:2172-2179.
370. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases 
endothelial superoxide anion production. J  Clin Invest. 1993;91:2546- 
2551.
371. Landmesser U, Dikalov S, Price SR et al. Oxidation of tetrahydrobiopterin 
leads to uncoupling of endothelial cell nitric oxide synthase in 
hypertension. J  Clin Invest. 2003 ;111:1201-1209.
372. Laursen JB, Somers M, Kurz S et al. Endothelial regulation of vasomotion 
in apoE-deficient mice: implications for interactions between peroxynitrite 
and tetrahydrobiopterin. Circulation. 2001;103:1282-1288.
373. Huang A, Vita JA, Venema RC et al. Ascorbic acid enhances endothelial 
nitric-oxide synthase activity by increasing intracellular 
tetrahydrobiopterin. J  Biol Chem. 2000;275:17399-17406.
374. Dulak J, Polus M, Guevara I et al. Oxidized low density lipoprotein 
inhibits inducible nitric oxide synthase, GTP cyclohydrolase I and 
transforming growth factor beta gene expression in rat macrophages. J  
Physiol Pharmacol. 1999;50:429-441.
375. Scott-Burden T, Elizondo E, Ge T et al. Growth factor regulation of 
interleukin-1 beta-induced nitric oxide synthase and GTP: cyclohydrolase 
expression in cultured smooth muscle cells. Biochem Biophys Res 
Commun. 1993;196:1261-1266.
376. Chen Z, Ahluwalia A, Selwood DL, Vallance P, Hingorani AD. 
Enhancement of endothelium-dependent vasodilatation by oestradiol 17-B: 
role of the pterin pathway. British Journal of Pharmacology 126, 52P.
1999.
Ref Type: Abstract
377. Wemer-Felmayer G, Werner ER, Fuchs D et al. Pteridine biosynthesis in 
human endothelial cells. Impact on nitric oxide-mediated formation of 
cyclic GMP. J  Biol Chem. 1993;268:1842-1846.
378. Baker TA, Milstien S, Katusic ZS. Effect of vitamin C on the availability 
of tetrahydrobiopterin in human endothelial cells. J  Cardiovasc 
Pharmacol. 2001;37:333-338.
252
379. Heller R, Unbehaun A, Schellenberg B et al. L-ascorbic acid potentiates 
endothelial nitric oxide synthesis via a chemical stabilization of 
tetrahydrobiopterin. J  Biol Chem. 2001;276:40-47.
380. Heitzer T, Brockhoff C, Mayer B et al. Tetrahydrobiopterin improves 
endothelium-dependent vasodilation in chronic smokers : evidence for a 
dysfunctional nitric oxide synthase. Circ Res. 2000;86:E36-E41.
381. Cai S, Alp NJ, McDonald D et al. GTP cyclohydrolase I gene transfer 
augments intracellular tetrahydrobiopterin in human endothelial cells: 
effects on nitric oxide synthase activity, protein levels and dimerisation. 
Cardiovasc Res. 2002;55:838-849.
382. Maier W, Cosentino F, Lutolf RB et al. Tetrahydrobiopterin improves 
endothelial function in patients with coronary artery disease. J  Cardiovasc 
Pharmacol. 2000;35:173-178.
383. Stroes E, Kastelein J, Cosentino F et al. Tetrahydrobiopterin restores 
endothelial function in hypercholesterolemia. J  Clin Invest. 1997;99:41- 
46.
384. Heitzer T, Krohn K, Albers S et al. Tetrahydrobiopterin improves 
endothelium-dependent vasodilation by increasing nitric oxide activity in 
patients with Type II diabetes mellitus. Diabetologia. 2000;43:1435-1438.
385. Higman DJ, Strachan AM, Buttery L et al. Smoking impairs the activity of 
endothelial nitric oxide synthase in saphenous vein. Arterioscler Thromb 
Vase Biol. 1996;16:546-552.
386. Kuhlman G, Roth JA, Flakoll PJ et al. Effects of dietary leucine, alpha- 
ketoisocaproate and isovalerate on antibody production and lymphocyte 
blastogenesis in growing lambs. JNutr. 1988; 118:1564-1569.
387. Oemar BS, Tschudi MR, Godoy N et al. Reduced endothelial nitric oxide 
synthase expression and production in human atherosclerosis. Circulation. 
1998;97:2494-2498.
388. Wilcox JN, Subramanian RR, Sundell CL et al. Expression of multiple 
isoforms of nitric oxide synthase in normal and atherosclerotic vessels. 
Arterioscler Thromb Vase Biol. 1997;17:2479-2488.
389. Bossaller C, Habib GB, Yamamoto H et al. Impaired muscarinic 
endothelium-dependent relaxation and cyclic guanosine 5'-monophosphate 
formation in atherosclerotic human coronary artery and rabbit aorta. J  Clin 
Invest. 1987;79:170-174.
390. Perrault LP, Bidouard JP, Janiak P et al. Impairment of G-protein- 
mediated signal transduction in the porcine coronary endothelium during 
rejection after heart transplantation. Cardiovasc Res. 1999;43:457-470.
253
391. Shimokawa H, Flavahan NA, Vanhoutte PM. Loss of endothelial pertussis 
toxin-sensitive G protein function in atherosclerotic porcine coronary 
arteries. Circulation. 1991;83:652-660.
392. Liao JK, Clark SL. Regulation of G-protein alpha i2 subunit expression by 
oxidized low-density lipoprotein. J  Clin Invest. 1995;95:1457-1463.
393. Tsutsui M, Shimokawa H, Tanaka S et al. Endothelial Gi protein in human 
coronary arteries. Eur Heart J. 1994; 15:1261 -1266.
394. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in 
cardiovascular biology and disease. Circ Res. 2000;86:494-501.
395. Guzik TJ, Mussa S, Gastaldi D et al. Mechanisms of increased vascular 
superoxide production in human diabetes mellitus: role of NAD(P)H 
oxidase and endothelial nitric oxide synthase. Circulation. 2002; 105:1656- 
1662.
396. Harrison D, Griendling KK, Landmesser U et al. Role of oxidative stress 
in atherosclerosis. Am J  Cardiol. 2003;91:7A-11 A.
397. Griendling KK, Ushio-Fukai M. Redox control of vascular smooth muscle 
proliferation. J  Lab Clin Med. 1998;132:9-15.
398. Steinberg D. Lewis A. Conner Memorial Lecture. Oxidative modification 
ofLDL and atherogenesis. Circulation. 1997;95:1062-1071.
399. Marui N, Offermann MK, Swerlick R et al. Vascular cell adhesion 
molecule-1 (VCAM-1) gene transcription and expression are regulated 
through an antioxidant-sensitive mechanism in human vascular endothelial 
cells. JClin Invest. 1993;92:1866-1874.
400. Suzuki H, Swei A, Zweifach BW et al. In vivo evidence for microvascular 
oxidative stress in spontaneously hypertensive rats. Hydroethidine 
microfluorography. Hypertension. 1995;25:1083-1089.
401. Wamholtz A, Nickenig G, Schulz E et al. Increased NADH-oxidase- 
mediated superoxide production in the early stages of atherosclerosis: 
evidence for involvement of the renin-angiotensin system. Circulation. 
1999;99:2027-2033.
402. Verlangieri AJ, Bush MJ. Effects of d-alpha-tocopherol supplementation 
on experimentally induced primate atherosclerosis. J  Am Coll Nutr. 
1992;11:131-138.
403. Keaney JF, Jr., Gaziano JM, Xu A et al. Dietary antioxidants preserve 
endothelium-dependent vessel relaxation in cholesterol-fed rabbits. Proc 
Natl Acad Sci USA.  1993;90:11880-11884.
404. Mugge A, Elwell JH, Peterson TE et al. Chronic treatment with 
polyethylene-glycolated superoxide dismutase partially restores
254
endothelium-dependent vascular relaxations in cholesterol-fed rabbits.
Circ Res. 1991;69:1293-1300.
405. Guzik TJ, West NE, Black E et al. Vascular superoxide production by 
NAD(P)H oxidase: association with endothelial dysfunction and clinical 
risk factors, a r c  Res. 2000;86:E85-E90.
406. Sorescu D, Weiss D, Lassegue B et al. Superoxide production and 
expression of nox family proteins in human atherosclerosis, arculation. 
2002;105:1429-1435.
407. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: 
the role of oxidant stress, a r c  Res. 2000;87:840-844.
408. Tsimikas S, Palinski W, Halpem SE et al. Radiolabeled MDA2, an 
oxidation-specific, monoclonal antibody, identifies native atherosclerotic 
lesions in vivo. JN ucl Cardiol. 1999;6:41-53.
409. Krieger M. The other side o f scavenger receptors: pattern recognition for 
host defense. Curr Opin Lipidol. 1997;8:275-280.
410. Khan BV, Parthasarathy SS, Alexander RW et al. Modified low density 
lipoprotein and its constituents augment cytokine-activated vascular cell 
adhesion molecule-1 gene expression in human vascular endothelial cells. 
J  Clin Invest. 1995;95:1262-1270.
411. Kume N, Gimbrone MA, Jr. Lysophosphatidylcholine transcriptionally 
induces growth factor gene expression in cultured human endothelial cells. 
J  Clin Invest. 1994;93:907-911.
412. Anderson TJ, Meredith IT, Charbonneau F et al. Endothelium-dependent 
coronary vasomotion relates to the susceptibility of LDL to oxidation in 
humans. Circulation. 1996;93:1647-1650.
413. Sampson MJ, Gopaul N, Davies IR et al. Plasma F2 isoprostanes: direct 
evidence of increased free radical damage during acute hyperglycemia in 
type 2 diabetes. Diabetes Care. 2002;25:537-541.
414. Gniwotta C, Morrow JD, Roberts LJ et al. Prostaglandin F2-like 
compounds, F2-isoprostanes, are present in increased amounts in human 
atherosclerotic lesions. Arterioscler Thromb Vase Biol. 1997; 17:3236- 
3241.
415. Fenkci V, Fenkci S, Yilmazer M et al. Decreased total antioxidant status 
and increased oxidative stress in women with polycystic ovary syndrome 
may contribute to the risk of cardiovascular disease. Fertil Steril. 
2003;80:123-127.
416. Timimi FK, Ting HH, Haley EA et al. Vitamin C improves endothelium- 
dependent vasodilation in patients with insulin-dependent diabetes 
mellitus. J  Am Coll Cardiol. 1998;31:552-557.
255
417. Ting HH, Timimi FK, Haley EA et al. Vitamin C improves endothelium- 
dependent vasodilation in forearm resistance vessels of humans with 
hypercholesterolemia. Circulation. 1997;95:2617-2622.
418. Anderson TJ, Meredith IT, Yeung AC et al. The effect of cholesterol- 
lowering and antioxidant therapy on endothelium-dependent coronary 
vasomotion. N  Engl J  Med. 1995;332:488-493.
419. Perticone F, Ceravolo R, Maio R et al. Effects of atorvastatin and vitamin 
C on endothelial function of hypercholesterolemic patients. 
Atherosclerosis. 2000; 152:511-518.
420. Taddei S, Virdis A, Ghiadoni L et al. Vitamin C improves endothelium- 
dependent vasodilation by restoring nitric oxide activity in essential 
hypertension. Circulation. 1998;97:2222-2229.
421. Heitzer T, Just H, Munzel T. Antioxidant vitamin C improves endothelial 
dysfunction in chronic smokers. Circulation. 1996;94:6-9.
422. Cross JM, Donald AE, Nuttall SL et al. Vitamin C improves resistance but 
not conduit artery endothelial function in patients with chronic renal 
failure. Kidney Int. 2003;63:1433-1442.
423. Prasad A, Andrews NP, Padder FA et al. Glutathione reverses endothelial 
dysfunction and improves nitric oxide bioavailability. J  Am Coll Cardiol. 
1999;34:507-514.
424. Gokce N, Keaney JF, Jr., Frei B et al. Long-term ascorbic acid 
administration reverses endothelial vasomotor dysfunction in patients with 
coronary artery disease. Circulation. 1999;99:3234-3240.
425. Heitzer T, Schlinzig T, Krohn K et al. Endothelial dysfunction, oxidative 
stress, and risk of cardiovascular events in patients with coronary artery 
disease. Circulation. 2001;104:2673-2678.
426. Undenffiend E, Clark CT, Axelrod J et al. Ascorbic acid in aromatic 
hydroxylation I. A model system for aromatic hydroxylation. J  Biol 
Chem. 1954;208:731-739.
427. Carr A, Frei B. Does vitamin C act as a pro-oxidant under physiological 
conditions? FASEBJ. 1999;13:1007-1024.
428. Suh J, Zhu BZ, Frei B. Ascorbate does not act as a pro-oxidant towards 
lipids and proteins in human plasma exposed to redox-active transition 
metal ions and hydrogen peroxide. Free Radic Biol Med. 2003;34:1306- 
1314.
429. Heitzer T, Yla HS, Wild E et al. Effect of vitamin E on endothelial 
vasodilator function in patients with hypercholesterolemia, chronic 
smoking or both. J  Am Coll Cardiol. 1999;33:499-505.
256
430. Neunteufl T, Kostner K, Katzenschlager R et al. Additional benefit of 
vitamin E supplementation to simvastatin therapy on vasoreactivity of the 
brachial artery of hypercholesterolemic men. J  Am Coll Cardiol. 
1998;32:711-716.
431. Chowienczyk PJ, Kneale BJ, Brett SE et al. Lack of effect of vitamin E on 
L-arginine-responsive endothelial dysfunction in patients with mild 
hypercholesterolaemia and coronary artery disease. Clin Sci (Lond). 
1998;94:129-134.
432. Gazis A, White DJ, Page SR et al. Effect of oral vitamin E (alpha- 
tocopherol) supplementation on vascular endothelial function in Type 2 
diabetes mellitus. Diabet Med. 1999;16:304-311.
433. Kushi LH, Folsom AR, Prineas RJ et al. Dietary antioxidant vitamins and 
death from coronary heart disease in postmenopausal women. N  Engl J  
Med. 1996;334:1156-1162.
434. Khaw KT, Bingham S, Welch A, Luben R, Wareham N, Oakes S, Day N. 
Relation between plasma ascorbic acid and mortality in men and women 
in EPIC-Norfolk prospective study: a prospective population study. 
European Prospective Investigation in Cancer and Nutrition. Lancet 
357[9257], 657-663. 3-3-2001.
Ref Type: Abstract
435. Stephens NG, Parsons A, Schofield PM et al. Randomised controlled trial 
of vitamin E in patients with coronary disease: Cambridge Heart 
Antioxidant Study (CHAOS). Lancet. 1996;347:781-786.
436. Yusuf S, Dagenais G, Pogue J et al. Vitamin E supplementation and 
cardiovascular events in high-risk patients. The Heart Outcomes 
Prevention Evaluation Study Investigators. N  Engl J  Med. 2000;342:154- 
160.
437. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection 
Study of antioxidant vitamin supplementation in 20,536 high-risk 
individuals; a randomised placebo-controlled trial. Lancet 360[9326], 23- 
33. 6-7-2002.
Ref Type: Abstract
438. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin 
E after myocardial infarction: results of the GISSI-Prevenzione trial. 
Gruppo Italiano per lo Studio della Soprawivenza nell'Infarto miocardico. 
Lancet. 1999;354:447-455.
439. Shohaimi S, Bingham S, Welch A, Luben R, Day N, Wareham N, Khaw 
KT. Occupational social class, educational level and area deprivation 
independently predict plasma ascorbic acid concetration: a cross-sectional 
population based study in the Norfolk cohort of the European Prospective 
Investigation into Cancer (EPIC-Norfolk). Eur J Clin Nutr. Epub. 31-3-
2004.
257
Ref Type: Abstract
440. Cardillo C, Kilcoyne CM, Cannon RO, III et al. Xanthine oxidase 
inhibition with oxypurinol improves endothelial vasodilator function in 
hypercholesterolemic but not in hypertensive patients. Hypertension. 
1997;30:57-63.
441. Motoyama T, Okamoto K, Kukita I et al. Possible role of increased 
oxidant stress in multiple organ failure after systemic inflammatory 
response syndrome. Crit Care Med. 2003;31:1048-1052.
442. Zhang H, Slutsky AS, Vincent JL. Oxygen free radicals in ARDS, septic 
shock and organ dysfunction. Intensive Care Med. 2000;26:474-476.
443. Taylor DE, Piantadosi CA. Oxidative metabolism in sepsis and sepsis 
syndrome. J  Crit Care. 1995;10:122-135.
444. Pratico D, Tillmann C, Zhang ZB et al. Acceleration of atherogenesis by 
COX-1-dependent prostanoid formation in low density lipoprotein 
receptor knockout mice. Proc Natl Acad Sci USA.  2001 ;98:3358-3363.
445. Husain S, Andrews NP, Mulcahy D et al. Aspirin improves endothelial 
dysfunction in atherosclerosis. Circulation. 1998;97:716-720.
446. Noon JP, Walker BR, Hand MF et al. Impairment of forearm 
vasodilatation to acetylcholine in hypercholesterolemia is reversed by 
aspirin. Cardiovasc Res. 1998;38:480-484.
447. Angus JA, Wright CE. Techniques to study the pharmacodynamics of 
isolated large and small blood vessels. J  Pharmacol Toxicol Methods. 
2000;44:395-407.
448. Chowienczyk PJ, Cockcroft JR, Ritter JM. Differential inhibition by NG- 
monomethyl-L-arginine of vasodilator effects of acetylcholine and 
methacholine in human forearm vasculature. Br J  Pharmacol. 
1993;110:736-738.
449. Benjamin N, Calver A, Collier J et al. Measuring forearm blood flow and 
interpreting the responses to drugs and mediators [see comments]. 
Hypertension. 1995;25:918-923.
450. Lenders J, Janssen GJ, Smits P et al. Role of the wrist cuff in forearm 
plethysmography. Clin Sci (Lond). 1991;80:413-417.
451. Corretti MC, Anderson TJ, Benjamin EJ et al. Guidelines for the 
ultrasound assessment of endothelial-dependent flow-mediated 
vasodilation of the brachial artery: a report of the International Brachial 
Artery Reactivity Task Force. J  Am Coll Cardiol. 2002;39:257-265.
452. Mullen MJ, Kharbanda RK, Cross J et al. Heterogenous nature of flow- 
mediated dilatation in human conduit arteries in vivo: relevance to
258
endothelial dysfunction in hypercholesterolemia. Circ Res. 2001 ;88:145- 
151.
453. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. 
Modifications to the tetrazolium dye procedure giving improved 
sensitivity and reliability. J  Immunol Methods. 1986;89:271-277.
454. Williams RL, Courtneidge SA, Wagner EF. Embryonic lethalities and 
endothelial tumors in chimeric mice expressing polyoma virus middle T 
oncogene. Cell. 1988;52:121-131.
455. Darbre A. Analytical methods. In: Darbre A, editor. Practical Protein 
Chemistry: A Handbook. John Wiley and Sons, New York, 1986: 227-
335.
456. Nandi M, Arrigoni F, Leiper J, Vallance P, Haworth S. 
Tetrahydrobiopterin enhances pulmonary arterial relaxation after birth. 
Br.J.Pharmacol. 135,199P. 2002.
Ref Type: Abstract
457. de Beer FC, Pepys MB. Isolation of human C-reactive protein and serum 
amyloid P component. J  Immunol Methods. 1982;50:17-31.
458. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood. 
1991;77:1627-1652.
459. Kishimoto T. The biology of interleukin-6. Blood. 1989;74:1-10.
460. Eda S, Kaufmann J, Molwitz M et al. A new method of measuring C- 
reactive protein, with a low limit of detection, suitable for risk assessment 
of coronary heart disease. ScandJClin Lab Invest Suppl. 1999;230:32-35.
461. WHO Expert Committee on Biological Standardisation tR. WHO 
technical report series 760. 1987. Geneva. 1987.
Ref Type: Report
462. Dhamrait SS, Stephens JW, Cooper JA et al. Cardiovascular risk in 
healthy men and markers of oxidative stress in diabetic men are associated 
with common variation in the gene for uncoupling protein 2. Eur Heart J. 
2004;25:468-475.
463. Laight DW, Gunnarsson PT, Kaw AV et al. Physiological microassay of 
plasma total antioxidant status in a model of endothelial dysfunction in the 
rat following oxidant stress in vivo. ETAP. 1999;7:27-31.
464. Stephens JW. Increased plasma oxidative stress is associated with 
coronary heart disease in males with diabetes mellitus and with 10-year 
prospective risk in males without diabetes. Diabet.Med. 22[Suppl 2], 145.
2005.
Ref Type: Abstract
259
465. Joannides R, Haefeli WE, Linder L et al. Nitric oxide is responsible for 
flow-dependent dilatation of human peripheral conduit arteries in vivo. 
Circulation. 1995 ;91:1314-1319.
466. Steinberg HO, Bayazeed B, Hook G et al. Endothelial dysfunction is 
associated with cholesterol levels in the high normal range in humans. 
Circulation. 1997;96:3287-3293.
467. Goldsmith IR, Blann AD, Patel RL et al. Plasma fibrinogen, soluble P- 
selectin, and von Willebrand factor in aortic valve disease: evidence for 
abnormal haemorheology, platelet activation, and endothelial dysfunction 
[letter]. Heart. 2000;83:577-578.
468. Bombeli T, Mueller M, Haeberli A. Anticoagulant properties of the 
vascular endothelium. Thromb Haemost. 1997;77:408-423.
469. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis 
and restenosis: an assessment of the evidence and need for future research. 
Circulation. 1997;96:4095-4103.
470. Thom DH, Grayston JT, Siscovick DS et al. Association of prior infection 
with Chlamydia pneumoniae and angiographically demonstrated coronary 
artery disease. JAMA. 1992;268:68-72.
471. Ohkawa F, Ikeda U, Kanbe T et al. Effects of inflammatory cytokines on 
vascular tone. Cardiovasc Res. 1995;30:711-715.
472. Honing ML, Smits P, Morrison PJ et al. Bradykinin-induced vasodilation 
of human forearm resistance vessels is primarily mediated by 
endothelium-dependent hyperpolarization. Hypertension. 2000;35:1314- 
1318.
473. Kauser K, da C, V, Fitch R et al. Role of endogenous nitric oxide in 
progression of atherosclerosis in apolipoprotein E-deficient mice. Am J  
Physiol Heart Circ Physiol. 2000;278:H1679-H1685.
474. Chen J, Kuhlencordt PJ, Astern J et al. Hypertension does not account for 
the accelerated atherosclerosis and development of aneurysms in male 
apolipoprotein e/endothelial nitric oxide synthase double knockout mice. 
Circulation. 2001;104:2391-2394.
475. Cross JM, Donald AE, Kharbanda R et al. Acute administration of L- 
arginine does not improve arterial endothelial function in chronic renal 
failure. Kidney Int. 2001;60:2318-2323.
476. Nappo F, De Rosa N, Marfella R et al. Impairment of endothelial 
functions by acute hyperhomocysteinemia and reversal by antioxidant 
vitamins. JAMA. 1999;281:2113-2118.
477. Hirooka Y, Imaizumi T, Tagawa T et al. Effects of L-arginine on impaired 
acetylcholine-induced and ischemic vasodilation of the forearm in patients 
with heart failure. Circulation. 1994;90:658-668.
260
478. Katusic ZS. Vascular endothelial dysfunction: does tetrahydrobiopterin 
play a role? Am J  Physiol Heart Circ Physiol. 2001;281:H981-H986.
479. Clausen P, Jensen JS, Jensen G et al. Elevated urinary albumin excretion is 
associated with impaired arterial dilatory capacity in clinically healthy 
subjects. Circulation. 2001; 103:1869-1874.
480. Stehouwer CD, Nauta JJ, Zeldenrust GC et al. Urinary albumin excretion, 
cardiovascular disease, and endothelial dysfunction in non-insulin- 
dependent diabetes mellitus. Lancet. 1992;340:319-323.
481. Pedrinelli R, Dell'Omo G, Di B, V et al. Microalbuminuria, an integrated 
marker of cardiovascular risk in essential hypertension. J  Hum Hypertens. 
2002;16:79-89.
482. Tsang GM, Allen S, Pagano D et al. von Willebrand factor and urinary 
albumin excretion are possible indicators of endothelial dysfunction in 
cardiopulmonary bypass. Eur JCardiothorac Surg. 1998;13:385-391.
483. Abid O, Sun Q, Sugimoto K et al. Predictive value of microalbuminuria in 
medical ICU patients: results of a pilot study. Chest. 2001;120:1984-1988.
484. Ueda S, Matsuoka H, Miyazaki H et al. Tetrahydrobiopterin restores 
endothelial function in long-term smokers. J  Am Coll Cardiol. 
2000;35:71-75.
485. Du WD, Yuan ZR, Sun J et al. Therapeutic efficacy of high-dose vitamin 
C on acute pancreatitis and its potential mechanisms. World J  
Gastroenterol. 2003;9:2565-2569.
486. Suba EA, McKenna TM, Williams TJ. In vivo and in vitro effects of 
endotoxin on vascular responsiveness to norepinephrine and signal 
transduction in the rat. Circ Shock. 1992;36:127-133.
487. Miller GJ, Bauer KA, Barzegar S et al. The effects of quality and timing of 
venepuncture on markers of blood coagulation in healthy middle-aged 
men. Thromb Haemost. 1995;73:82-86.
488. O'Brien AJ, Wilson AJ, Sibbald R et al. Temporal variation in endotoxin- 
induced vascular hyporeactivity in a rat mesenteric artery organ culture 
model. Br J  Pharmacol. 2001;133:351-360.
489. Buga GM, Griscavage JM, Rogers NE et al. Negative feedback regulation 
of endothelial cell function by nitric oxide. Circ Res. 1993;73:808-812.
261
